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1 Introduction 
This chapter should give a brief introduction into the research field of bioreducible 
polycationic carriers for nucleic acid delivery. 
  
1.1 Non-viral gene therapy 
This chapter gives a brief introduction into chemically designed, artificial vectors for 
nucleic acid delivery. It does not aim at giving a full review of the advances in polymer-
based gene therapy since its invention in the 1960’s. This, as well as an appropriate 
review of advances in viral gene therapy and a comparison of both would exceed the 
intended introduction of this Ph.D. thesis.  
However, Lächelt and Wagner [1] as well as Herzog and colleagues [2] reviewed 
recent advances in detail. 
 
So far, genetic disorders like mucoviscidosis [3], severe combined immunodeficiency 
(SCID) [4], haemophilia [5], β-thalassemia [6], as well as adrenoleukodystrophy (ALD) 
[7], metachromatic leukodystrophy [8], aromatic L-amino acid decarboxylase (AADC) 
deficiency [2] among others [9-11] have been tackled by classical, viral gene therapy.  
Thereby, classical gene therapy addresses these diseases by inserting functional DNA 
into the human genome in order to replace defect gene sections.  
However, it took until 2012 until the first therapeutic product, Glybera, was approved 
by the European Medicines Agency (EMA) for the treatment of lipoprotein lipase 
deficiency (LPLD). Facing high therapy costs, the company will not extend the 
admission of Glybera® after its ended in October 2017. However, in the meantime 
Strimvelis®, for the treatment of adenosine deaminase (ADA)‐deficient severe 
combined immunodeficiency (SCID), was approved on the european market [12].  
The RNA interference (RNAi) discovered in 1998 by Fire et al. [13] also significantly 
increased therapeutic options within recent years. Specific gene silencing and hence 
the inhibition of cellular expression of a protein was since then widely explored for 
double stranded small (synthetic) interfering RNA (siRNA) as well as micro RNA 
   Introduction 
   12 
(miRNA) [14]. To investigate nucleic acid delivery, artificial vectors mimicking viruses 
have been considered since its discovery in the 1960’s besides the established viral 
delivery [1]. Carriers, however, need to comprise several functionalities and overcome 
several barriers for a successful gene delivery in vitro as well as in vivo. These 
properties are addressed in the upcoming chapter.  
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1.1.1 The delivery pathway of non-viral nucleic acid carriers 
Non-viral nucleic acid carriers face several obstacles prior to an efficient intracellular 
delivery. These barriers are schematically illustrated (cf. Scheme 1) to exhibit the very 
complex delivery pathway of polymer-based systems. The following chapter addresses 
the critical steps of nucleic acid complexation (1), cellular binding and uptake (2), 
endosomal escape (3), cargo release and intracellular trafficking (4) towards the 
compartment of further processing. 
 
Scheme 1 The cellular delivery pathway of polymer-based nucleic acid carriers
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A large size, anionic charge, as well as sensitivity towards degradation by nucleases 
are rather inefficient properties for the delivery of naked nucleic acids to their target 
location [15, 16], however, it rarely is possible [17, 18]. To overcome these issues, 
chemically engineered cationic polymers along with cationic lipids [19-21] were 
developed. By complexing nucleic acid, they were intended to shade the cargo in the 
extracellular environment and prevent them from degradation, but also facilitate the 
nucleic acid to be transported into the cytoplasm [22]. Within cationic polymers, 
polylysine (pLL) [23, 24], which was first evaluated clinically as a delivery vehicle for 
pDNA [25], the branched [26-29] and linear [30-33] versions of polyethyleneimine (PEI) 
as well as dendritic polyamidoamine (PAMAM) [34-36] (cf. Figure 1A-D) represent the 
most prominent candidates besides many others [1].  
  
Figure 1 A) PLL, poly-L-lysine; B) LPEI, linear polyethylenimine prepared by hydrolysis of poly(2-ethyl-
2-oxazoline); C) BPEI, branched polyethylenimine (partially); D) PAMAM, polyamidoamine dendrimer 
Generation 0; E) DAMP (3,3′-Diamino-N-methyldipropylamine); F) Spermine (N,N-(butane-1,4-
diyl)bis(propane-1,3-diamine)); G) Artificial amino acids derived from PEI repeat unit which are 
assembled by SPS to retrieve a nucleic acid binding domain within sequence-defined oligomers. Gtt 
represents glutaryl-triethylene tetramine, Stp succinyl tetraethylene pentamine, Gtp glutaryl-
tetraethylene pentamine and Sph succinyl pentaethylene hexamine.   
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These cationic carriers, all comprise basic amines, are partially protonated at neutral 
pH and are thereby able to bind and compact negatively charged nucleic acids via 
electrostatic interaction. This complexation is entropy driven and leads to the formation 
of nano-sized complexes, so-called “polyplexes” [37, 38].  
These polyplexes need to exhibit a certain size as well as stability for the successful 
delivery. Nanoparticles with a size of 5.5 nm or below suffer from rapid clearance by 
the kidney [39], while particles with a size between 20 and 400 nm can penetrate into 
highly vascularized solid tumors as a result of the enhanced permeability and retention 
(EPR) effect due to passage through leaky vessels of the tumor tissue [40-42]. 
However, the extent of passive tumor accumulation via EPR effect is strongly 
dependent on the size-threshold of the porous tumor vasculature which varies within 
different types of cancer [43-45].   
As already mentioned before, also stability within the biological environment 
represents a crucial property for polyplex delivery. Here the positive surface charge of 
unshielded polyplexes can mediate interaction with proteins and electrolytes, causing 
polyplex dissociation or severe aggregation due to counterion exchange. This stability 
issue can be addressed by increased cationic charge or by the introduction of 
crosslinking domains (e.g. terminal cysteines) via formation of bio-reducible disulfide 
bonds [46-50], or the introduction of hydrophobic elements [51-53].  
 
Cellular binding followed by endocytosis represents the next step towards gene 
delivery. By its nature, nanoparticles formed with cationic polymers exhibit a positive 
surface charge, due to a usual excess of amines per nucleic acid phosphate during 
polyplex formation. This can be beneficial for binding to the negatively charged cell 
surface via electrostatic interaction but represents a very unspecific and rather 
ineffective way compared to the receptor-mediated uptake route (cf. Scheme 1(2)) [54, 
55]. Hence, the introduction of a targeting domain, exposed on the polyplex surface, is 
a convenient approach to enhance cellular uptake. The selection of the proper 
targeting domain is dependent of the receptor expression in the target tissue. 
Generally oncogenic transformation is accompanied by excessive proliferation and an 
elevated metabolic activity [56]. Therefore, transport proteins for the uptake of nutrients 
and cofactors, such as the folate receptor (FR) and transferrin receptor (TfR), growth 
factor receptors or integrins are often upregulated and represent auspicious targets 
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[55, 57-67]. As polyplex targeting represents a crucial part of this Ph.D. work, the two 
key targets (EGFR and HGFR) are described in more detail later on (cf.1.1.2.3). 
Polyplex shielding, often impaired by the introduction of a targeting domain, represents 
another issue to be addressed as polyplexes with a positive surface charge can 
undergo aggregation or dissociation with electrolytes or proteins within the 
bloodstream. In addition, a positive surface charge can lead to the activation of the 
immune system. However, as polyplex shielding presents a key topic of this thesis, it 
is elucidated in more detail later on (cf. 1.1.2.2.1).  
 
When having reached the intracellular space by endocytosis [68], the next barrier 
within the delivery pathway is represented by endosomes. These intracellular vesicles 
are the major site for the sorting, trafficking and recycling of endocytosed material [69, 
70]. To circumvent recycling to the cell membrane or degradation in late endo- and 
lysosomes, the entrapped polyplexes have to be released from the vesicles to reach 
the cytoplasm. This can be reached by different strategies. The so-called proton 
sponge effect, first described by J.P. Behr [71] represents the most common 
hypothesis on evasion from the endosome. Polymers with amines, becoming 
protonated under acidic pH, like LPEI, can increase osmotic pressure due to its buffer 
abilities, ultimately leading, due to endosomal swelling, to an endosomal burst [26, 72]. 
This effect can also be mediated by shorter diaminoethane motif containing chains. 
Here an even number of protonable amines is preferred [73]. Additionally, introduction 
of histidines (with a pKa of the imidazole group of 6.5) enhance endosomal buffer 
capacity due to their favorable protonation at endosomal pH [50, 74, 75]. Alternatively, 
endosomal escape is mediated by interaction of peptides with a high content of basic 
amino acids [76], such as Tat [77], KALA [78, 79], GALA [80], influenza (Inf) virus-
derived peptides [81, 82] and others [83-85] with the endosomal membrane. Also, 
lipids can contribute to the endosomal escape by lysing membranes in a favorable pH-
dependent manner due to their amphiphilic character and cationization at endosomal 
pH [49]. As evaluated by Fröhlich et al., the unsaturated fatty acids oleic acid and 
linoleic acid emerged as the most potent candidates, balancing oligomer mediated 
siRNA delivery and cytotoxicity [51].  
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After having reached the cytoplasm, the delivered polyplexes now have to release the 
cargo. For this reason, particle stability needs to be well balanced between sufficient 
extracellular stability and fast nucleic acid release at the target site. Here, previously 
mentioned disulfide bonds can be reduced by cytosolic GSH, releasing the cargo and 
the single polymers, thereby reducing cytotoxicity due to an increased biodegradability 
of smaller units.  
The released pDNA then needs to be transported into the nucleus for transcription 
towards mRNA. However, nuclear transport represents a critical hurdle within non-viral 
gene delivery [86]. This is achieved preferentially when the nuclear envelope dissolves 
during the cell division process [87]. After nuclear transcription [88], the mRNA needs 
to undergo ribosomal translation towards the protein of interest. 
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1.1.2 Cationic carriers: From polydisperse polymers towards sequence-
defined oligomers 
Artificial vectors as potent nucleic acid vehicles need to comprise different 
functionalities to be bioresponsive.  
Previously, cationic vectors like pLL, PEI, PAMAM were generated by different kinds 
of polymerization techniques and resulted in polydisperse polymers. With improved 
chemistries, such as controlled radical polymer synthesis or specific ligation strategies, 
products with decreased polydispersity and more highly controlled architecture of 
carries were obtained [89-94]. 
Further development of cationic delivery systems requires clear-cut structure-activity 
relationships to be drawn. Therefore, a technique to obtain polymers with a precisely 
defined sequence is needed. A series of researchers have applied the well-established 
method of solid-phase assisted synthesis (SPS) to develop linear [84, 85, 95-103] and 
branched [75, 104-109] peptide-based as well as lipid-based [110-113] nucleic acid 
carriers. Recently, also artificial amino acids have been assembled to sequence-
defined oligomers as shuttles for pDNA and siRNA (cf. Figure 1E-G) [49, 51, 64, 113-
122].  
Merrifield was the first to introduce SPS to assemble peptides in a non-liquid 
environment. Therefore, pre-activated polystyrene served as a solid support for 
synthesis [123]. The synthesis is initiated by loading the first protected amino acid onto 
these so-called resins. Orthogonally protected amino acids are coupled sequentially, 
with easy washing steps between coupling and removal of the protection group of the 
primary amine to constantly grow the macromolecule on the solid support. In 
comparison to solution-phase synthesis, solid-phase synthesis offers the following 
important advantages. Firstly, purification of intermediates is possible, due to the 
simple removal of unreacted reagents by washing during synthesis. Secondly, side 
products (produced by repeated couplings or capping) can be reduced, leading to 
increased product yields. And thirdly, due to the repetitive nature of the process, the 
whole assembly can be automated with the help of peptide synthesizers.  
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1.1.2.1 SPS as a method to develop sequence-defined cationic vectors for 
structure activity relationships 
This chapter is partly based on:  
Krhac Levacic A., Morys, S., Wagner E. Solid-phase Supported Design of Carriers for 
Therapeutic Nucleic Acid Delivery. Bioscience Reports 2017, 37 (5). 
 
Initially, tBoc chemistry was applied to protect the α-amino group of the amino acids. 
As mentioned previously, a solid support was introduced to assemble peptides 
sequentially [123]. The first amino acid with a tBoc α-amine (cf. Figure 2A) is linked to 
the solid support via the free, C-terminal carboxy group. Then, the resin-bound amino 
acid is treated with trifluoroacetic acid (TFA) to remove the tBoc protecting group and 
to free the α-amine. Now, the next tBoc protected α-amino acid can be coupled. For 
sequential amino acid coupling, the carboxylic acid group of each amino acids needs 
to be activated. Most commonly this is achieved by the addition of N,N’-
dicyclohexylcarbodiimid (DCC). Dichloromethane (DCM) and dimethylformamide 
(DMF) are used as organic solvents, to create the required, non-aqueous environment 
for successful coupling, while facilitating swelling of the solid support during the 
reaction. After coupling the last amino acid, the resin is treated with hydrofluoric acid 
(HF) to cleave the peptide off the resin and to remove all side chain protecting groups. 
SPS advanced with more scientists facilitating this method of defined synthesis. 
Classical tBoc chemistry was soon replaced by introducing the base-labile protecting 
group Fmoc (N-α-9-fluorenylmethyloxycarbonyl) into SPS chemistry [124-127].   
This approach no longer required the application of the hazardous HF as a cleavage 
reagent and thereby opened peptide manufacture to a wider range of operators.  
The use of resins with novel acid labile linkers, like the hydroxymethyl based Wang 
resin, the Rink amide resin or the trityl chloride (especially 2-chlorotrityl chloride) [127] 
enabled cleavage from the resin with TFA instead of HF. Instead of tBoc, Fmoc serves 
until today, as the state of the art protecting group of the amino acid’s α-amines (e.g. 
Figure 2B). Easy removal by non-nucleophilic bases like piperidine or 1,8-
Diazabicyclo[5.4.0]undec-7-en (DBU), maintained orthogonality to acid labile side 
chain protecting groups such as tBu, Trt, tBoc or Pbf [128]. Also, strategies for the 
synthesis of more highly sophisticated peptides, requiring orthogonality to Fmoc was 
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achieved by introduction of novel protecting groups [129].  
A schematical cycle of SPS is given in Figure 2D pointing out the different, repetitive 
steps to obtain a fully deprotected peptide at the end of the synthesis. 
 
 
Figure 2 Protected lysine for A) tBoc (tBoc-L-Lys(Cbz)-OH) or B) Fmoc (Fmoc-L-Lys(tBoc)-OH) 
strategy. C) Fmoc, tBoc protected artificial oligoamino acids derived from PEI repeat units. tBoc 
represents tert-butyloxycarbonyl, Cbz Benzyloxycarbonyl, Fmoc N-α-9-fluorenylmethyloxycarbonyl, Gtt 
glutaryl-triethylene tetramine, Stp succinyl tetraethylene pentamine, Gtp glutaryl-tetraethylene 
pentamine and Sph succinyl pentaethylene hexamine D) Standard procedure of a solid phase peptide 
synthesis cycle. tBoc, as well as Fmoc strategy, follow the same procedure of a repetitive coupling cycle. 
Resins are commonly swollen in DCM. Coupling requires activation of the carboxylic function of the 
amino acid either by carbodiimides or by formation of activated esters with PyBOP, HBTU or HOBt and 
the addition of DIPEA or TEA. Washing steps are performed with non-aqueous, peptide grade DMF and 
DCM. A Kaiser test [130] for detection of unprotected amines via ninhydrine reaction is done to verify 
successful coupling and deprotection. Nevertheless, tBoc and Fmoc strategies differ significantly 
regarding protecting groups, their removal (deprotection) as well as the final cleavage from the solid 
support. In tBoc strategy α-amines of amino acids are tBoc protected, removal after coupling is 
performed with TFA and the final peptide cleavage is conducted with HF. In Fmoc strategy α-amines of 
amino acids are Fmoc protected, removal after coupling is performed with a mixture of piperidine/DMF 
and the final peptide cleavage is conducted with a cleavage cocktail mainly consisting of TFA. This 
figure is adapted from Krhac Levacic A., Morys, S., Wagner E. Solid-phase Supported Design of Carriers 
for Therapeutic Nucleic Acid Delivery. Bioscience Reports 2017, 37 (5)  
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Besides the previously mentioned, mostly lysine-based, oligomers [95, 96, 98, 100, 
101, 104] the Fmoc peptide SPS strategy has been adopted for the synthesis of 
sequence-defined oligo(ethylenamino)amides (Figure 2C). Instead of natural amino 
acids, artificial oligoamino acids such as Stp (succinyl tetraethylene pentamine), Gtp 
(glutaroyl-tetraethylene pentamine) or Sph (succinyl pentaethylene hexamine) in 
Fmoc, tBoc-protected forms [49, 131, 132] can be used for manual as well as 
automated SPS, the latter requiring a peptide synthesizer [133]. These building blocks 
introduced the diaminoethane motif of LPEI, a well-established nucleic acid binding 
and endosomal buffering domain, for solid phase synthesis. 
 
1.1.2.2 Tailoring topologies and functionalizing oligomers to improve nucleic 
acid delivery 
With these artificial amino acids, a library of more than 1100 oligomers has been 
established and the oligomers have been tested for different nucleic acids (pDNA, 
siRNA, miRNA, mRNA) to evaluate the best suitable carriers. The choice of the artificial 
amino acids mentioned above, significantly influenced the nucleic acid binding and 
endosomal buffer ability of the first oligomers generated. Different topologies, including 
linear [134] as well as branched [49] structures, incorporating different artificial cationic 
building blocks were generated and evaluated [50, 132]. However, Stp (Fmoc-
Stp(boc)3-OH) was introduced into most of the later mentioned oligomers, as it can be 
obtained by a highly reproducible synthesis with good yield, nevertheless providing the 
required key features for a successful gene delivery. To achieve a more sophisticated 
multifunctionality, different topologies with the diamino acid lysine as a branching point 
were developed (cf. Figure 3).   
Structures consisting of three Stp enriched cationic arms (3-arm) [49, 64, 133], as well 
as oligomers with PEG of a defined length instead of a third cationic arm (PEGylated 
2-arm) were investigated (cf Figure 3A,B). The latter topology facilitated the 
introduction of a targeting domain like folic acid [135-137], as well as peptidic ligands 
like cmb, targeting the HGFR [64] or the GE11 peptide [138], targeting EGFR as well 
as other peptidic ligands [139, 140].  
Also, oligomers with 4-arms [132] were built (cf. Figure 3C), and the effect of histidines 
as an endosomal buffering domain with its pKa of 6.5, introduced between the artificial 
amino acids was evaluated [50]. The combined buffering capacity of alternately placed 
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histidines and cationic building blocks thereby led to a significantly improved buffer 
capacity at endosomal pH. Increased buffering enhanced cellular electrolyte influx, 
finally leading to endosomal burst due to osmotic swelling. In the 1990’s Behr et al. 
already pointed out that this effect, also known as the proton sponge effect, importantly 
contributes to LPEI’s intracellular performance [71]. Similar findings were made with 
highly branched HK rich peptides by Mixson et al. [105, 106], demonstrating that the 
proton sponge effect is also transferrable to sequence-defined vehicles, finally 
resulting in improved transduction efficacy in vitro as well as in vivo.   
 
Figure 3 Common topologies of oligomers generated by SPS. A) histidine-rich 3-arm, B) histidine-rich 
shielded 2-arm, C) histidine-rich 4-arm. D)-F) represent fatty acid containing i-shape, T-shape and U-
shapes, respectively. C represents cysteine, H histidine, K lysine and Y tyrosine. HD represents 
hydrophobic domains like aliphatic fatty acids or cholanic acid. TD represents a targeting domain such 
as peptides or small molecules targeting receptors overexpressed on tumor cell surfaces. SD represents 
shielding domains like PEG or (Pro-Ala-Ser) repeats. BD represents the cationic binding domain, in 
sequence-defined oligomers; Gtt glutaryl-triethylene tetramine, Stp succinyl tetraethylene pentamine, 
Gtp glutaryl-tetraethylene pentamine and Sph succinyl pentaethylene hexamine could be introduced, 
however, Stp was introduced mostly.  
 
These findings then were transferred to the previously mentioned PEGylated 2-arm 
topology, resulting in significantly improved in vitro performance, not requiring the 
addition of the endosmolytic reagent chloroquine for successful gene delivery in vitro 
any further [64, 133, 137, 141]. In combination with a histidine-rich non-PEGylated 3-
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arm oligomer these polyplexes even mediated sufficient stability for HGFR directed 
pDNA delivery in vivo [64, 65].  
Within time, the existing histidine-rich 4-arm topology was further improved by the 
introduction of additional lysines between the cationic building blocks and the 
histidines, contributing to enhanced nucleic acid binding with its free - amine. This 
resulted in increased pDNA compaction and improved gene delivery in vitro as well as 
in vivo [142].  
Besides the artificial amino acids and lysine all the above-mentioned topologies 
contained terminal cysteines. These were proven, within the evaluation of the first 
oligomers generated by SPS, to mediate significantly improved polyplex stability, 
resulting in enhanced nucleic acid delivery. An explanation for this is given due to the 
crosslinking abilities of cysteines by forming bioreducible disulfide bonds. Thereby, 
larger cationic chains exhibiting LPEI-like properties were generated within the 
polyplex [134]. The importance of disulfide formation and its characteristics is 
summarized in a review by Klein and Wagner [46], pointing out, that the general toxicity 
of LPEI [143] could be overcome by the assembly of shorter cationic oligomers to 
potent nucleic acid shuttles via disulfide crosslinking. Previous investigations on SPS 
derived oligolysine previously came to similar conclusions [95].   
Fatty acids like oleic acid, myristic acid and other aliphatic acids were introduced to 
generate i-shaped, T-shaped or U-shaped structures (cf. Figure 3D-F) [49, 51, 52] for 
siRNA as well as pDNA delivery. For nucleic acids in general, but especially for siRNA 
delivery, these topologies mediated significantly improved gene delivery in vitro as well 
as in vivo [49]. So far, siRNA delivery with sequence-defined oligomers was only 
partially possible, as polyplexes suffered from the lack of suitable endosomal escape 
domains and instability in vivo. However, oligomers comprising fatty acids, with its 
highly hydrophobic aliphatic chain, mediated the required elevated polyplex stability - 
especially in combination with peripheral cysteines [49]. Also, oligomers equipped with 
fatty acids overcame the lack of endosomal escape, due to the enhanced endosomal 
membrane disrupture facilitated by a pH-dependent lytic activity of the fatty acids at 
endosomal/lysosomal pH [49, 51]. Within these studies, T-shapes with central fatty 
acids, fulfilled the desired properties regarding nucleic acid binding, polyplex size (and 
particle dispersity), gene transfer efficacy and stability in vivo best. Therefore, this 
topology was further optimized by an introduction of a further hydrophobic domain, 
three sequentially coupled tyrosines (tyrosine trimers) at different positions of the 
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oligomer. In a series of experiments, it turned out, that also here, the combination of 
centrally placed fatty acids and terminal cysteines worked best in combination with 
peripheral tyrosine trimers. Nucleic acid delivery and polyplex stability could be further 
improved by increased hydrophobicity as well as - stacking between tyrosines of 
neighbored oligomers, resulting in extended polyplex circulation time and siRNA 
delivery in vivo [52]. The latter could be justified by an additional effect on endosomal 
buffering by the newly introduced tyrosines [52]. Consequently, tyrosine trimers were 
also incorporated into PEGylated 2-arm oligomers [137, 141], suffering from reduced 
polyplex stability mediated by PEGylation [133].   
Recently, the introduction of cholanic acid into T-shaped oligomers mediated notable 
gene knockdown after siRNA delivery in vitro as well as in vivo, while not exhibiting 
lytic activity [111]. These oligomers also comprised a bioreducible disulfide building 
block to destabilize the polyplex after its uptake via GSH mediated endosomal 
cleavage of the central hydrophobic domain. This again resulted in enhanced siRNA 
release from the endosome and increased gene knockdown.  
Besides the above-mentioned major topologies generated by SPS with the artificial 
amino acids, also comb-like oligomers were compared to linear oligomers to 
investigate structure-activity relationships for endosomal buffering, cellular uptake and 
pDNA transduction efficacy dependent on the positioning of the artificial building blocks 
[144].   
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1.1.2.2.1 Polyplex shielding 
During nucleic acid delivery, an excess of the positively charged carrier is usually 
required for nucleic acid complexation. By mixing nucleic acid and cationic carrier, 
nanoparticles with positive surface potential are generated.  
This positive charge offers advantages for the formed polyplexes, as it facilitates 
binding to negatively charged cell surfaces [145, 146] and contributes to endosomal 
escape after cellular uptake [147, 148].  
Putting these positively charged nanoparticles into living organisms, these cationic 
carriers may mediate undesired interactions in the extracellular space. Positively 
charged polyplexes might lead to activation of the complement system, blood cells or 
other blood components [143, 149-151].  
Polyplex surface shielding by introduction of a hydrophilic shielding domain into these 
artificial vectors has shown to reduce these interactions. Polyethylene glycol (PEG), 
with its hydrophilic properties, resulting in good solubility, is the most prominent and 
well-established shielding agent [152]. It has been successfully used for shielding of 
polyplexes in numerous instances, including solid-phase derived oligomers [59, 149, 
153-158].   
Due to reduced extracellular interaction of the polyplex, circulation time within the blood 
and biodistribution to the target tissue may greatly improve [152, 153]. However, its 
non-biodegradability, as well as recently reported formation of anti-PEG antibodies, 
gave reasons for the investigation of alternatives. Therefore, besides PEG, also 
poly(N-(2-hydroxypropyl)methacrylamide) (pHPMA) [142, 159, 160], hydroxyethyl 
starch (HES) [161] and polysarcosine [162] have been investigated as alternative 
hydrophilic shielding agents for polyplex shielding. Within this Ph.D. work, also a 
peptidic sequence composed of Pro-Ala-Ser (PAS) repeats has been examined [133] 
(cf. Figure 4).  
Also, PEGylation may have negative effects on nucleic acid compaction, polyplex 
stability, cellular uptake and endosomal escape of nanoparticles [163-165]. The latter 
can be explained as cationic, PEI-like polyplexes, require a combined effect of osmotic 
endosomal eruption and direct phospholipid destabilization by the cationized vehicle 
for endosomal escape [1, 143, 166]. PEG can obviously interfere with this direct 
cationic membrane destabilization. These negative properties, coming along with the 
favorable effects of PEGylation are often referred to as the “PEG-Dilemma” [167]. 
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Figure 4 Chemical structures of selected reagents used for shielding. A) poly(N-(2-
hydroxypropyl)methacrylamide) (HPMA), B) polyethylene glycol (PEG), C) polysarcosine, D) repetitive 
PAS blocks (Pro-Ala-Ser) 
 
To overcome the disadvantages of PEGylation, several approaches of implementing 
PEG directly during synthesis of the cationic oligomers (referred to as pre-PEGylation) 
as well as after formation of PEG- free polyplexes (referred to as post-PEGylation), 
were investigated.  
1.1.2.2.2 Approaches of pre-PEGylation, post-PEGylation 
Pre-PEGylation of sequence-defined cationic vehicles was greatly improved by 
adaption of PEG in defined repetitions for SPS. Recently, a multifunctionalized 
polyplex, formed with a folate-targeted, pre-PEGylated two arm oligomer was reported 
to mediate siRNA delivery in vivo successfully [135]. However, the used PEG with 
exactly 24 ethylene oxide repetitions was not universally applicable for systemic 
delivery as pointed out by Kos et al. [64]. Here, an HGF directed pDNA polyplex 
composed of a pre-PEGylated, histidine-rich, 2-arm oligomer required an improved 
cation to PEG ratio by co-incubation of a PEG-free histidine-rich 3-arm oligomer to 
obtain pDNA delivery in vivo successfully. Recent studies [32, 133] point out that 
nucleic acid compaction, polyplex size and stability are greatly influenced by this ratio 
between the cationic domain and the hydrophilic shielding domain. These findings 
suggest that synthesis of sequence-defined carriers, directly incorporating PEG as a 
   Introduction 
   27 
shielding domain on the solid support, requires careful consideration of the right chain 
length of PEG.  
In another approach, to avoid difficulties with nucleic acid compaction, non-PEGylated 
polyplexes were first formed and then PEG was introduced by receptor targeted 
PEGylation reagents via different chemical strategies. These approaches can be 
divided into thiol-dependent bioreducible and acid labile routes.  
Post-modification of cationic vehicles with PEG via thiol chemistry was first 
investigated by Blessing et al. on LPEI [168]. The herein used thiol-maleimide 
chemistry was transferred to T-shaped oligomers containing terminal cysteines. By 
addition of folate [169], transferrin [170], or EGF [171] receptor targeted PEGylation 
reagents, polyplexes were successfully shielded and mediated tumor-specific siRNA 
delivery in vitro as well as in vivo.  
Introducing acid labile hydrazone linked PEG onto cationic LPEI polyplexes via NHS 
chemistry was previously investigated by Fella et al. [156], also other pre-PEGylation 
of OEI polymers with acid labile PEG derivates depicted the improved endosomal 
release of polyplexes PEGylated with acid labile reagents [172-174].   
The acid labile post-modification approach has recently been transferred onto pDNA 
polyplexes, composed of sequence-defined oligomers, via an acid labile AzMMan 
linker [142]. Here, post-modification with PEG and HPMA significantly improved 
polyplex stability with a fully recovered transfection efficacy in vitro as well as in vivo 
after cleavage in the acidic tumor environment.  
 
1.1.2.3 Receptor targeting 
Nanoparticles up to a size of 1 µm are taken up by cells via unspecific endocytosis 
[175, 176]. In vivo particles up to 400 nm can accumulate in solid tumors due to 
enhanced permeability and retention (EPR) effect. This is favored, as these cancers 
have a high vascular density and leaky blood vessels [40, 177]. However, an actively 
tumor-targeted nanoparticle delivery not only represents a more elegant but 
sometimes even decisive role in overcoming the PEG dilemma [54, 163, 167]. 
Targeting polyplexes towards tumors is facilitated as cancer cells often overexpress 
receptors, rarely occurring on vivid cells [178-182]. Incorporation of more than one 
targeting ligand can even enhance cellular uptake and thereby help to overcome the 
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previously mentioned PEG-Dilemma [183, 184]. In the following subchapters the two 
growth factor (EGF and HGF) receptors, targeted within different projects of this thesis 
are depicted in more detail. 
 
1.1.2.3.1 HGFR targeting 
The receptor tyrosine kinase HGFR/cMet is over-expressed in epithelial-derived 
tumors as well as in stromal and interstitial cell-derived tumors such as sarcomas [185]. 
When the natural ligand hepatocyte growth factor (HGF) binds to its receptor, cMet, it 
thereby stimulates cell motility and migration, triggers mitogenesis and morphogenesis 
and thus promotes oncogenesis and tumor progression. Therefore, cMet signaling has 
been addressed by different cancer treatment approaches: (1) Antagonists preventing 
binding of HGF to its receptor, (2) cytosolic active tyrosine kinase inhibitors (TKI) as 
well as (3) inhibitors of the downstream cascade after receptor activation have been 
investigated [186]. Therapeutic drug-antibody conjugates have been applied to target 
cMet over-expressing cancer tissues [187]. Also, in vivo imaging by application of 
HGFR specific antibodies [188-190] or two phage display-derived peptides is 
mentioned [181, 191]. Recently, in our laboratory, one of these peptides 
(KSLSRHDHIHHH) was introduced into PEGylated 2- and 4-arm oligomers, mediating 
HGFR specific cellular polyplex uptake as well as in vivo gene delivery of pCMV-Luc 
[64] and pCpG-hCMV-NIS [65]. The latter coding for the human NIS (Natrium Iodide 
Symporter) facilitated application of therapeutic 131I, leading to significantly reduced 
tumor growth and longed survival rate in Huh7 tumor-bearing mice.  
 
1.1.2.3.2 EGFR targeting 
The overexpression of epidermal growth factor receptor (EGFR) offers another well-
established targeting strategy for the specific delivery of polyplexes [61-63, 68, 138, 
192].  
EGFR as a transmembrane receptor tyrosine kinase is involved in cell proliferation, 
survival, adhesion, migration and differentiation [193]. It is overexpressed in bladder, 
cervix, esophagus, head and neck, ovary, breast, endometrium, colon, lung and brain 
[194]. The EGFR has been a target of TKI (Erlotinib and gefitinib) reversibly inhibiting 
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its tyrosine kinase activity, as well as various monoclonal antibodies [180] (e.g. 
cetuximab and panitumumab) inhibiting ligand binding leading to enhanced receptor 
internalization and thereby promoted cytotoxicity [195]. EGFR represents an 
interesting target for the directed delivery of polyplexes. For polyplex targeting, murine 
EGF was successfully applied for LPEI polyplexes [55, 168, 196, 197]. Regarding the 
ratio of cation to targeting ligand, a short peptide offers advantages when used for 
oligomer targeting. Li et al. reported a phage display-derived peptide (GE11) exhibiting 
efficient and specific binding to the EGFR [198]. The hydrophobic GE11 peptide with 
a sequence of YHWYGYTPQNVI revealed less mitogenic activity compared to EGF, 
the original substrate of EGFR. GE11 as a targeting ligand for PEGylated LPEI 
conjugates has been widely explored [61, 62, 68, 192] without inducing receptor 
activation [62]. Mickler et al. investigated uptake mechanisms for EGF-PEG-PEI/pDNA 
and GE11-PEG-PEI/pDNA polyplexes, concluding that GE11 mediated uptake 
happens via more time consuming clathrin-mediated endocytosis, while EGF-PEG-PEI 
polyplexes are promptly taken up by EGFR activated endocytosis. However, the 
delayed, GE11 dependent uptake turned out to be as efficient as the faster EGFR 
activating pathway [68].  
These findings led to the establishment of GE11 as a suitable targeting peptide within 
pre-PEGylated oligoaminoamides, used for a dual targeting approach for pDNA 
delivery [138] and lately as an EGFR targeted PEGylation reagent of bis-oleoyl-
oligoethanamino amides [170] for siRNA delivery. 
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1.2 Aim of the thesis 
The recent development of a solid-phase synthesis platform for the assembly of 
sequence-defined oligo(ethanamino)amides enables quick and easy synthesis of 
cationic oligomers complexing and delivering nucleic acids [131]. By introducing 
artificial amino acids [131], based on the diaminoethane motif of PEI which is well 
known for its nucleic acid binding and endosomal buffering abilities [26], differently 
shaped oligomers were synthesized. Into these oligomers, different functionalities, for 
shielding, polyplex stabilization and targeting can be introduced via SPS.  
As the first aim of this thesis, the effect of different PEG lengths within 2-arm oligomers 
on biophysical properties and their biological performance in vitro as well as in vivo 
were to be investigated, incorporating pDNA as cargo. Also, an alternative to PEG, a 
more hydrophilic shielding motif sequentially comprising the natural amino acids 
proline-alanine-serine (PAS) was to be examined. 2-arm oligomers containing four and 
eight repetitions as shielding domain were to be compared in parallel to the PEGylated 
2-arm oligomers equipped with 12, 24 or 48 EO units. The oligomers generated by 
SPS for this study should contain histidines for improved endosomal buffering [50], and 
cysteines for bioreducible crosslinking via intermolecular disulfide formation. Also, a 
peptide (cmb), mediating HGF dependent polyplex uptake, was to be introduced in a 
set of oligomers.  
The second aim of the thesis was to optimize pDNA delivery via post-modification of 
oligomers after polyplex formation. Firstly, this approach was introduced for pDNA 
polyplexes formed of PEI [168] and later applied for sequence-defined T-shaped 
oligomers for siRNA delivery [169, 170]. Within this study, targeted as well as 
untargeted PEGylation reagents, equipped with either 1 (monovalent) or 2 (bivalent) 
activated cysteines were to be synthesized. To target hepatocellular cancer, the well-
established targeting peptide GE11 was to be chosen and be compared to alanine 
decorated PEGylation reagents. Within this in vitro study, like for siRNA delivery, the 
cysteine-rich T-shaped oligomer 454 turned out to be most promising, facilitating 
conjugation via disulfide exchange between oligomer and PEGylation reagent. 
Successful post-modification as well as EGF dependent delivery and stability of 
454/pDNA polyplexes was to be investigated. 
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The last aim of the thesis, was to examine structure-activity relationship within T-
shaped oligomers, leading to improved candidates for in vivo pDNA delivery of post-
modified polyplexes. The generation of oligomers developed for this study was based 
on oligomer 454 and should address the effect of increased cationic charge (by 
applying 4, 6 or 8 Stp units), the stabilizing effect of peripheral tyrosines (Y3 or Y6) and 
the influence of the fatty compound either oleic acid or cholanic acid. Also, the effect 
of histidines within T-shaped oligomers was to be examined, by either alternating Stp 
and histidines or by generating oligomers with histidine blocks.  
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2 Materials and Methods 
2.1 Materials 
The solvents, reagents and buffers used for the experiments are summarized in Table 
1, Table 2 and Table 3. 
Table 1 Solvents used for experimental procedures 
Solvent CAS-No. Supplier 
Acetonitrile1,11 75-05-8 VWR Int. (Darmstadt, Germany) 
Chloroform2,11 67-66-3 VWR Int. (Darmstadt, Germany) 
Chloroform-d3,11 865-49-6 Euriso-Top (Saint-Aubin Cedex, France) 
Deuterium oxide3 7789-20-0 Euriso-Top (Saint-Aubin Cedex, France) 
Dichloromethane4 75-09-2 Bernd Kraft (Duisburg, Germany) 
N,N-Dimethylformamide5 68-12-2 Iris Biotech (Marktredewitz, Germany) 
Ethanol absolute4,11 64-17-5 VWR Int. (Darmstadt, Germany) 
Ethyl acetate7,11 141-78-6 Staub & Co. (Nürnberg, Germany) 
n-Heptane8,11 142-82-5 Grüssing (Filsum, Germany) 
n-Hexane8 110-54-3 Brenntag (Mülheim/Ruhr, Germany) 
Methanol4 67-56-1 Fisher Scientific (Schwerte, Germany) 
Methyl-tert-butyl ether9 1634-04-4 Brenntag (Mülheim/Ruhr, Germany) 
N-Methyl-2-pyrrolidone5 872-50-4 Iris Biotech (Marktredewitz, Germany) 
Tetrahydrofuran4 109-99-9 Fisher Scientific (Schwerte, Germany) 
Water10 7732-18-5 In-house purification 
 
1 HPLC grade; 2 DAB grade, distilled before use; 3 NMR grade (> 99.9 %); 4 analytical grade; 5 peptide grade; 
6 BioReagent grade (> 99.9 %); 7 purum, distilled before use; 8 purissimum; 9 synthesis grade; 10 purified, deionized; 
11only used within synthesis of Fmoc-Stp(boc)3-OH 
 
Table 2 Reagents used for experimental procedures 
Reagent CAS-No. Supplier 
1-Hydroxybenzotriazole hydrate 123333-53-9 Sigma-Aldrich (Munich, Germany) 
2-Chlorotritylchloride resin 42074-68-0 Iris Biotech (Marktredewitz, Germany) 
5,5′-Dithiobis(2-nitrobenzoic acid) 69-78-3 Sigma-Aldrich (Munich, Germany) 
5β-Cholanic acid 546-18-9 Sigma-Aldrich (Munich, Germany) 
Agarose NEEO Ultra 9012-36-6 Carl Roth (Karlsruhe, Germany) 
Boc-L-Cys(NPys)-OH 76880-29-0 Bachem (Bubendorf, Switzerland) 
Boc-L-Cys(Trt)-OH 21947-98-8 Iris Biotech (Marktredewitz, Germany) 
Bromophenol blue 115-39-9 Sigma-Aldrich (Munich, Germany) 
Chloroquine diphosphate 50-63-5 Sigma-Aldrich (Munich, Germany) 
4′,6-Diamidin-2-phenylindol (DAPI) 28718-90-3 Sigma-Aldrich (Munich, Germany) 
D-(+)-Glucose monohydrate 14431-43-7 Merck Millipore (Darmstadt, Germany) 
DBU 6674-22-2 Sigma-Aldrich (Munich, Germany) 
Dde-L-Lys(Fmoc)-OH 156648-40-7 Iris Biotech (Marktredewitz, Germany) 
EDTA disodium salt dihydrate 6381-92-6 Sigma-Aldrich (Munich, Germany) 
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Reagent CAS-No. Supplier 
Ethidium bromide  1239-45-8 Sigma-Aldrich (Munich, Germany) 
Fmoc-L-Asn(Trt)-OH 132388-59-1 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Arg(Pbf)-OH 154445-77-9 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Cys(Trt)-OH 103213-32-7 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Gln(Trt)-OH 132327-80-1 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Gly-OH 29022-11-5 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-His(Trt)-OH 109425-51-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Ile-OH 71989-23-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Leu-OH 35661-60-0 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Lys(Boc)-OH 71989-26-9 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Lys(Fmoc)-OH 78081-87-5 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Lys(Dde)-OH 204777-78-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Pro-OH 71989-31-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Ser(tBu)-OH 71989-33-8 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Thr-OH 73731-37-0 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Trp(Boc)-OH 43824-78-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Tyr(tBu)-OH 71989-38-3 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Val-OH 68858-20-8 Iris Biotech (Marktredewitz, Germany) 
Fmoc-N-amido-dPEG12-acid 756526-01-9 Quanta Biodesign (Powell, Ohio, USA) 
Fmoc-N-amido-dPEG24-acid 756526-01-9 Quanta Biodesign (Powell, Ohio, USA) 
Fmoc-OSu 82911-69-1 Iris Biotech (Marktredewitz, Germany) 
Fmoc-STODTA-OH 172089-14-4 Sigma-Aldrich (Munich, Germany) 
Fmoc-Stp(Boc3)-OH - In-house synthesis [131, 199] 
GelRed - Biotium Inc. (Hayward, CA, USA) 
HBTU 94790-37-1 Multisyntech (Witten, Germany) 
Heparin sodium 5000 I.E/mL 9041-08-1 ratiopharm GmbH (Ulm,.Germany) 
HEPES 7365-45-9 Biomol (Hamburg, Germany) 
Hydrazine monohydrate 7803-57-8 Merck Millipore (Darmstadt, Germany) 
Hydrochloric acid solution (1 M) 7647-01-0 Sigma-Aldrich (Munich, Germany) 
LPEI 9002-98-6 In-house synthesis [197] 
MTT 298-93-1 Sigma-Aldrich (Munich, Germany) 
N,N-Diisopropylethylamine 7087-68-5 Iris Biotech (Marktredewitz, Germany) 
Ninhydrin 485-47-2 Sigma-Aldrich (Munich, Germany) 
Oleic acid 112-80-1 Sigma-Aldrich (Munich, Germany) 
Phenol 108-95-2 Sigma-Aldrich (Munich, Germany) 
Piperidine 110-89-4 Iris Biotech (Marktredewitz, Germany) 
Potassium cyanide 151-50-8 Sigma-Aldrich (Munich, Germany) 
Propodium Iodide (PI) 25535-16-4 Sigma-Aldrich (Munich, Germany) 
PyBOP® 128625-52-5 Multisyntech GmbH (Witten, Germany) 
Sephadex® G-10 9050-68-4 GE Healthcare (Freiburg, Germany) 
Sodium hydroxide (anhydrous) 1310-73-2 Sigma-Aldrich (Munich, Germany) 
Succinic anhydride 108-30-5 Sigma-Aldrich (Munich, Germany) 
Tetraethylene pentamine 5*HCl 4961-41-5 Sigma-Aldrich (Munich, Germany) 
Triethylamine 121-44-8 Sigma-Aldrich (Munich, Germany) 
Trifluoroacetic acid 76-05-1 Iris Biotech (Marktredewitz, Germany) 
Triisopropylsilane 6485-79-6 Sigma-Aldrich (Munich, Germany) 
Triton™ X-100 9002-93-1 Sigma-Aldrich (Munich, Germany) 
Trizma® base 77-86-1 Sigma-Aldrich (Munich, Germany) 
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Table 3 Buffers used for experimental procedures 
Buffer Composition 
10 mM HCl SEC solvent 693 mL water, 300 mL acetonitrile, 7 mL 1M HCl 
solution 
Electrophoresis loading buffer 6 mL glycerine, 1.2 mL 0.5 M EDTA solution (pH 8.0), 
2.8 mL H2O, 20 mg bromophenol blue 
Ellman buffer 0.1 M sodium phosphate buffer (pH 8.0), 1 mM EDTA 
HBG 20 mM HEPES, 5 % glucose, pH 7.4 
TBE buffer 89 mM Trizma® base, 89 mM boric acid, 2 mM EDTA-
Na2 
 
Citrate-buffered erythrocytes for erythrocyte adhesion assays were kindly provided by 
Klinikum der Universität München, Großhadern (Munich, Germany). 
 
2.1.1 Equipment for solid-phase synthesis  
Automated parallel synthesis or synthesis supported with microwave irradiation was 
carried out using a Biotage Syro Wave (Biotage, Uppsala, Sweden) peptide 
synthesizer. Disposable polypropylene (PP) syringe microreactors with the volume 
sizes 2 mL, 5 mL, and 10 mL were purchased from Multisyntech (Witten, Germany). It 
was conducted with polytetrafluoroethylene (PTFE) filters. The recommended size of 
the reactors was chosen according to the amount of resin. For manual solid-phase 
synthesis microreactors with polyethylene filters (Multisyntech, Witten, Germany) were 
used. Reactions were carried out under steady shaking with an overhead shaker. 
 
2.1.2 Plasmid DNA  
The plasmid pCMVLuc (encoding for firefly luciferase under control of the CMV 
promoter) was purchased from Plasmid Factory (Bielefeld, Germany). The 
concentration of nucleic acid solutions was determined photometrically using an 
Eppendorf BioPhotometer (Eppendorf, Hamburg, Germany). Cy5-labeled nucleic 
acids were produced with a Cy5-labelling kit obtained from Mirus Bio (Madison, WI, 
USA). 
The plasmid pCpG-hCMV-NIS (human NIS plasmid DNA driven by the human 
elongation factor 1α promotor and human cytomegalovirus enhancer element) was 
prepared by Plasmid Factory (Bielefeld, Germany) as of a concentration of 1 mg/mL.  
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2.1.3 Cell culture  
Cell culture work was carried out by Sarah Urnauer (Klinikum der Universität München, 
AG Spitzweg) and Ana Krhac Levacic, (Pharmaceutical Biotechnology, LMU). Cell 
culture media, antibiotics and fetal bovine serum (FBS) were purchased from 
Invitrogen (Karlsruhe, Germany) or Sigma Aldrich (Munich, Germany). The individual 
media used for the different cell cultures are summarized in Table 4. All media were 
supplemented with 10 % FBS, 4 mM stable glutamine, 100 U/mL penicillin and 100 
μg/mL streptomycin. Cell lines were cultured at 37 °C and 5 % CO2 in an incubator 
with a relative humidity of 95 %.  
Exponentially growing cells were detached from the culture flasks using Millipore 
water, supplemented with 0.05 % trypsin-EDTA (Invitrogen, Karlsruhe, Germany), 
followed by resuspension in the required culture media. Cell suspensions were seeded 
at the desired density for each experiment. Luciferase cell culture lysis buffer and D-
luciferin sodium salt were purchased from Promega (Mannheim, Germany). 
 
Table 4 Overview of the used cell lines and corresponding culture media 
Cell line Description Medium 
Neuro2A Mouse neuroblastoma cells DMEM, low glucose 
DU145 Human prostate cancer cells RPMI-1640 
Huh7 Human hepatocellular carcinoma cells DMEM, low glucose 
MCF7 Human breast cancer cells DMEM, high glucose 
FTC-133 Human follicular thyroid carcinoma cells DMEM/F12 (50:50) 
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2.2 Methods 
2.2.1 Synthesis of oligomers and PEGylation reagents via solid phase 
synthesis (SPS) 
2.2.1.1 General procedure for solid phase synthesis (SPS) 
2.2.1.1.1 Loading of a 2-chlorotrityl chloride resin with an Fmoc protected amino 
acid 
After swelling 750 mg of a 2-chlorotrityl chloride resin (1.2 mmol chloride) in dry DCM 
for 10 min, the first Fmoc protected amino acid (T-shape: 0.3 eq. Fmoc-L-Cys(Trt)-OH; 
3-arm: 0.3 eq. Fmoc-L-Cys(Trt)-OH or Fmoc-L-Lys(Dde)-OH; untargeted PEG/PAS 
shielded 2-arm: 0.4 eq. Dde-L-Lys(fmoc)-OH; targeted 2-arm: 0.2 eq. Fmoc-L-
Lys(Dde)-OH (cmb) or 0.3 eq. Fmoc-L-Ile-OH (GE11); GE11 targeted PEGylation 
reagents: 0.3 eq. Fmoc-L-Ile-OH and a threefold molar excess of DIPEA over Fmoc 
protected amino acid were added to the resin for 1 h. The reaction solvent was drained 
and a mixture of DCM/MeOH/DIPEA (80/15/5) was added for at least 30 min. After the 
removal of the reaction mixture, the resin was washed with DMF and DCM 5 times 
each. 
About 30 mg of the resin were removed and dried to determine the loading of the resin. 
Therefore, an exact amount of resin was treated with 1 mL deprotection solution (20 % 
piperidine in DMF) for 1 h. Afterwards, the solution was diluted and absorption was 
measured at 301 nm. The loading was then calculated according to the equation: resin 
load [mmol/g] = (A*1000)/(m [mg]*7800*df) with df as dilution factor. 
The resin was treated twice with 20 % piperidine in DMF and twice with 20 % piperidine 
and 2 % DBU in DMF to remove the Fmoc protection group. Reaction progress was 
monitored by Kaiser test (cf. 2.2.1.1.3). Afterwards, the resin was washed with DMF, 
DCM and n-hexane and dried in vacuo. 
2.2.1.1.2 Procedure of a manually conducted solid phase synthesis 
After amino acid (AA) loading and Fmoc removal (cf. 2.2.1.1.1), the synthesis was 
continued in a defined matter as a repetitive cycle to obtain the desired oligomer or 
PEGylation reagent. First the deprotected peptide resin is preswelled in 10 mL/g resin 
DCM. Then coupling of the Fmoc protected amino acids is performed with a fourfold 
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excess (based on the quantity of free amines) whilst an identical excess of HOBt and 
PyBOP was used for preactivation. DIPEA was added with an eightfold excess (also 
related to free amines). HOBt and PyBOP were dissolved in 5 mL of DMF/g of resin 
and the Fmoc protected amino acid was dissolved in 5 mL of DCM/g of resin. The 
corresponding amount of DIPEA was added, the solutions are mixed for preactivation 
and added to the resin. Routinely coupling time was chosen as 1 h, using an overhead 
shaker for steady shaking. After each coupling step (as well as after each step of 
deprotection), three washes with DMF and with DCM (10 mL/g of resin) were carried 
out. 20 % (v/v) piperidine/DMF was applied for Fmoc-removal four times per 10 min by 
default (10 mL/g resin). Coupling and deprotection were verified by testing for free 
amines qualitatively using Kaiser test (cf. 2.2.1.1.3). If the result was unsatisfying the 
previous coupling or deprotection step was repeated. After a completed cycle (coupling 
and deprotection, with washing steps in between), the prodecure was repeated until 
the desired oligomer is obtained. After the last coupling, the resin was dried and 
cleavage conducted (cf. 2.2.1.2). Synthesis conditions for manual synthesis are 
summarized in Table 5 and synthesis is displayed schematically in Scheme 2 
 
Table 5 General steps of a manually conducted synthesis cycle 
Step Description Solvent Volume Time 
1  Coupling DCM/DMF 50/50 10 mL/g resin 60 min 
2  Wash DMF and DCM 10 mL/g resin 3 x 1 min each 
3  Kaiser test - - - 
4  Fmoc deprotection 20 % piperidine/DMF 10 mL/g resin 4 x 10 min 
5  Wash DMF and DCM 10 mL/g resin 3 x 1 min each 
6  Kaiser test - - - 
 
 
 
Scheme 2 Illustration of a manually conducted SPS cycle 
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2.2.1.1.3 Kaiser test 
Free amines of deprotected amino acids on the resin were determined qualitatively by 
the Kaiser test [130]. Therefore, a small sample of DCM washed resin was transferred 
into an Eppendorf reaction tube. One drop of each 80 % phenol in EtOH (w/v), 5 % 
ninhydrin in EtOH (w/v) and 20 μM potassium cyanide (KCN) in pyridine (mixture of 1 
mL aqueous 0.001 M KCN solution and 49 mL pyridine) were added. The tube was 
incubated at 99 °C for 4 min under shaking. A deep blue color indicated the presence 
of free amines. 
 
2.2.1.1.4 Procedure of an automated solid phase synthesis 
After amino acid loading and Fmoc removal (cf. 2.2.1.1.1), automated synthesis also 
follows a repetitive cycle of coupling, washing, deprotection, washing after the 
deprotected resin is preswelled. Nevertheless, compared to manual synthesis, several 
steps required optimization. Firstly, during automated synthesis, all washing steps 
were conducted with the system liquid DMF (5 × 1 min). Also, within automated 
synthesis, special reactors had to be used (cf. 2.1.1) and DCM, as a volatile solvent, 
was replaced by NMP. During coupling, PyBOP® was replaced by HBTU, providing 
improved stability of the activation reagent in solution within syntheses. Since the 
automated synthesis does not offer the opportunity to separate resin samples for the 
Kaiser test, improved coupling conditions and extended deprotection steps were 
applied. Briefly, during automated synthesis, coupling steps were conducted in double 
(tech. double couplings) prior to washing and Fmoc removal due to the lack of control. 
Within microwave assisted synthesis, thus the coupling solution was applied twice for 
12°min at 50 °C and during automated parallel synthesis twice for 60 min at RT. 
Reagents were prepared as followed, calculated per AA on the resin: 4 eq. of amino 
acid, dissolved together with 4 eq. of HOBt in NMP, 4 eq. of activation reagent (HBTU) 
dissolved in DMF, and 8 eq. of DIPEA in NMP were set up in separate bottles. Also, 
the amino acid solutions were supplemented with Triton X-100, leading to a final 
concentration of 1 % (v/v), when applied to the resin. Double coupling of Boc-L-
Cys(Trt)-OH was conducted at room temperature for 60 min in all synthesis to avoid 
racematization. Deprotection was carried out with 40 % piperidine/DMF, supplemented 
with 1 % Triton X-100, for 5 × 10 min. 
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Synthesis conditions for automated synthesis are summarized in Table 6 and are 
schematically displayed in Scheme 3. 
 
Table 6 General steps of an automated synthesis cycle using the Biotage Syro Wave synthesizer 
Step Description Solvent Volume Time 
1  
Coupling NMP/DMF 5 mL/g resin 
60 min at RT 
or 
12 min at 50 °C 
Wash DMF 8 mL/g resin 2 x 1 min 
Recoupling NMP/DMF 5 mL/g resin 
60 min at RT 
or 
12 min at 50 °C 
2  Wash DMF 8 mL/g resin 5 x 1 min 
3  Fmoc deprotection 40 % piperidine/DMF 7 mL/g resin 5 x 10 min 
4  Wash DMF 8 mL/g resin 5 x 1 min 
 
 
 
Scheme 3 Illustration of an automated synthesis using the Biotage Syro Wave synthesizer 
 
2.2.1.2 Cleavage of oligomers and reagents 
2.2.1.2.1 General cleavage of oligomers  
This protocol was applied for all 2-arm, 3-arm oligomers and T-shaped oligomers 
containing cholanic acid. Oligomers were cleaved off the resin by incubation with TFA–
EDT–H2O–TIS (94 : 2.5 : 2.5 : 1.0; 10 mL g−1 resin) for 90 min. The cleavage solution 
was concentrated by flushing nitrogen and oligomers were precipitated in 50 mL of pre-
cooled MTBE–n-hexane (1 : 1). All oligomers were purified by size exclusion 
chromatography (SEC) using an Äkta purifier system (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden), a Sephadex G-10 column and 10 mM hydrochloric acid 
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solution–acetonitrile (7 : 3) as solvent. The relevant fractions were lyophilized, 
obtaining HCl salts of all oligomers.  
2.2.1.2.2 Cleavage of oligomers containing oleic acid 
The cleavage of t-shape oligomers containing oleic acid off the resin require an 
optimized protocol [200]. Therefore a mixture of TFA–EDT–H2O–TIS 
(94 : 2.5 : 2.5 : 1.0; 10 mL g−1 resin cooled to 4 °C prior to addition) was applied for 
30 min, followed by immediate precipitation in 50 mL of pre-cooled MTBE–n-hexane 
(1 : 1). The oleic acid containing oligomers were then purified by SEC without further 
delay. A Äkta purifier system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), a 
Sephadex G-10 column and 10 mM hydrochloric acid solution–acetonitrile (7 : 3) as 
solvent were used. The relevant fractions were lyophilized, obtaining HCl salts of all 
oligomers. 
2.2.1.2.3 Cleavage of NPys containing PEGylation reagents 
The cleavage of the structures off the resin was performed by incubating the dried resin 
with TFA–TIS–H2O (95 : 2.5 : 2.5) for 90 min followed by immediate precipitation in 50 
mL of pre-cooled MTBE–n-hexane (1 : 1). Purification was conducted with SEC, using 
a Äkta purifier system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), a 
Sephadex G-10 column and 10 mM hydrochloric acid solution–acetonitrile (7 : 3) as 
solvent. The relevant fractions were lyophilized, obtaining HCl salts of all PEGylation 
reagents. 
 
2.2.1.3 Synthesis of oligomers  
Unless mentioned otherwise, oligomers were synthesized using a 2-chlorotrityl resin 
preloaded with the first C-terminal amino acid of the respective topology (cf. 2.2.1.1.1) 
as solid support. All sequences and topologies of oligomers can be found in Table 21. 
 
2.2.1.3.1 Synthesis of untargeted, PEGylated 2-arm oligomers  
(Oligomers 1088,1091,1120) 
PEGylated two-arm oligomers with a C-terminal lysine, exhibiting a positive net charge 
and serving as a substitute for the targeting ligand cmb, were synthesized in 0.02 mmol 
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scale on a 2-chlorotrityl chloride resin, preloaded with Dde-L-Lys(fmoc)-OH. Fmoc was 
removed, as described in 2.2.1.1.1, prior to synthesis. To reduce costs, coupling of 
Fmoc-N-amido-dPEG12/24-OH was carried out manually by adding the reagents 
dissolved in NMP/DMF and applying microwave irradiation for 50 °C for 12 min. After 
washing five times for one min, a Kaiser test has been performed. The peptides were 
placed separately into the automated peptide synthesizer, starting with a deprotection 
step. From now on synthesis was conducted with microwave irradiation as described 
in 2.2.1.1.4. Fmoc-L-His(Trt)-OH, Fmoc-L-Lys(Fmoc)-OH, Fmoc-L-His(Trt)-OH, Fmoc-
L-Lys(Fmoc)-OH, Fmoc-Stp(Boc)3-OH [131, 199] and Boc-L-Cys(Trt)-OH were 
attached in the order as described in Table 21. Prior to cleavage, the Dde group 
protecting the - amine of the C-terminal lysine was removed by 15 cycles of 4 % 
hydrazine in DMF (v/v) for 3 min each. After a final washing step, the resins, now 
containing the completed oligomers, were dried and cleavage was conducted as 
described in 2.2.1.2.1. 
 
2.2.1.3.2 Synthesis of untargeted 2-arm oligomers containing Pro-Ala-Ser 
repeats  
(Oligomers 1094, 1097) 
Two-arm oligomers containing Pro-Ala-Ser repeats with a C-terminal lysine, exhibiting 
a positive net charge and serving as a substitute for the targeting ligand cmb, were 
synthesized in 0.02 mmol scale on a 2-chlorotrityl chloride resin, preloaded with Dde-
L-Lys(fmoc)-OH. Fmoc was removed, as described in 2.2.1.1.1, prior to synthesis. 
Fmoc-Ser(tBu)-OH, Fmoc-Ala-OH and Fmoc-Pro-OH (from now on called PAS) were 
attached sequentially, with four or eight triple sequence repeats (PAS4, PAS8) by 
automated, microwave assisted synthesis (cf. 2.2.1.1.4). After an analytical cleavage, 
MALDI-TOF mass spectroscopy was carried out, verifying the correct sequence. Next, 
the peptides were placed separately into the automated peptide synthesizer, starting 
with a deprotection step. From now on synthesis was conducted with microwave 
irradiation as described in 2.2.1.1.4. Fmoc-L-His(Trt)-OH, Fmoc-L-Lys(Fmoc)-OH, 
Fmoc-Stp(Boc)3-OH [131, 199] and Boc-L-Cys(Trt)-OH were coupled in the order as 
described in Table 21. Prior to cleavage, the Dde group protecting the - amine of the 
C-terminal lysine was removed by 15 cycles of 4 % hydrazine in DMF (v/v) for 3 min 
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each. After a final washing step, the resins, now containing the completed oligomers, 
were dried and cleavage was conducted as described in 2.2.1.2.1.  
 
2.2.1.3.3 Synthesis of untargeted 3-arm oligomer  
(Oligomer 689) 
In the case of non-shielded three-arm oligomer, a Cys(Trt)-OH preloaded 2-chlorotrityl 
resin was used and automated microwave-assisted synthesis (cf. 2.2.1.1.4) was 
carried out to obtain the sequence mentioned in Table 21. 
 
2.2.1.3.4 Synthesis of cmb containing two and 3-arm oligomers  
(Oligomers 442, 694, 901, 996, 1000, 1078) 
For hepatocyte growth factor (HGF) receptor/cMet targeted delivery, oligomers 
containing a cMet binding peptide (cmb) were synthesized. Chlorotrityl chloride resin 
preloaded with Fmoc-Lys(Dde)-OH was used for the synthesis of 2 x 0.1 mmol. After 
Fmoc removal with 5 times 20% piperidine, and a Kaiser test for verification of the 
deprotection, the cmb ligand (KSLSRHDHIHHH) was synthesized with a Syro Wave 
(Biotage, Uppsala, Sweden), following the synthesis protocol as previously described 
in 2.2.1.1.4. The terminal lysine was bocylated with 10 eq. Di-tert-butyldicarbonate and 
20 eq DIPEA in NMP for 60 min to terminate synthesis at this arm of the lysine. After 
this coupling, an analytical cleavage (cf. 2.2.1.2.1) of a small fraction for MALDI-TOF 
mass spectroscopy was done to verify the identity of the peptide (cf. 6.5.2). 
Then Dde deprotection at the side chain was conducted with 15 cycles of 4 % 
hydrazine in DMF (v/v) for 3 min each. For the cmb targeted oligomers containing 
PEG12, PEG24, and PEG48 either Fmoc-N-amido-dPEG12-OH or Fmoc-N-amido-
dPEG24-OH was attached onto the previously freed - amine of the C-terminal lysine 
as described previously in 2.2.1.3.1. PAS4 or PAS8 was attached onto the previously 
freed - amine of the C-terminal lysine by successive coupling of (Fmoc-L-Ser(tBu)-
OH, Fmoc-L-Ala-OH and Fmoc-L-Pro-OH) repetitively four or eight times. Again, the 
Syro Wave, applying microwave irradiation (cf. 2.2.1.1.4) was chosen due to 
complexity of the sequence. Afterwards, all resins were placed separately into the 
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microwave cavity of the Syro Wave automated synthesizer and the cationic backbone 
again was built with Fmoc-L-His(Trt)-OH, Fmoc-L-Lys(Fmoc)-OH, Fmoc-Stp(Boc)3-OH 
performing double couplings. The sequence then was terminated with a double 
coupling of Boc-L-Cys(Trt)-OH for 1 h per coupling at room temperature. Instead of a 
hydrophilic shielding block, cmb-3-arm was built of three cationic arms containing 
alternating Fmoc-L-His(Trt)-OH, Fmoc-Stp(Boc)3-OH, Fmoc-L-Lys(Fmoc)-OH, and 
was terminated by coupling Boc-L-Cys(Trt)-OH at room temperature. Synthesis 
followed the same coupling procedure as of the 3-arm (689), with the only difference 
that the C-terminal arm was not started with a Fmoc-L-Cys(Trt)-OH, but was attached 
to the H2N-cmb-K, previously synthesized on the solid support. The exact sequences 
can be found in Table 21 and deprotected oligomers were obtained after cleavage, 
following the standard protocol (cf. 2.2.1.2.1). 
 
2.2.1.3.5 Synthesis of PEGylated 2-arm oligomers with GE11 ligand and alanine 
(Oligomers 835 and 440) 
Synthesis of GE11 targeting peptide (YHWYGYTPQNVI) was carried out on a resin 
preloaded with Fmoc-L-Ile-OH. The peptide sequence was assembled with an 
automated Syro Wave peptide synthesizer equipped with a microwave cavity (cf. 
2.2.1.1.4) in 0.1 mmol scale size. After the last coupling cycle, an analytical cleavage 
(cf. 2.2.1.2.1) of a small fraction for MALDI-TOF mass spectroscopy and HPLC was 
done to verify identity and purity of the peptide. 
Then oligomer synthesis was carried out. In case of oligomer 440 0.02 mmol of a 
commercially available Wang resin, preloaded with Fmoc-L-Ala-OH low-loaded (LL) 
was deprotected as described in 2.2.1.1.1. In case of 835, 0.02mmol of the GE11 
peptide loaded resin (prepared as described above) was used. As coupling of Fmoc-
N-amido-dPEG24-OH represents a crucial step in synthesis, this step was conducted 
manually, and successful coupling and deprotection was monitored by Kaiser test (cf. 
2.2.1.1.3). Coupling was performed manually for 1 h under steady shaking with 4 eq of 
PyBOP, 8 eq of DIPEA, 4 eq of HOBt and 4 eq of Fmoc-N-amido-dPEG24-acid 
dissolved in 50:50 (v/v) of DCM/DMF. Deprotection was performed as described before 
by addition of 40% piperidine in DMF (v/v) for 5 × 10 min (cf. 2.2.1.1.2). Then both 
reactors were placed in the automated Syro Wave peptide synthesizer and cationic 
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backbones were synthesized in parallel. Reagents were prepared as for synthesis of 
GE11 and double couplings were performed at room temperature for 1 h each. First 
Fmoc-L-His(Trt)-OH, followed by Fmoc-L-Lys(Fmoc)-OH, was attached. Fmoc-L-
His(Trt) and our novel building block Fmoc-Stp(boc)3-OH were attached alternately 
four times, leading to five histidines and four Stp units. Synthesis was terminated by 
coupling of Boc-L-Cys(Trt)-OH. The exact sequences can be found in Table 21 and 
deprotected oligomers were obtained after cleavage, following the standard protocol 
(cf. 2.2.1.2.1). 
 
2.2.1.3.6 Synthesis of the T-shaped lipo-oligomer for post-modification 
(Oligomer 454) 
Oligomer 454 was synthesized on a 2-chlorotrityl chloride resin preloaded with Fmoc-
L-Cys(Trt)-OH. The resin was placed in the microwave cavity of the Syro Wave peptide 
synthesizer. The cationic backbone, was attached using the protocol described in 
2.2.1.1.4. First Fmoc-L-Tyr(tBu)-OH was coupled three times, then the artificial amino 
acid Fmoc-Stp(boc)3-OH was coupled twice. Fmoc-L-Lys(Dde)-OH served as a mirror 
axis so again two Fmoc-Stp(boc)3-OH and three times Fmoc-L-Tyr(tBu)-OH were 
coupled. Coupling of Boc-L-Cys(Trt)-OH at room temperature for 2 x 1 h terminated 
the cationic backbone. To introduce the hydrophobic domains, Dde removal was 
conducted with 4 % hydrazine in DMF (v/v) for 15 cycles lasting 3 min each. Then 
Fmoc-L-Lys(Fmoc)-OH was coupled for symmetrical branching prior to attaching oleic 
acid on both arms. The deprotected oligomer was obtained after cleavage, following 
the protocol for oleic acids (cf. 2.2.1.2.2). 
 
2.2.1.3.7 Synthesis of improved T-shaped lipo-oligomers  
(Oligomers 1021-1024, 1026, 1173-1180)  
All oligomers were synthesized on a 2-chlorotrityl chloride resin preloaded with Fmoc-
L-Cys(Trt)-OH. After Fmoc deprotection, the cationic backbones C-Y3-Stp2-K(Dde)-
Stp2-Y3-C (1021), C-Y6-Stp2-K(Dde)-Stp2-Y6-C (1173,1174), C-Y3-Stp3-K(Dde)-Stp3-
Y3-C (1022, 1023), C-Y3-Stp4-K(Dde)-Stp4-Y3-C (1175, 1176), C-Y3-(H-Stp)2-H-
K(Dde)-H-(Stp-H)2-Y3-C (1024), C-Y3-H3-Stp2-K(Dde)-Stp2-H3-Y3-C (1026) were 
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synthesized in a scale size of 0.04 mmol each, within the parallel block of the Syro 
Wave automated synthesizer. Double couplings at room temperature, following the 
protocol described in 2.2.1.1.2, were conducted to obtain the cationic backbones. 
Small amounts of resin were separated and cleaved of the resin for analysis with 
MALDI-TOF mass spectroscopy. For synthesis of the more complex backbones  
C-Y6-Stp4-K(Dde)-Stp4-Y6-C (1177,1178), C-Y3-(H-Stp)4-H-K(Dde)-H-(Stp-H)4-Y3-C 
(1179) and C-Y3-H5-Stp4-K(Dde)-Stp4-H5-Y3-C (1180) 0.04 mmol of a deprotected 2-
chlorotrityl chloride resin, preloaded with Fmoc-L-Cys(Trt)-OH, were each placed 
separately into the microwave cavity of the Syro wave synthesizer and double 
couplings were performed according to 2.2.1.1.4. Also here, small amounts of resin 
were separated and the backbones were cleaved of the resin for analysis of MALDI-
TOF mass spectroscopy. 
Then all reactors were placed in the parallel block of the Syro Wave peptide 
synthesizer and automated Dde removal was conducted with 4 % hydrazine in DMF 
(v/v) for 15 cycles lasting 3 min each. Next, Fmoc-L-Lys(Fmoc)-OH was coupled for 
symmetrical branching at room temperature applying double couplings and Fmoc was 
removed with 40 % piperidine in DMF (v/v), followed by a Kaiser test (cf. 2.2.1.1.3) 
after washing each resin with DMF for 5 × 1 min. At this point, resins were split into 
two. Reactors for manual synthesis (containing 0.02 mmol each) were chosen and 
either oleic acid or cholanic acid (4 eq. per free amine) was attached, applying 
conditions for manual coupling (cf. 2.2.1.1.2). A negative Kaiser test verified successful 
coupling and termination of the syntheses. The resins were dried and either general 
cleavage conditions for cholanic acid containing oligomers (1021, 1023, 1174, 1176, 
1178) or optimized cleavage conditions for oleic acid containing oligomers (1022, 
1024, 1026, 1173, 1175, 1177, 1179, 1180), followed by SEC, were applied. For more 
details see 2.2.1.2.1 or 2.2.1.2.2 respectively. 
 
2.2.1.4 Synthesis of PEGylation reagents for polyplex post-modification 
All sequences of PEGylation reagents can be found in Table 22, unless stated 
otherwise. Coupling steps were carried out manually using 4 eq. Fmoc-amino acid, 
4 eq. HOBt, 4 eq. PyBOP® and 8 eq. DIPEA (10 mL g−1 resin) per free amine for 60 
min at room temperature under steady shaking. General steps within manual synthesis 
are summarized in Table 5 and explained in detail in 2.2.1.1.2.  
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2.2.1.4.1 Synthesis of monovalent PEGylation reagents.  
Monovalent PEGylation reagents were either synthesized on a deprotected, 
commercially available, preloaded Ala-Wang resin (for the Ala control reagent) or were 
attached to GE11 previously assembled on the solid support as described above (cf. 
2.2.1.3.5). Reaction scale size was chosen as 0.02 mmol. First Fmoc-N-amido-
dPEG24-acid was coupled onto both resins followed by Boc-L-Cys(Npys). The resins 
were dried under high vacuum and then cleavage was conducted following the 
cleavage protocol for NPys containing PEGylation reagents (cf. 2.2.1.2.3). 
 
2.2.1.4.2 Synthesis of bivalent PEGylation reagents 
As described for the monovalent PEGylation reagents, either a commercially available, 
preloaded Ala-Wang resin (for the Ala control reagent) or a 2-chlorotrityl chloride resin, 
containing the previously synthesized GE11 ligand was used. Scale size was here 
chosen between 0.02 and 0.035 mmol. First Fmoc-N-amido-dPEG24-acid was coupled 
onto both resins followed by Fmoc-L-Lys(Fmoc)-OH was attached onto the resins 
manually. After Fmoc deprotection, STOTDA was introduced as a short spacer before 
terminating the sequence by coupling of Boc-L-Cys(NPys)-OH. Finally, resins were 
dried under high vacuum and cleavage was conducted following the cleavage protocol 
for NPys containing PEGylation reagents (cf. 2.2.1.2.3). 
 
2.2.2 pDNA polyplex formation 
Nucleic acid and oligomers were dissolved at concentrated stock solutions in water, 
and diluted with 20 mM HEPES buffered 5 % glucose pH 7.4 (HBG). pDNA and 
oligomer were prepared in separate tubes. According to the indicated 
nitrogen/phosphate (N/P) ratio, oligomer solutions were prepared and the same 
volume of diluted pDNA was added to the oligomer. Only protonatable nitrogens were 
considered in the N/P calculations (cf. Table 21). The mixture was rapidly pipetted 15 × 
and incubated for at least 30 min at room temperature (RT). 
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2.2.2.1 Post-modification with PEGylation reagents 
For post-modifiying pDNA polyplexes with mono- or bivalent PEGylation reagents, 
pDNA and oligomers were mixed at N/P 12 (unless stated elsewhere) and incubated 
for 30 min to form the core polyplex. Then PEGylation reagents were added, the 
polyplex solution was gently mixed and further incubated for 15 min. Amounts of 
PEGylation reagents were calculated as molar eq per –SH in the T-shaped lipo-
oligomers. 
 
2.2.3 pDNA binding assays 
A 1 % agarose gel for pDNA analyses was prepared by dissolving agarose in TBE 
buffer (Trizma base 10.8 g, boric acid 5.5 g, disodium EDTA 0.75 g, and 1 L of water) 
and boiled up to 100 °C. After cooling down to about 50 °C and addition of GelRed™ 
(Biotum, Hayward, U.S.A.), the agarose gel was casted in the electrophoresis unit. 
Polyplexes prepared with 200 ng pDNA were formed as described at indicated N/P 
ratios and placed into the sample pockets after addition of 4 μL of loading buffer 
(prepared from 6 mL of glycerine, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 0.02 g of 
bromophenol blue). Electrophoresis was performed at 120 V for 80 min. 
 
2.2.4 Particle size and zeta potential 
Particle size and zeta potential of polyplexes were measured by dynamic laser-light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, 
UK). 2 µg pDNA was diluted to 30 µL in HBG and was added to an amount of oligomers 
corresponding to N/P 12 prepared in 30 µL HBG. After rapid mixing, polyplexes were 
incubated for 30 min at RT. In case of post-modification, 0.5 or 1.0 eq of PEGylation 
reagents were added and further incubated at RT for 15 min. Then 740 µL of 10 mM 
sodium chloride solution (pH 7.4) was added to all samples and particle size and zeta 
potential was measured. Results were plotted as Z-Average (DH in nm) and SD out of 
three runs with 12 sub-runs each. Zeta potential (ZP) is displayed as average (mV) of 
three runs with up to 15 sub-runs each. For size measurements, the equilibration time 
was 0 min, the temperature was 25 °C and an automatic attenuator was used. The 
refractive index of the solvent was 1.330 and the viscosity was 0.8872 mPa•s. Every 
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sample was measured 3 times with at least 6 sub runs each. Zeta potentials were 
calculated by the Smoluchowski equation. Ten to fifteen sub runs lasting 10 s each at 
25 °C (n = 3) were determined.  
 
2.2.5 Transmission electron microscopy (TEM) of polyplexes 
Samples were prepared as follows. The formvar/carbon-coated 300 mesh copper grids 
(Ted Pella Inc., Redding, CA, USA) were activated by mild plasma cleaning. 
Afterwards, the grids were incubated with 20 µL of the polyplex solution at N/P 12 for 
2.5 min. Polyplexes were previously prepared in water with 1 µg pDNA / 0.1 ml and, if 
indicated, post-modified with 1.0 eq. of PEGylation reagent. Excess liquid was blotted 
off using filter paper until the grid was almost dry. Prior to staining, the grids were 
washed with 5 µL of staining solution for 5 s. Then, the copper grids were incubated 
with 5 μL of a 2% aqueous uranylformate solution for 5 s, excess liquid was blotted off 
using filter paper, followed by air-drying for 30 min. Samples were then analyzed at 80 
kV using a JEM 1011 (Jeol, Freising, Germany) by Susanne Kempter or Caroline Hartl 
(LMU Munich, Department of Physics). 
 
2.2.6 Ethidium bromide compaction assay and polyanionic stress test 
Polyplexes containing 2 μg pDNA were formed at N/P ratio of 12 in a total volume of 
200 μL HBG. LPEI polyplexes formed at N/P 12 served as positive control. If indicated, 
PEG agents were added at indicated ratios. HBG buffer (200 μL) served as blank and 
2 μg pDNA in 200 μL HBG buffer was considered as maximum ethidium bromide (EtBr) 
fluorescence intensity (100% value). These samples were prepared in parallel to the 
polyplexes. After incubation at room temperature, 700 μL of a EtBr solution (c = 0.5 
μg/mL) was added. The fluorescence intensity of EtBr was measured after an additional 
3 min incubation using a Cary Eclipse spectrophotometer (Varian, Germany) at the 
excitation wavelength λex = 510 nm and emission wavelength λem = 590 nm. The 
fluorescence intensity of EtBr was determined in relation to free pDNA. As a further 
experiment, 250 IU of heparin (Ratiopharm, Ulm, Germany) was added to the samples 
after EtBr addition to investigate polyplex stability against polyanionic stress and the 
samples were remeasured. 
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2.2.7 Stability of polyplexes in serum and media 
Polyplex stability in full serum (FBS) or in DMEM supplemented with 10% serum was 
determined by DLS. Polyplexes were prepared as described previously with 8 µg 
pDNA and oligomers at N/P 12 in a total volume of 50 µL HBG. After incubation for 30 
min, if indicated, polyplexes were PEGylated for 15 min, then 30 μL of HBG and 720 
μL FBS (or DMEM) were added to reach a final concentration of 90% serum or DMEM. 
For measurement 60 µL were placed in a DTS1070 cuvette and t=0 min was 
determined. Polyplexes in serum or media were incubated under steady shaking at 37 
°C and aliquots were taken for further measurements at indicated time points. Each 
time point represents one measurement averaged from 6 sub runs. 
 
2.2.8 Polyplex stability in the presence of salt  
Polyplexes were prepared with oligomers at N/P 12 and 2 μg pCMVLuc in a total 
volume of 60 μL deionized water. After 30 min and, if indicated, post-modification with 
1.0 eq of the bivalent PEGylation reagents for 15 min, 500 μL of phosphate-buffered 
saline (PBS) was added and a dynamic laser-light scattering (DLS) measurement with 
three runs (including six sub-runs each) was performed immediately. Samples were 
incubated at room temperature, and further measurements were conducted. In case of 
investigation within 3.1.5 samples were taken after 5, 30, 60, 180 min as well as after 
24 h (if indicated). In 3.3.2.3 polyplex stability was investigated after 30 min, 60 min, 
180 min and if indicated after 24 h.  
 
2.2.9 Polyplex adhesion to erythrocytes or serum  
Polyplexes were prepared at N/P 12 and 2 μg pDNA (20% Cy5 labeled) in a total 
volume of 60 μL HBG. After 30 min, three groups were treated differently. Either HBG, 
3 × 106 erythrocytes in HBG, or serum (to a final concentration of 90%) were added. 
After further 30 min of incubation at 37 ◦C, erythrocytes containing polyplexes were 
sedimented by centrifugation (1500 rpm for 10 min at room temperature) and the 
supernatant was taken. Then, 3500 IU of heparin sulfate was added to dissociate the 
polyplex and determine the remaining amount of pDNA via Cy5 excitation/emission 
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(λex = 649 nm and emission wavelength λem = 670 nm). Data were calculated in 
comparison to equally treated free pDNA.  
 
2.2.10 UV spectrometrical investigation of polyplex modification 
Polyplexes consisting of 8 µg pDNA and 454 at N/P 12 in 50 µL HBG were prepared. 
After 30 min samples were either diluted to 100 µL HBG or post-modified with 1.0 eq 
of Ala-PEG24-Cys(NPys)2 for 15 min prior to dilution. HBG served as blank; 8µg pDNA 
in HBG, its correlating amount of 454 at N/P 12 and 1.0 eq of Ala-PEG24-K-(STOTDA-
(Cys(NPys))2 were treated as controls. For all samples UV/Vis spectra from 200-700 
nm were recorded with a Genesys 10S UV-VIS spectrophotometer (Thermo Scientific, 
Schwerte, Germany). 
 
2.2.11 Ellman’s assay of oligomers 
Oligomer stock solutions (10 mg/mL) were diluted to a theoretical amount of 
approximately 0.4 mM free thiols in water. DTNB dissolved in MeOH (4 mg/mL) was 
diluted 1:40 with Ellman’s buffer obtaining an Ellman’s working solution. 30 µL of the 
diluted oligomer solution and 170 µL of the Ellman’s working solution were mixed and 
incubated for 15 min at 37 °C under steady shaking. Absorbance at A412 was 
determined against a mixture of 30 µL of Water and 170µL of Ellman’s working 
solution. The theoretical used concentration of free thiols was set as 100% per 
oligomer and related to the concentration determined by a correlation curve of cysteine.  
 
2.2.12 Ellman´s assay of polyplexes 
Polyplexes were formed in 50 µL HBG (containing 8 µg pDNA and 454 at N/P 12). 
Solutions containing unmodified 454/pDNA polyplexes as well as post-modified 
polyplexes (15 min with 1.0 eq (Cys)2-PEG24-Ala), were diluted with 275 µL Ellman’s 
Buffer (0,2M Na2HPO4, 1mM EDTA, pH 8,0) and eight µL of a DTNB solution (4mg/ml 
dissolved in MeOH). After addition of DTNB, both solutions were incubated for 15 min 
at 37 °C and absorbance at 412 nm was measured. Post-modified polyplex absorption 
was measured at 412 nm prior and after DTNB addition in order to exclude distortion 
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mediated by 3-nitro-2-thiopyridone, released during post-modification. A Genesys 10S 
UV-VIS spectrophotometer (Thermo Scientific, Schwerte, Germany) was used for 
measurement. A412 of PEGylated polyplexes then was calculated according to the 
following formula: A412 (Sample) = A412 (+DTNB) – A412 (-DTNB). The percentage of 
free mercapto groups is based on the theoretical amount (100%) of thiols. 
 
2.2.13 Release of 3-nitro-2-thiopyridone 
The amount of (Cys)2-PEG24-Ala corresponding to 1.0 molar eq of 454 was diluted with 
HBG (pH 7.4) to 300 µL and 33 µL of a 1M DTT (dithiothreitol) solution was added to 
the solution. The maximum absorbance of 3-nitro-2-thiopyridone was determined at 
324 nm. Absorbance, then was consequently measured at A324 and compared to the 
amount released from the PEGylated polyplex. Therefore 50 µL of polyplex solution 
(containing 8 µg of pDNA, and 454 at N/P 12) was post-modified with 1.0 eq (Cys)2-
PEG24-Ala for 15 min and the polyplex solution was diluted with 275 µL of Ellman’s 
Buffer prior to measurement. Absorbance of (Cys)2-PEG24-Ala reduced with 1M DTT 
was considered as 100% and was put in relation to 3-nitro-2-thiopyridone release after 
PEGylation. 
2.2.14 EGF and HGF receptor measurement 
Huh7 and DU145 cells for HGFR measurement and Huh7, MCF-7 and FTC-133 cells 
for EGFR measurement were detached with trypsin. Then 8 × 105 in case of HGFR 
receptor screening and 1 × 106 cells in case of EGFR screening were washed with 
PBS (supplemented with 10% FBS) and incubated with either an HGFR specific 
antibody (1:100; monoclonal mouse IgG1, R&D Systems, Minneapolis, MN, USA) or 
an EGFR specific antibody (1:100; monoclonal mouse IgG1 - Dako, Glostrup, 
Denmark). In both cases similar cells counts incubated with an IgG-anti-mouse 
antibody (BD Bioscience, Franklin Lakes, USA) served as control. Cells were treated 
for 1 h on ice and were subsequently washed with buffer (10% FBS in PBS) twice. 
Next, cells were washed with PBS supplemented with 10% FBS and incubated with an 
AlexaFluor 488 labeled goat anti-mouse secondary antibody (1:400 - Invitrogen, 
Langenselbold, Germany) for 1 h on ice. After a final washing step, cells were 
resuspended in PBS (supplemented with 10% FBS) and flow cytometry analysis was 
performed on a CyanTM ADP flow Cytometer (Dako, Hamburg, Germany) using 
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SummitTM acquisition software (Summit, Jamesville, NY, USA) in case of HGF receptor 
measurement and on a BD Accuri C6 flow cytometer (BD Bioscience, Franklin Lakes, 
USA) in case of EGF receptor measurement. Cells were gated by forward/sideward 
scatter and pulse width for exclusion of doublets. In case of HGF measurement cells 
were counterstained with DAPI in case of HGFR measurement and with propidium 
iodide (PI) in case of EGFR measurement to discriminate between viable and dead 
cells. Experiments were carried out by Ana Krhac Levacic (PhD study, Department of 
Pharmaceutical Biotechnolgy, LMU) for c-Met receptor measurements and by Sarah 
Urnauer (PhD study, University Hospital of LMU, Department of Internal Medicine IV) 
of EGF receptor measurements on Huh7, MCF-7 and FTC-133. Wei Zhang, PhD 
(Department of Pharmaceutical Biotechnology, LMU) performed receptor level 
measurements on KB cells.  
 
2.2.15 In vitro pCMVLuc gene transfer and metabolic activity of transfected 
cells (MTT assay)  
For determining luciferase activity, cells were seeded 24 h prior to pDNA delivery. 
10,000 cells/well were added into 96-well plates for all used cell lines. Transfection 
efficiency of oligomers at indicated N/P ratios was determined. 200 ng pCMVLuc per 
well were used for polyplex formation (cf. 2.2.2). If indicated, lipopolyplexes were 
PEGylated according to 2.2.2.1. Before treatment, cells received 80 μL of fresh 
medium containing 10% FBS. Polyplex solution (20 μL) was added to each well and 
incubated on cells at 37 °C for either 45 min or 24 h. In the first case, medium was 
replaced 45 min after transfection by fresh medium. In the second case, cells were 
incubated with polyplex solution for 24 h after initial transfection. All experiments were 
performed in quintuplicate. LPEI or LPEI-PEG2k-GE11 (N/P 6) was used as a positive 
control and HBG buffer served as negative control. Luciferase activity of cells was 
determined after lysis with 100 µL lysis buffer using a Centro LB 960 plate reader 
luminometer (Berthold Technologies, Bad Wildbad, Germany) and LAR buffer 
supplemented with 1 mM luciferin. Transfection efficiency was evaluated as relative 
light units (RLU) per well.  
For metabolic activity, cells, plated as 10,000 per well, were also transfected with 
polyplexes, as described above. 24 h after initial transfection, 10 µL of MTT (3-(4,5-
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dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added to each well 
reaching a final concentration of 0.5 mg/mL. Medium with unreacted dye was removed 
after an incubation time of 2 h at 37 °C. The 96-well plates were stored at −80 °C for 
at least one hour and afterwards the purple formazan product was dissolved in 100 µL 
DMSO per well. The absorbance was determined by using a microplate reader at 
530 nm with background correction at 630 nm. The relative cell viability (%) related to 
the buffer treated control cells was calculated as ([A] test/[A] control) × 100 %. 
Experiments were carried out by Ana Krhac Levacic (PhD study, Department of 
Pharmaceutical Biotechnolgy, LMU) and Sarah Urnauer (PhD study, University 
Hospital of LMU, Department of Internal Medicine IV). 
 
2.2.16 In vitro pCMVLuc gene transfer and metabolic activity of transfected 
cells (MTT assay) with addition of endosomolytic chloroquine or LPEI 
Cells were seeded 24 h prior to pDNA delivery. 10,000 Huh7 cells/well were added 
into 96-well plates. Transfection efficiency of the novel lipo-oligomers (454, 1026, 
1176-1178) at N/P 12 was determined. Therefore 200 ng pCMVLuc per well were used 
for polyplex formation (cf. 2.2.2). If indicated, lipopolyplexes were PEGylated according 
to 2.2.2.1. Before treatment, cells received 80 μL of fresh medium containing 10% FBS. 
Polyplex solution (20 μL) was added to each well and either incubated on cells at 37 °C 
for 45 min, followed by addition of endosomolytic chloroquine for 4 h prior to an 
additional media change, or lipopolyplexes were incubated for 2 h and media was 
replaced by a media enriched with LPEI, another endosomolytic reagent, 
corresponding to N/P 9 per well. In both types of experiments, total incubation time 
was 24 h and a MTT assay to investigate polyplex toxicity was performed in parallel in 
quintuplicate. Calculations were performed as mentioned previously (cf. 2.2.15), and 
experiments were performed by Ana Krhac Levacic (PhD study, Department of 
Pharmaceutical Biotechnolgy, LMU). 
2.2.17 Cellular association of pDNA polyplexes 
Cells were seeded 24 h prior to transfection into 24-well plates at a density of 50,000 
cells per well. Culture medium was replaced with 400 μL fresh growth medium 24 h 
after seeding the cells. pDNA polyplexes were formed with oligomers (N/P 12) and 1 
μg pCMVLuc (20% of Cy5-labeled pCMVLuc) and incubated for 30 min in 100 µL HBG 
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on ice. PEGylation reagents were, if indicated, co-incubated for further 15 min prior to 
addition onto the cells. Subsequently, cells were washed twice with 500 µL PBS, 
detached with trypsin/EDTA and resuspended in PBS supplemented with 10% FBS. 
Cellular association of the polyplexes was measured by excitation of Cy5 at 635 nm 
and detection of emission at 665 nm. DAPI (4′,6-diamidino-2-phenylindole) or PI 
(propidium iodine) staining was used to discriminate between viable and dead cells. 
Cells were properly gated by forward/sideward scatter and pulse width for exclusion of 
doublets. Experiments were carried out by Ana Krhac Levacic (PhD study, Department 
of Pharmaceutical Biotechnolgy, LMU) and Sarah Urnauer (PhD study, University 
Hospital of LMU, Department of Internal Medicine IV).  
 
2.2.18 Cellular internalization of pDNA polyplexes 
Cells were seeded 24 h prior to transfection into 24-well plates at a density of 50 000 
cells/well. Culture medium was replaced with 400 μL fresh growth medium 24 h after 
seeding the cells. pDNA polyplexes, formed at N/P ratio 12 in 100 μL HBG, containing 
1 μg pCMVLuc (20 % of Cy5-labeled pCMVLuc) were added to each well and 
incubated at 37 °C for 45 min. PEGylation reagents were, if indicated, co-incubated for 
further 15 min prior to addition to cells. Subsequently, cells were washed once with 
500 µL PBS containing 1000 IU heparin for 15 min on ice to remove any polyplexes 
sticking to the cell surface and again washed once with 500 μL PBS only. Cells were 
detached with trypsin/EDTA and resuspended in PBS supplemented with 10 % FBS. 
Cellular internalization of the polyplexes was measured by excitation of Cy5 at 635 nm 
and detection of emission at 665 nm. DAPI (4′,6-diamidino-2-phenylindole) or PI 
(propidium iodine) staining was used to discriminate between viable and dead cells. 
Cells were properly gated by forward/sideward scatter and pulse width for exclusion of 
doublets. Experiments were carried out by Ana Krhac Levacic (PhD study, Department 
of Pharmaceutical Biotechnolgy, LMU) and Sarah Urnauer (PhD study, University 
Hospital of LMU, Department of Internal Medicine IV). 
 
2.2.19 In vivo gene transfer 
Animal experiments were performed in female 6-week-old nude mice, Rj: NMRI-nu 
(nu/nu) (Janvier, Le-Genest-St-Isle, France) which were housed in isolated ventilated 
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cages with a 12 h day/night interval and food and water ad libitum. Huh7 (5×106 cells) 
suspended in 150 μL PBS were injected subcutaneously into the left flank. After 
injection, tumor size was monitored with a caliper and determined by formula a × b2 /2 
(a = longest side of the tumor; b = widest side vertical to a). When tumors reached a 
size of approximately 1200 mm3, the experiments started by intratumoral injection of 
60 μL polyplex solution containing 50 μg pCMVLuc at N/P 12 in HBG. For each 
polymer, a group of 5 mice (n=5) was treated. Mice were euthanized 48 hours later, 
and tumors were collected to assess luciferase activity via ex vivo luciferase assay. 
Tumors were homogenized in 500 μL cell lysis buffer using a tissue and cell 
homogenizer (FastPrep®-24). To separate insoluble cell components, the samples 
were centrifuged at 3000 g at 4 °C for 10 min. Luciferase activity was measured in the 
supernatant using a Centro LB 960 luminometer. All animal experiments were 
performed according to the guidelines of the German law for the protection of animal 
life and were approved by the local animal ethics committee. Experiments were 
performed by Sarah Kern and Jasmin Kuhn (Doctoral studies, Pharmaceutical 
Biotechnology, LMU). 
 
2.2.20 Iodide uptake activity after hNIS gene delivery 
For determining iodide uptake activity after NIS gene delivery, 200,000 cells/well were 
plated in 6-well plates. Transfection efficiency of (post-modified) polyplexes formed at 
N/P 12 was evaluated using 2 µg hNIS pDNA. After 24 h incubation with polyplexes, 
cells were washed with HBSS (Hank's Balanced Salt Solution; Thermo Fisher 
Scientific, Waltham, USA) and then incubated with HBSS supplemented with 10 μm 
NaI, 0.1 μCi of Na125I / ml and 10 mm HEPES at pH 7.3 for 45 min at 37°C. Sodium 
perchlorate (NaClO4; 100 μM) as NIS-specific inhibitor was added to control wells. After 
incubation with iodide, cells were washed with HBSS and trapped iodide was removed 
from cells by a 20 min incubation in 1 M NaOH and measured by γ-counting and 
expressed as counts per minute (cpm). 
Metabolic activity of transfected cells was determined as described in 0. Here, 200 µL 
of MTT reagent was added to each well, reaching a final concentration of 0.5 mg/mL. 
Medium with unreacted dye was removed after incubation for 2 h at 37 °C and washed 
with PBS (phosphate-buffered saline) and measurement and calculation was 
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conducted as mentioned before. Experiments were performed by Sarah Urnauer (PhD 
study, University Hospital of LMU, Department of Internal Medicine IV). 
 
2.2.21 MALDI-TOF mass spectrometry 
One µL matrix consisting of a saturated solution of Super-DHB (mixture of 2,5-
dihydroxybenzoic acid and 2-hydroxy-5-methoxybenzoic acid) in acetonitrile / water 
(1:1) containing 0.1% (v/v) trifluoroacetic acid was applied on a MTP AnchorChip 
(Bruker Daltonics, Bremen, Germany). After the Super-DHB matrix dried and 
crystalized, one µL of the sample solution (10 mg/mL in water) was added to the matrix 
spot. Samples were analyzed using an Autoflex II mass spectrometer (Bruker 
Daltonics, Bremen, Germany). Spectra were recorded after positive or negative 
ionization. 
 
2.2.22 Proton NMR spectroscopy 
1H-NMR spectra were recorded using an AVANCE III HD500 (500 MHz) by Bruker with 
a 5 mm CPPBBO probe. Spectra were recorded without TMS as internal standard and 
therefore all signals were calibrated to the residual proton signal of the deuterium oxide 
(D2O) solvent. Chemical shifts are reported in ppm and refer to the solvent as internal 
standard (D2O at 4.79). Integration was performed manually. The spectra were 
analyzed using MestreNova (Ver.9.0 by MestReLab Research). Integrals were 
normalized to the succinic acid peaks.  
 
2.2.23 Analytical RP-HPLC 
Reversed-phase HPLC (RP-HPLC) was carried out with a VWR-Hitachi Chromaster 
5160 Pump System (VWR, Darmstadt, Germany), VWR-Hitachi Chromaster 5260 
Autosampler (VWR, Darmstadt, Germany) and a Diode Array Detector (VWR-Hitachi 
Chromaster 5430; VWR, Darmstadt, Germany) at 214 nm detection wavelength. As a 
column either a YMC Hydrosphere 302 C18 (YMC Europe, Dinslaken, Germany) or a 
Waters Sunfire C18 (Waters, Saint-Quentin en Yvelines Cedex, France) was used. A 
gradient starting at 95:5 (water / acetonitrile) to 0:100 within 20 min was applied. All 
solvents were supplemented with 0.1% trifluoroacetic acid. 
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2.2.24 ESI mass spectrometry 
Electrospray ionization (ESI) mass spectrometry was carried out using a 
Thermoscientific LTQ FT Ultra Fourier transform ion cyclotron and an IonMax source. 
Samples were dissolved in water containing 1% formic acid to a concentration of 1 
mg/ml. Data is shown after positive ionization as (M+X). Samples were kindly 
processed by Dr. Werner Spahl from the analytical core facilty at the Department of 
Chemistry, LMU Munich.  
 
2.2.25 Statistical analysis 
The results are presented as mean values of experiments performed in at least 
triplicates. Unless stated otherwise, error bars display standard deviation (SD). 
Statistical analysis of the results (mean ± SD) was evaluated by unpaired t test: *p < 
0.05; **p<0.01; ***p < 0.001; ****p < 0.0001. Calculations and graphical presentation 
were performed with Prism 6 (GraphPad Software Inc.).  
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3 Results 
3.1 Influence of defined hydrophilic blocks within oligoaminoamide 
copolymers: compaction versus shielding of pDNA nanoparticles 
This chapter has been adapted from: 
Morys, S.; Krhac Levacic, A.; Urnauer, S.; Kempter, S.; Kern, S.; Rädler, J.O.; 
Spitzweg, C.; Lächelt, U.; Wagner, E. Influence of Defined Hydrophilic Blocks within 
Oligoaminoamide Copolymers: Compaction versus Shielding of pDNA 
Nanoparticles. Polymers 2017, 9, 142. 
 
Cationic sequence-defined oligoaminoamides equipped with polyethylene glycole 
polymers as non-viral vectors for nucleic acid delivery need to comprise several 
functionalities. Besides a nucleic acid (NA) binding element, also a shielding block and 
a tumor-specific targeting domain is required for a successful in vitro as well as in vivo 
delivery of the NA. Recently solid phase synthesis (SPS) derived oligomers were 
successfully applied as pDNA shuttles for receptor targeted gene delivery in vitro and 
in vivo [64, 65], investigating the capabilities (PEG) of a defined length and a HGF 
(hepatocyte growth factor) binding peptide (cmb), targeting hepatocellular cancer. This 
work focuses on the modification of histidine-rich oligoaminoamide [50] carriers with 
hydrophilic shielding blocks mediating receptor specific gene delivery due to the 
nanoparticle’s shielding potential and introduction of a targeting domain [64, 65, 137, 
201]. It was described earlier that polyplex shielding is necessary to prevent 
aggregation or dissociation of NA polyplexes in vitro [202], and hinder opsonization 
[153] with blood components in vivo.   
Herein, the oligomers equipped with either the shielding agent PEG, in three defined 
lengths (12, 24, or 48 oxyethylene repeats) or with peptidic shielding blocks composed 
of four or eight repeats of sequential proline-alanine-serine (PAS) are compared.  
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3.1.1 Peptide and oligomer synthesis 
The objective of this study was to examine different hydrophilic blocks—PAS and 
PEG—with varying length in combination with a cationic oligoaminoamide backbone 
for their “shielding abilities” in pDNA polyplexes. The cationic oligomers can mainly be 
divided into two subgroups: a three-arm cationic topology without shielding domain [49] 
for control carriers, or shielded two-arm structures comprising certain PEG or PAS 
repetitions—topologies are described in Scheme 4. PAS represents the three neutral 
amino acids proline, alanine, and serine, ordered from N to C terminus. Solid phase 
assisted synthesis (SPS) was used for the assembly of the oligomers listed in Table 
7. This method allowed oligomers to be easily tailored to our needs. The non-shielded 
positive control with three-arm topology had a similar number of charge-bearing units 
(9 Stp, 12 histidines) as the shielded two-arm oligomers (8 Stp, 11 histidines). A two-
arm structure without shielding agent might have been considered as a suitable control, 
but previous studies [134] revealed a lower efficacy of short cationic two-arm 
oligomers. Moreover, a shielded two-arm in fact presents a three-arm topology (with 
the shielding polymer block arm representing the third arm). The length of shielding 
blocks used in this study were chosen along the commercially available, precise PEG 
derivates of 12 or 24 ethylenoxide (EO) units and analogous PAS peptides. So PAS4 
consisting of four PAS repeats (4 × 3 = 12 amino acids) was considered as backbone 
analog to 12 EO units (PEG12), and PAS8 (8 × 3 = 24 amino acids) as analog to 24 EO 
units (PEG24). Due to the amino acid side groups, the molecular weight of a PAS tri-
amino acid block is substantially higher (273 g/mol) than the analogous EO trimer block 
(3 × 44 g/mol = 132 g/mol).  
Table 7 List of oligomers included in this study. Internal polymer numbers, structures from N to C 
terminus, as well as abbreviations used within the paper. 
ID # Structure Abbreviation 
689 [C-(H-Stp)
3
-H]
α,ε
-K-H-(Stp-H)
3
-C 3-arm 
1088 {[C-(H-Stp)
4
-H]
α,ε
-K-H-dPEG
12
}
ε
-K PEG
12
 
1091 {[C-(H-Stp)
4
-H]
α,ε
-K-H-dPEG
24
}
ε
-K PEG
24
 
1120 {[C-(H-Stp)
4
-H]
α,ε
-K-H-dPEG
24
-dPEG
24
}
ε
-K PEG
48
 
1094 {[C-(H-Stp)
4
-H]
α,ε
-K-H-(PAS)
4
}
ε
-K PAS
4
 
1097 {[C-(H-Stp)
4
-H]
α,ε
-K-H-(PAS)
8
}
ε
-K PAS
8
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In case of shielded two-arm structures, first a Dde-L-Lysine-(Fmoc) was loaded on a 
2-chlorotrityl resin. Consequently, the shielding domain was attached to the ε-amine 
after successful Fmoc deprotection. It consisted of either monodisperse polyethylene 
glycol (PEG) of 12, 24, or 2 × 24 units, or of four or eight repetitive Ser–Ala–Pro units. 
The cationic backbone consists of histidines, the artificial amino acid Stp (succinyl-
tetraethylene pentamine) [131, 199], lysine, and cysteine. Histidines were introduced 
for enhanced endosomal buffering [50, 64, 203]. Stp was used for nucleic acid 
packaging, endosomal buffering, and endosomal escape [49, 132]. The diamino acid 
lysine served as a branching point, and N-terminal cysteines were introduced for 
polyplex stabilization via disulfide-crosslinking [49, 52, 134]. Each oligomer was 
characterized by 1H-NMR and RP-HPLC and can be found in the appendix (cf. 6.5) 
 
Scheme 4 Schematic structures of the oligomer topologies evaluated in this paper. PAS: proline-
alanine-serine; PEG: polyethylene glycol. 
 
3.1.2 Physicochemical polyplex characterization 
Oligomer/pDNA interaction was examined in different assays, focusing on pDNA 
binding abilities, stability, and compaction. First, pDNA binding potency of the 
oligomers was investigated by agarose gel electrophoresis shift assays. Here 
polyplexes were formed with different ratios of oligomer to pDNA. This ratio is displayed 
as N/P, with varying amount of oligomer but constant amount of 200 ng pDNA (cf. 
Figure 5 and Figure 6) This assay revealed that all tested oligomers efficiently 
complex pDNA at an N/P ratio between 2 and 2.5. We already reported similar findings 
with oligomers composed of the same cationic backbone [64, 137]. Importantly, the 
presence and nature of shielding elements did not influence the pDNA binding of the 
cationic backbone in this assay for shielding agents with the length up to PEG24. Only 
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the oligomer with longest PEG48 shielding domain exhibited slightly decreased binding 
potency, since certain fractions of free pDNA could still be observed at N/P 3 and 6. 
Notably, pDNA binding does not necessarily correlate with its degree of compaction or 
polyplex shape. Polyplex properties regarding DNA compaction were therefore 
investigated with alternative techniques (cf. Figure 7).  
 
Figure 5 Retardation of formed pDNA complexes in agarose gel of untargeted 
polyplexes between N/P of 0 (free pDNA) and 3 in an agarose gel shift assay. 
 
   Results 
   62 
 
Figure 6 Retardation of formed pDNA complexes in agarose gel at N/P 3 to 20 with 
non-shielded 3-arm (A) PEGylated (B) and PASylated (C) oligomers. Left lane: free 
pDNA. 
 
After pDNA binding was confirmed, particle sizes and zeta potential were determined 
by dynamic light scattering at N/P 12. Results revealed very homogenous particles with 
a polydispersity index (PDI) between 0.04 and 0.33, where 1.0 represents the highest 
polydispersity (cf. Table 8). All polyplexes show DH values (displayed as Z-Average in 
nm) in the range between 98 nm and 147 nm. It has been reported that particles up to 
200 nm can be taken up via a clathrin-dependent pathway [175], indicating that 
subsequent uptake into cells should be possible via endocytosis. DLS data provide a 
hint that particles with shorter shielding agents (PEG12 or PAS4) exhibit smaller particle 
sizes than longer shielding agents. This could be explained by more compact and 
condensed particles. Also increased length of the shielding agents resulted in 
decreased zeta potential, indicating improved surface shielding. 
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Table 8 Particle size (Z-average), polydispersity index (PDI), and zeta potential of plasmid DNA 
(pDNA) polyplexes formed in HEPES-buffered 5% glucose (HBG) buffer determined with dynamic 
laser-light scattering (DLS). Mean of three measurements of the same sample is indicated. Polymer 
at nitrogen-to-phosphate ratio (N/P) 12 and 2 µg plasmid DNA (pDNA) were separately diluted with 
HBG pH 7.4 to 30 µL each. Then solutions were mixed and incubated for 30 min. Polyplexes were 
diluted to 800 µL with 10 mM NaCl pH 7.4 prior to measurement. # indicates internal library 
compound IDs.  
ID # Abbreviation Z-average [nm] Mean PDI Mean zeta potential [mV] 
689 3-arm 126.8 ± 2.7 0.15 ± 0.02 32.0 ± 3.5 
1088 PEG12 97.9 ± 1.1 0.14 ± 0.02 6.7 ± 2.3 
1091 PEG24 111.6 ± 0.9 0.16 ± 0.01 3.1 ± 0.6 
1120 PEG48 87.2 ± 1.4 0.33 ± 0.05 1.6 ± 0.5 
1094 PAS4 127.7 ± 0.8 0.12 ± 0.01 7.1 ± 1.5 
1097 PAS8 147.0 ± 1.8 0.15 ± 0.01 3.4 ± 0.8 
PDI: Polydispersity index.  
 
3.1.3 Steric shielding 
As a next step to characterize polyplexes, a stress assay was performed with salt to 
evaluate the behavior in isotonic salt concentration. Therefore, PBS buffered at pH 7.4 
was added to the polyplexes after 30 min of incubation in deionized water. DLS 
measurements were performed immediately after addition, and at 5, 30, 60, and 180 
min. In case of polyplexes stable for 180 min, also a measurement after 24h was 
conducted. As displayed in Figure 7A, the unshielded three-arm started to aggregate 
within 5 min after addition of PBS. Along with the three-arm, PAS4 and PEG12 also 
underwent colloidal aggregation. Meanwhile PEG24-, PEG48-, and PAS8-decorated 
polyplexes showed colloidal stability over 24 h without any significant aggregation. This 
indicates that longer PEG or PAS chains provide improved colloidal stability with lower 
risk for aggregation, while polyplexes with shorter PEG length or lack of shielding agent 
show immediate aggregation after salt addition. These findings (together with the DNA 
binding studies) are in accordance with previously published work where PEG 
shielding of PEI polyplexes increased the colloidal stability of polyplexes against salt-
induced stress, however at the expense of reduced pDNA binding [29, 204]. 
The next experiment was designed to investigate the interaction of polyplexes with 
erythrocytes. Results are displayed in Figure 7B. Polyplexes in HBG and polyplexes 
after incubation with erythrocytes were dissociated by heparin addition, and Cy5 
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emission of released labeled pDNA was detected. pDNA can be fully released by 
heparin (Figure 7B, dark bars) within the range of experimental accuracy. The data 
reveal a reduced pDNA recovery due to erythrocyte binding (grey bars); they also 
reveal that interaction with erythrocytes decreases with ascending length of the 
shielding agents. PEGylation is known to reduce the interaction of polyplexes with 
erythrocytes [29], which is in accordance with our findings. 
 
 
Figure 7 (A) Stability testing of untargeted polyplexes against phosphate-buffered saline (PBS). After 
30 min of polyplex incubation (2 µg pDNA; N/P 12) in deionized water and addition of 500 µL PBS, DLS 
measurement was performed. Time points 0, 5, 30, 60, and 180 min were displayed. In case of 
colloidally-stable polyplexes of PEG24, PEG48, and PAS8, a measurement after 24 h is also displayed. 
Data are presented as mean value (±SD) out of triplets; (B) Polyplexes (2 µg pDNA; N/P 12) were 
incubated in HBG with or without 3 × 106 erythrocytes. After centrifugation, the supernatant was taken, 
and 3500 IU of heparin were added to release pDNA of the polyplexes. Cy5 fluorescence was compared 
to uncomplexed (free) pDNA. Statistical analysis (Student’s t-test): ns p > 0.05, * p ≤0.05; ** p ≤0.01; *** 
p ≤0.001, **** p ≤0.0001  
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3.1.4 DNA compaction 
Transmission electron microscopy (TEM) was performed to investigate polyplex size 
and shape. While differences between shielding agents could not be observed by TEM, 
we observed a clear difference compared to DH in general, but more unexpected 
between polyplexes decorated with shorter or longer shielding agents (cf. Figure 8A). 
Particles formed out of oligomers with shorter shielding agents tend to be not only 
smaller, but also more condensed regarding their structure compared to polyplexes 
shielded with longer shielding agents. Polyplexes with PEG12 or PAS4 exhibited sizes 
of around 50 nm and a more condensed “rod-like” structure, while PEG24 or PAS8 
decorated polyplexes revealed sizes of approximately 80–100 nm in a “doughnut-like” 
state. PEG48 decorated polyplexes revealed the lowest level of compaction and a very 
erratic shape of around 100 nm in size. Polyplexes including no shielding agent 
displayed the most condensed population with sizes around 40–50 nm in a very 
compact globular shape. However, polyplexes tend to aggregate due to their charged 
surface; this effect is not visible in case of polyplexes decorated with short shielding 
agents. These findings are in accordance with recent observations [205], where 
particle morphology changed from long rods to globular condensed polyplexes with 
decreasing amounts of conjugated PEG. To further investigate the ability to compact 
pDNA depending on the shielding agent used, pDNA compaction was determined with 
an ethidium bromide (EtBr) exclusion assay (cf. Figure 8B). Therefore, 2 µg of pDNA 
was mixed with oligomers at either N/P 6 or 12, incubated for 30 min, and then 
measured after the addition of EtBr. As reference, linear PEI (LPEI) was included in 
this study. The intensity of EtBr fluorescence normalized to uncomplexed pDNA is 
displayed in Figure 8B (left). These data support the findings from previous agarose 
gel shifts and confirm the findings from TEM images. All oligomers complex pDNA well, 
but with increased length of shielding agent, pDNA compaction decreased, which can 
be seen most pronounced in the case of the longest shielding element PEG48. In the 
right part of Figure 8B, fluorescence of the released pDNA of polyplexes is displayed 
after the addition of 250 IU of heparin sulfate to cause anionic dissociative stress.  
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Figure 8 Transmission electron microscopy images of polyplexes formed at N/P 12 in deionized water 
and stained with uranylformate. Scale bar represents 100 nm; (B) Left: pDNA compaction, correlating 
with the remaining fluorescence of ethidium bromide (EtBr). Results are calculated against free pDNA. 
Right: Polyplexes at N/P 12 after addition of 250 IU of heparin. Statistical analysis (Student’s t-test): ns 
p > 0.05, * p ≤0.05; ** p ≤0.01; *** p ≤0.001, **** p ≤0.0001. TEM was performed by Susanne Kempter 
(Faculty of Physics, LMU). 
  
Here it can be seen that polyplexes formed with LPEI and polyplexes decorated with 
PEG48 completely release pDNA and cause full EtBr fluorescence, while all other 
polyplexes are at least partly resistant to the applied heparin stress. Most interestingly, 
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the shorter the PEG respectively PAS shield, the more resistant the polyplexes were 
towards heparin stress. In other words, long PEG (24 or 48 units) or eight PAS repeats 
tend to destabilize the polyplex. These results suggest that the cationic charge density 
of the backbone is just one critical point for nucleic acid interaction, but the length of 
the shielding agent also plays a certain role. These findings from EtBr exclusion assay 
confirm our results from TEM. They are also in accordance with a most recent report 
on LPEI polyplexes [32], where PEGylation caused more sensitivity towards heparin 
stress as well as lower compaction in general. 
 
3.1.5 Serum stability 
Stability of polyplexes in the blood protein environment presents a most relevant and 
critical issue, as interaction with proteins can cause aggregation or partial to complete 
dissociation of the polyplex. Thus, further experiments were designed to investigate 
polyplex stability in serum. We applied an assay to measure polyplex size in 90% FBS 
with DLS. This method offered the possibility to monitor polyplex behavior over a long-
time period from the point of serum addition up to 24 h. Time points t = 0, 2, 4, 24 h 
are displayed in Figure 9B–G. Firstly, the size of all polyplexes increased in serum, 
from 100–150 nm in 10 mM NaCl to 250–300 nm immediately after addition of FBS. 
From here on, a decay (loss of intensity and increase in size) of the polyplexes was 
observed over time in the case of the longer shielding agents PEG24 and PAS8, with a 
tendency towards a higher colloidal stability of PAS8. PEG12 and PAS4 were the most 
promising candidates, with almost no decay over time. While polyplexes shielded with 
PEG48 underwent immediate decay and aggregation, unshielded three-arm underwent 
no additional changes after the initial size increase within the following 24 h. An 
explanation for the elevated stability of three-arm, PAS4, and PEG12 might be the 
formation of a serum corona around the polyplexes (which also explains the increased 
size), and due to the higher compaction, the ionic complexes remain stable despite 
serum interaction. Serum corona - especially when attached to PEGylated 
nanostructures - has been demonstrated to mediate favorable shielding properties 
[206]. In Figure 9H, the behavior of polyplexes after 30 min of incubation with 90% 
FBS is compared to polyplexes maintained for the same time in HBG. The amount of 
released Cy5-labeled pDNA after addition of heparin was determined. In all cases, 
pDNA release was lower after polyplex incubation with FBS. In the case of PEGylated 
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polyplexes, a trend towards less pDNA release could be observed with increasing PEG 
length. At least at this early time point, the formation of a serum corona seems to 
mediate increased resistance towards polyanionic stress. However, this protective 
effect seems to reverse when polyplexes are incubated over a long time in serum, 
maybe due to the lack of compaction (cf. Figure 9C,F,G). 
 
 
Figure 9 (A) DLS measurements of 90% fetal bovine serum (FBS, green) and pDNA polyplexes of the 
three-arm oligomer in HBG (red) as references to discriminate polyplex and serum peaks; (B–G) Display 
behavior of polyplexes with indicated oligomers in 90% FBS over time. In (H), the amount of recovered 
pDNA of polyplexes containing Cy5-labeled pDNA after treatment with 3500 IU heparin is displayed 
after incubation with FBS for 30 min; HBG-treated polyplexes served as control.   
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3.1.6 Tumor cell interactions in vitro 
Different interactions of our polyplexes were investigated on N2a (mouse 
neuroblastoma) cells. In Figure 10A,B cellular binding is shown. Only polyplexes 
decorated with PEG48 showed strong shielding against unspecific binding within 30 
min of interaction with cells. 
 
 
Figure 10 In (A,B) cellular association of polyplexes with N2a cells after 30 min incubation at 4 °C as 
determined by flow cytometry is plotted; In (C,D) cellular internalization of polyplexes after 45 min 
incubation at 37 °C followed by removal of extracellularly-bound polyplexes is displayed; Logarithmic X-
scale in (A–D) represents Cy5 fluorescence of polyplexes; (E) Luciferase reporter gene expression in 
N2a cells after 0.75 h (without pattern) and after 24 h (with pattern). Transfections were performed at 
two different ratios: N/P = 6 (red) and N/P = 12 (green). (F) Cell viability assay was performed in parallel. 
Assays were performed by Ana Krhac Levacic (PhD study, Pharmaceutical Biotechnology, LMU). 
 
Figure 10C,D displays cellular uptake within 45 min of incubation on cells. Again, only 
PEG48 polyplexes did not interact with cells and did not mediate significant uptake. In 
Figure 10E, gene transfer activity is shown after 0.75 h and 24 h at N/P ratios 6 and 
12. After the early 0.75 h time point, only unshielded three-arm and LPEI polyplexes 
caused notable gene transfer, while after 24 h of incubation, all polyplexes showed 
similar transfection efficacy; it is noteworthy that they were as efficient as LPEI. None 
of the polyplexes mediated cytotoxicity at any time point (cf. Figure 10F). These results 
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suggest that rapid binding and cellular uptake takes place only in case of unshielded 
cationic polyplexes (three-arm, LPEI) with sufficient critical endosomal amount of 
cationic proton sponge carrier required for efficient endosomal escape and transfection 
[26, 71, 202]. In case of oligoaminoamide carriers with short shielding elements, the 
internalized amounts of polyplexes increases over time, reaching sufficient levels for 
endosomal escape. Only for PEG48 polyplexes, notable transfection is not even 
reached after 24 h. Either the critical amount for endosomal escape is not reached, or 
the longer PEG domain hampers the endosomal membrane disruption. The widely 
known effect that introduction of PEG into cationic transfection complexes can reduce 
transfection efficacy has been referred to as the “PEG dilemma” [163]. For PEI-type 
polyplexes, it has been assumed that a combined effect of osmotic endosomal burst 
and direct phospholipid destabilization by the cationized carrier is required for 
endosomal escape [1, 143, 147, 166]; obviously, PEGylation can hinder the direct 
cationic membrane destabilization. Consistently, bioreversible PEGylation was 
demonstrated to resolve this dilemma [163, 165, 172]. 
 
3.1.7 Tumor cell interactions in vitro without and with targeting 
For this study, a phage-derived peptide (cmb) binding specifically to the HGF receptor 
cMet [191, 201] was introduced into our oligomers via modification at the α-amine of 
the c-terminal lysine. A complete list of cmb-containing oligomers can be found in 
Table 9. cMet is widely overexpressed in epithelial-derived tumors as well as stromal 
and interstitial cell-derived tumors (e.g., sarcomas) [185], and was pointed out 
previously as a suitable target for tumor targeting [65, 181, 201]; introduction of cmb 
into sequence-defined oligomers improved transfection efficacy over untargeted 
controls in vitro and in vivo [64, 65].  
In the current work, transfections of two cMet–overexpressing cell lines, the prostate 
cancer cell line DU145 (cf. Figure 12A) and the hepatocellular cancer cell line Huh7 
(cf. Figure 12B) - were carried out with polyplexes without or with a cMet targeted 
ligand. Receptor levels of both cell lines are displayed in Figure 11. 
 
 
   Results 
   71 
 
Figure 11 HGFR expression of HGFR/cMet positive DU145 (left) and Huh7 (right) cell lines are 
displayed, obtained with a monoclonal mouse anti-human HGFR antibody and IgG control. Alexa 488-
labeled goat anti-mouse secondary antibody was used for the detection of receptor expression by flow 
cytometry. Control cells are presented in black, HGFR positive cells are presented in grey. Receptor 
levels were determined by Ana Krhac Levacic (PhD study, Pharmaceutical Biotechnology, LMU). 
 
Table 9 List of cMet targeted oligomers. cmb represents cMet binding peptide, structures from N 
to C terminus, as well as an abbreviation used within the paper. # indicates internal library 
compound IDs 
ID # Structure Abbreviation 
1078 cmb-[(C-(H-Stp)3-H)α,ε-K-H-(Stp-H)3]εK cmb-3-arm 
996 cmb-[(C-(H-Stp)4-H)α,ε-K-H-dPEG12]εK cmb-PEG
12
 
442 cmb-[(C-(H-Stp)4-H)α,ε-K-H-dPEG24]εK cmb-PEG
24
 
694 cmb-[(C-(H-Stp)4-H)α,ε-K-H-dPEG24-dPEG24]εK cmb-PEG
48
 
1000 cmb-[(C-(H-Stp)4-H)α,ε-K-H-(PAS)4]εK cmb-PAS
4
 
901 cmb-[(C-(H-Stp)4-H)α,ε-K-H-(PAS)8]εK cmb-PAS
8
 
 
With both cell lines, results were consistent with the previous N2a transfections; short-
term incubations with polyplexes for 45 min only mediated moderate gene transfer, 
while higher gene expression was observed after a longer transfection time of 24 h. 
Transfection of Huh7 with cmb-PAS8 (no increase with time) presents an exemption 
from this rule. In case of the PEG12 containing polymer, we observed an elevating 
effect of the introduction of the cmb targeting peptide on transfection efficacy. Further 
on, transfection efficacy of PEG12 decorated polyplexes tended to be higher than with 
PEG24-decorated polyplexes. This increased transfection efficacy could be affiliated 
with the beneficial compact, rod-like structure of PEG12-containing polyplexes [207]. 
MTT assays for both cell lines were also performed in parallel to transfections, and did 
not show notable cytotoxicity at any time point (cf. Figure 13). In addition to the 
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transfections of cMet-positive cell lines, transfections of receptor negative N2a cells 
(for 0.75 h and 24 h) with targeted polyplexes can be found in Figure 14A. No 
significant gene transfer was observed after 0.75 h. After 24 h, polyplexes had been 
taken up unspecifically and caused notable gene transfer in the case of cmb-3-arm, 
cmb-PEG12, and cmb-PEG24. cmb-PAS4 and cmb-PAS8 hardly mediated any gene 
transfer. Cytotoxicity was not observed (cf. Figure 14B). 
 
Figure 12 (A) Luciferase reporter gene expression in human prostate cancer cell line DU145 as well as 
in (B) human hepatocellular cancer cells Huh7 after 0.75 h (without pattern), and after 24 h (with pattern). 
Transfections were performed at two different ratios: N/P = 6 (red) and N/P = 12 (green);  
(C) Luciferase gene expression at 48 h after intratumoral administration of pCMVLuc polyplexes at N/P 
= 12 into Huh7 tumor-bearing mice. Luciferase gene expression is presented as relative light units per 
gram tumor (RLU/g tumor; n = 5, mean ± SEM). Lysis buffer RLU values were subtracted. Transfections 
on DU145 cell line and ex vivo Luc assay were performed by Ana Krhac Levacic (PhD study, 
Pharmaceutical Biotechnology, LMU), transfections on Huh7 were performed by Sarah Urnauer (PhD 
study, University Hospital of LMU, Department of Internal Medicine IV) and animal experiments were 
carried out by Sarah Kern and Jasmin Kuhn (PhD studies, Pharmaceutical Biotechnology, LMU).
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Figure 13 Cell viability assay of (A) DU145 and (B) Huh7 was performed in parallel to luciferase 
transfection. An MTT assay was performed after 0.75 h (without pattern), and after 24h (with pattern) at 
two different N/P ratios, N/P = 6 (red) and N/P = 12 (green). MTT Assays were performed by Ana Krhac 
Levacic (PhD study, Pharmaceutical Biotechnology, LMU) for DU145 cells and by Sarah Urnauer (PhD 
study, University Hospital of LMU, Department of Internal Medicine IV) for Huh7 cells.  
 
3.1.8 Tumor cell interactions in vivo without and with targeting 
An in vivo experiment was the next logical step to further evaluate the potency of our 
oligomers. As a first step, intratumoral application into a subcutaneous Huh7 mouse 
model was chosen. Kos et al. [64] pointed out in the same model that polyplexes 
formed with cmb-PEG24 were superior to cmb-PEG48 in gene transfer. Therefore, in 
the current experiments, untargeted as well as targeted polyplexes of 3-arm, PEG12, 
and PAS4 were intratumorally injected into mice. Untargeted, unshielded 3-arm 
mediated the highest gene transfer, as already observed in vitro (see Figure 10E and 
Figure 12A,B). This might be explained by the local stickiness of unshielded surface 
and in the tumor. At the same time, polyplexes with PEG12 mediated decreased 
transgene expression, indicating a successful shielding in vivo. By introduction of 
targeting peptide cmb into PEG12-shielded polyplexes, transfection efficacy was 
recovered again. Overall, luciferase gene expression was also increased as compared 
to cmb-PEG24 [64], which extends the already previously observed trend of increasing 
gene transfer activity with decreasing PEG length (PEG48 < PEG24 < PEG12). 
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Interestingly, recent work with LPEI polyplexes [32] also reported favorable properties 
for incorporating targeting peptides via a 500–700 Da PEG molecule, which has similar 
size as PEG12. 
 
 
Figure 14 (A) Luciferase reporter gene expression in cMet negative cell line N2a after 0.75 h (without 
pattern) and after 24 h (with pattern). Transfections were performed at two different N/P rations, N/P = 
6 (red) and N/P = 12 (green). (B) An MTT assay was performed after 0.75 h (without pattern) in parallel 
after 24 h (with pattern) at two different N/P ratios, N/P = 6 (red) and N/P = 12 (green). Assays were 
performed by Ana Krhac Levacic (PhD study, Pharmaceutical Biotechnology, LMU). 
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3.2 EGFR targeting and shielding of pDNA lipopolyplexes via bivalent 
attachment of a sequence-defined PEG agent 
This chapter has been adapted from: 
Morys S.*, Urnauer S.*, Spitzweg C., Wagner E., EGFR Targeting and Shielding of 
pDNA Lipopolyplexes via Bivalent Attachment of a Sequence-Defined PEG Agent, 
Macromol. Biosci. 2017. (* indicates that authors contributed equally to this work) 
Stephan Morys thereby designed the study, developed and synthesized the oligomers 
and PEGylation reagents, and carried out biophysical experiments (e.g. DLS, EtBr 
compaction assay, Ellman’s assay, NPys release assay, polyplex stability assays), 
while Sarah Urnauer conducted all cell related experiments (association and uptake 
assays via FACS, receptor screening, transfections and iodide uptake assay). The 
draft manuscript was written together. 
 
For successful non-viral gene delivery, cationic oligomers are promising DNA carriers 
which need to comprise several functionalities. Shielding and directing polyplexes 
specifically towards the tumor by introduction of a specific targeting molecule or peptide 
represents two important characteristics for gene delivery. Therefore, the cationic 
oligomers can be either pre-PEGylated and a targeting ligand can be introduced during 
synthesis, or polyplexes can be post-modified with PEG reagents comprising a 
targeting domain. The latter was recently successfully applied for siRNA lipopolyplexes 
by introduction of an EGFR targeted GE11-PEG reagent via cysteine dependent 
maleimide chemistry [170]. Within this chapter, this approach has been transferred to 
pDNA/lipopolyplexes and further optimized in regards of chemistry. Here, the bis-
oleoyl-oligoaminoethanamide 454 containing tyrosine trimer - cysteine ends was 
applied for complex formation with pDNA coding for luciferase or sodium iodine 
symporter (NIS). In a second step, the lipopolyplexes were modified via disulfide 
formation with sequence-defined monovalent or bivalent PEGylation reagents 
containing one or two 3-nitro-2-pyridinesulfenyl (NPys)-activated cysteines, 
respectively. For targeting, the PEG reagents comprise the EGFR targeting peptide 
GE11. Polyplexes were investigated for their biophysical properties as well as EGFR 
specificity on different cell lines in vitro. 
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3.2.1 pDNA nanoparticle design, peptide and oligomer syntheses 
As published in 2001 by Blessing et al [168], EGF-PEG-PEI pDNA polyplexes were 
successfully generated by two different methods; either via pre-conjugation of PEI 
(25 kDa) with EGF before pDNA complex formation, or by post-modification of 
previously formed PEI/pDNA polyplexes. Also in the current study, the pre- and post-
modification strategy was compared for generation of EGFR-targeted polyplexes. 
Instead of PEI 25kDa, in the novel investigation shorter sequence-defined oligomers 
were applied as pDNA carriers, with far higher biocompatibility and chemical precision 
(cf. Table 10). Instead of EGF as targeting ligand, the phage-display derived EGFR 
targeting peptide GE11 (YHWYGYTPQNVI) [198] was applied; and instead of 
polydisperse PEG linkers, a precise monodisperse PEG of exactly 24 ethylenoxide 
repeats (dPEG24) was used. Like all other components, also the PEG reagents 
required for the post-modification strategy (cf. Table 11) were synthesized in precise 
fashion by solid-phase synthesis as described in 2.2.1.4. Analytical data can be found 
in the appendix (cf. 6.5). 
Table 10 List of oligomers as pDNA carriers used in this study. An internal ID, an abbreviation as well 
as its sequence (N to C terminus) are displayed. Detailed chemical structures can be found in Figure 
15 
ID # Structure Abbreviation 
440 (C-(H-Stp)
4
-H)
α,ε
-K-dPEG
24
-A 2-arm-PEG
24
-His-Ala 
454 C-Y3-Stp2-K-(K(OleA)
α,ε
)-Stp2-Y3-C T-shape 
835 (C-(H-Stp)
4
-H)
α,ε
-K-dPEG
24-YHWYGYTPQNVI 2-arm-PEG24-His-GE11 
 
The pre-conjugation strategy is based on a 2-arm oligomer topology of ligand-PEG-
Stp/His, which had already proven as effective for receptor targeted gene transfer in 
vitro as well as in vivo for several receptor/ligand combinations [50, 64, 65, 137]. Four 
cationizable alternating Stp/histidine repeats provide effective nucleic acid binding and 
endosomal buffering [50, 203], a lysine as symmetrical branching point links the 
dPEG24 molecule, which is end-modified with the targeting ligand. In the current case, 
the EGFR targeted oligomer 835 contains GE11, whereas the analogous control 
structure 440 contains alanine instead (cf. Table 10 and Figure 15). These oligomers 
also contain terminal cysteines for polyplex-stabilizing disulfide cross-link formation. 
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Figure 15 Chemical structures from N- to C- terminus of oligomers 440 (A), 835 (B) and 454 (C). Oleic 
acid (OleA) is shown in (D). 
 
In the novel post-modification strategy (cf. Scheme 5), activated disulfide exchange 
chemistry was used for introduction of the targeted PEG reagents. Core pDNA 
lipopolyplexes were formed using the T-shaped lipo-oligomer 454, which had been 
designed to mediate efficient siRNA knockdown due to its optimized structure [52]. 
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Scheme 5 EGFR-targeted pDNA lipopolyplexes designed by post-modification of 454 (Table 10) core 
complexes with mono- or bi-valent PEG reagents (Table 11). (A) Lipopolyplex formation. (B) Post-
PEGylation via disulfide exchange chemistry. 
 
Four units of the cationizable artificial amino acid Stp (12 protonatable nitrogens in 
total) provide nucleic acid binding and endosomal buffering [50, 131, 134], two centrally 
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placed oleic acids contribute to hydrophobic polyplex stability and have lytic potential 
upon acidification within the endosome [49, 51, 52]. Peripheral tyrosine trimers (Y3) 
increase polyplex stability via inter-oligomeral π – π stacking of aromatic rings [208]; 
C-terminal as well as N-terminal cysteine residues provide additional, disulfide 
triggered polyplex stabilization [134] as well as anchors for the subsequent post-
PEGylation. This oligomer has been extensively investigated as core oligomer for 
receptor dependent siRNA delivery in vitro as well as in vivo, e.g. via folate receptor 
[169], transferrin receptor [170] as well as EGFR [170], but has never been used as 
core carrier for receptor targeted pDNA delivery. Pre-PEGylation of 454 before 
polyplex formation was unsuccessful, resulting in polyplex aggregation (unpublished 
data).  
For modification of 454/pDNA polyplexes via activated disulfide exchange, monovalent 
or bivalent PEGylation reagents, comprising precise dPEG24 with GE11 or alanine as 
control, were synthesized by SPS with introduction of Boc-L-Cys(NPys)-OH as 
terminal coupling. In case of the bivalent reagent, the diamino acid Fmoc-L-
lysine(Fmoc)-OH was inserted for symmetrical branching following the PEG domain, 
and a short PEG spacer (STOTDA) was introduced for increasing flexibility of the 
reagent. The sequence was terminated by introduction of Boc-L-Cys(NPys)-OH on 
both branches. 
Table 11 Sequences of PEGylation reagents (N to C terminus) as well as used abbreviation are 
displayed. Detailed chemical structures can be found in Figure 16. 
ID # Structure Abbreviation 
1059 Cys(NPys)-dPEG24-A Cys-PEG24-Ala 
999 Cys(NPys)-dPEG24-YHWYGYTPQNVI Cys-PEG24-GE11 
1060 (Cys(NPys)-STOTDA)

-K-dPEG24-A (Cys)2-PEG24-Ala 
1056 (Cys(NPys)-STOTDA)

-K-dPEG24-YHWYGYTPQNVI (Cys)2-PEG24-GE11 
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Figure 16 Chemical structures from N- to C- terminus of Cys(NPys)-dPEG24-Ala (A), Cys(NPys)-
dPEG24-GE11 (B), (Cys(NPys)-STOTDA)α,ε-K-dPEG24-Ala (C) and (Cys(NPys)-STOTDA)α,ε-K-dPEG24-
GE11 (D). 
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3.2.2 Physicochemical polyplex characterization 
Oligomer/pDNA interaction was examined in different assays, focusing on pDNA 
binding ability, stability and compaction. Polyplexes with and without post-PEGylation 
were evaluated. First, complete binding of 200 ng of pDNA by oligomers at N/P 12 was 
verified by agarose gel electrophoresis shift assays (Figure 17A). N/P 12 was 
previously determined as the required ratio for complete pDNA binding of 454 and 
therefore was chosen for all further experiments [52]. Most important, it is to note that 
post-modification of 454 polyplexes did not influence pDNA binding, independent of 
the amounts attached to the core particle (Figure 17B). 
 
Figure 17 Retardation of formed pDNA complexes in agarose gel at N/P 12. (A) Pre-conjugated 2-arm-
His-PEG24 (440 and 835) as well as unmodified 454. (B) Post-PEGylated 454 polyplexes with indicated 
PEGylation reagents. 
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Also, pre-PEGylated polyplexes, consisting of targeted or untargeted 2-arm-His-PEG24 
and 200 ng of pDNA, showed complete pDNA retention (Figure 17A) at N/P 12. It was 
reported that lower N/P ratios for these kinds of carriers were sufficient to completely 
bind pDNA [64, 133]. For reasons of comparability between post-PEGylated 
lipopolyplexes and pre-PEGylated 2-arm polyplexes, all further experiments were 
conducted with N/P 12. After pDNA binding was confirmed, particle sizes and zeta 
potential were determined by dynamic light scattering. Results of 454 (post-PEGylated) 
polyplexes revealed very homogenous particles with a polydispersity index (PDI) 
between 0.11 and 0.20, where 1.0 represents the highest polydispersity (cf. Table 12).  
Table 12 Particle size (Z-average), PDI and zeta potential of pDNA polyplexes formed in HBG buffer 
determined with DLS. Mean of three measurements of the same sample is indicated. Polymer at N/P 
12 and 2 µg pDNA were separately diluted with HBG pH 7.4 to 30 µL each. Then solutions were mixed 
and incubated for 30 min. If indicated, PEGylation was carried out with 0.5 eq or 1.0 eq for further 15 
min. Polyplexes then were diluted to 800 µl with 10 mM NaCl pH 7.4 prior to measurement. 
ID # Z-Average [nm] Mean PDI Mean zeta potential [mV] 
440 1367 ± 134.0 0.39 ± 0.11 1.2 ± 0.2 
835 1947 ± 211.7 0.51 ± 0.04 4.5 ± 0.1 
454 81.4 ± 5.2 0.18 ± 0.02 29.9 ± 1.3 
454  -  0.5 eq Cys-PEG24-Ala 85.1 ± 1.3 0.13 ± 0.01 17.8 ± 0.3 
454  -  1.0 eq Cys-PEG
24
-Ala 82.4 ± 0.4 0.15 ± 0.01 14.7 ± 0.9 
454  -  0.5 eq Cys-PEG24-GE11 95.2 ± 0.3 0.11 ± 0.01 20.8 ± 1.4 
454  -  1.0 eq Cys-PEG
24
-GE11 121.1 ± 0.8 0.12 ± 0.01 16.9 ± 1.3 
454  -  0.5 eq (Cys)2-PEG24-Ala 79.3 ± 0.5 0.18 ± 0.01 14.7 ± 0.8 
454  -  1.0 eq (Cys)
2
-PEG
24
-Ala 83.8 ± 0.8 0.12 ± 0.02 15.6 ± 0.9 
454  -  0.5 eq (Cys)2-PEG24-GE11 189.0 ± 1.4 0.20 ± 0.02 22.0 ± 1.5 
454  -  1.0 eq (Cys)
2
-PEG
24
-GE11 283.8 ± 0.4 0.17 ± 0.01 17.7 ± 2.0 
PDI: Polydispersity index.  
 
At the same time polyplexes formed with 2-arm PEG-oligomers 440 and 835 showed 
very inhomogeneous particle populations with a PDI between 0.4 and 0.5. This non-
homogeneity resulted in DH values (displayed as Z-Average in nm) of more than 1000 
nm (cf. Table 12) for pre-PEGylated polyplexes. This could be explained by the high 
degree of PEGylation in comparison to a rather small cationizable pDNA compacting 
domain and the associated large amount of hydrophobic GE11 peptide; it is known that 
hydrophobic peptides tend to cause aggregation [209, 210]. 
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Unmodified 454 polyplexes exhibited a size of approximately 80 nm. It is to note that 
the polyplex size increased after post-modification with the monovalent GE11 reagent 
up to 121 nm and with the bidentate reagent up to 284 nm (1.0 eq each). In contrast, 
post-PEGylation with alanine containing reagents (independent of its topology or 
amount up to 1.0 eq) did not influence polyplex size. Similar findings of increasing 
polyplex size after post-PEGylation were observed for 454/siRNA polyplexes post-
modified with GE11-PEG28-maleimide [170]. In sum, these data indicate a special 
property of the hydrophobic GE11 ligand which can be better handled by the post-
modification strategy. At the same time the zeta potential of post-shielded polyplexes 
was reduced from 30 mV (unmodified 454) as far as 15 mV, thereby indicating the 
successful post-modification. To validate post-PEGylation, UV spectra of a 454 
polyplex before and after addition of 1.0 eq of (Cys)2-PEG24-Ala was recorded and 
compared to the reagents solely. A change in absorbance around 350-400 nm 
compared to the unconjugated PEGylation agent demonstrates the successful release 
of NPys. Data can be found in Figure 18.  
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Figure 18 UV/Vis detection of PEGylation reaction. (A) 8 µg of pDNA, corresponding amount of 454 at 
N/P 12 and 1.0 eq of Ala-PEG24-K-(STOTDA-Cys(NPys))2 were used. 454 - (Cys(NPys)-STOTDA)2-K-
PEG24-Ala mixed without pDNA served as positive control (mol Cys 454 / mol Cys(Npys)). (B) The same 
reagents were used to form polyplexes. 454/pDNA, as well as 454/pDNA PEGylated with 1.0 eq of 
(Cys)2-PEG24-Ala indicated successful reaction. 
 
Further on, quantitative evidence of successful PEGylation of the 454/pDNA 
lipopolyplexes is provided by determination of free lipo-oligomer thiols (Figure 19A) as 
well as release of 3-nitro-2-thiopyridone from the PEGylation reagent (Figure 19B). 
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Significant reduction of free thiols (100% in free oligomers) to approximately 80% after 
polyplex formation and to 15% after PEGylation was observed. 
 
 
Figure 19 (A) Percentage of residual cysteine mercapto (SH) groups as determined with Ellman’s assay 
for 454 polyplexes before (black) and after (grey) modification with 1.0 molar eq of (Cys)2-PEG24-Ala. 
The percentage of free mercapto groups is based on the theoretical amount (100%) of cysteines (two 
molar eq in Oligomer 454) applied in the polyplex formation. (B) Release of 3-nitro-2-thiopyridone 
(detected at 324 nm) from 1.0 molar eq (Cys)2-PEG24-Ala after reduction. Complete 3-nitro-2-
thiopyridone release after addition of 1M DTT solution (black bar) and after addition to a 454/pDNA 
polyplex for further 15 min (grey bar) is displayed. 
 
Next, transmission electron microscopy (TEM) was performed to investigate polyplex 
size and shape. In Figure 20A and Figure 21A TEM images of pre- as well as post-
PEGylated polyplexes are shown. Polyplexes of 835 and 440 exhibited a 
homogeneous size of around 50 nm, appearing in short rods, while aggregation as 
determined by DLS, could not be seen. These findings indicate that bigger particles 
can either not be detected by TEM, or that they only occurred in minor extent, 
influencing size distribution by intensity in a severe manner. 
At the same time, non-PEGylated 454 polyplexes form globules of around 40 nm, not 
undergoing significant changes due to post-modification, regardless of the topology of 
applied reagents (monovalent or bivalent). These findings suggest that the mean 
particle size could be much smaller as determined by dynamic light scattering, 
facilitating cellular uptake by standard pathways [175]. 
Next, the ability of the oligomers to compact pDNA was investigated by an ethidium 
bromide (EtBr) compaction assay. Interestingly, a significant difference between 2-
arm-PEG24-His and post-PEGylated 454 polyplexes was found (cf. Figure 20B). Within 
the first group, the remaining EtBr fluorescence was determined as more than 20% 
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(compared to untreated pDNA). In comparison to polyplexes formed with 440 and 835, 
EtBr compaction of polyplexes formed with 454 was decreased by 50% to 
approximately 10% in total, even in case of post-functionalization with 1.0 eq.  
 
 
Figure 20 (A) Transmission electron microscopy images (TEM) of polyplexes formed with 1 µg of pDNA 
at N/P 12. Average diameters (nm) of polyplexes (n=5) ± SD are displayed. Scale bar represents 100 
nm. (B) pDNA compaction of polyplexes determined with an EtBr assay. Untargeted controls are 
displayed in white, while polyplexes targeted with GE11 peptide are marked with pattern. For post 
PEGylation 1.0 eq was used, additional EtBr data can be found in Figure 21. TEM was performed by 
Susanne Kempter and Caroline Hartl (Faculty of Physics, LMU).   
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Figure 21 (A) Transmission electron microscopy images (TEM) of pre-conjugated polyplexes 440 and 
835 formed with 1 µg of pDNA at N/P 12. Average diameters (nm) of polyplexes (n=5) ± SD are 
displayed. Scale bar represents 100 nm. (B) pDNA compaction of polyplexes post-PEGylated with 0.5 
eq of reagents determined with EtBr assay. (C) Polyplex stability in presence of 250 IU heparin 
determined with EtBr assay. Untargeted controls are displayed in white, while polyplexes targeted with 
GE11 peptide are marked with pattern. TEM was performed by Susanne Kempter and Caroline Hartl 
(Faculty of Physics, LMU).    
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No difference between modified (data for 0.5 eq can be found in Figure 21B) and 
unmodified 454 polyplex was observed, indicating that post-PEGylation does not have 
an influence on pDNA compaction of the core particle. Also, no difference between C-
terminal alanine or the GE11 peptide was found. The highest pDNA compaction 
nevertheless can be achieved by LPEI, a far larger polycation, with a remaining EtBr 
fluorescence of less than 5%. To the same samples 250 IU of heparin sulfate was 
added to determine anionic stress tolerance (Figure 21C). Here we found, as reported 
previously [133], that LPEI polyplexes are very sensitive, leading to 100% EtBr 
fluorescence corresponding to full pDNA release. These effects were minor 
pronounced for LPEI-PEG2k-GE11, retaining approximately 13% pDNA, nevertheless 
they were notably increased in comparison to 454 based polyplexes, where only 70% 
could be released. By increasing the cationic charge, even better pDNA retention could 
be achieved. While no difference between unmodified 454/pDNA polyplexes and post-
PEGylated could be observed, pre-PEGylated polyplexes were also very prone to 
heparin stress and fully released pDNA. This could be explained by the increased size, 
also leading to looser polyplexes.  
Stability of polyplexes in the protein environment presents a most critical issue. 
Therefore, polyplexes have been investigated by DLS after incubation with 10% FBS 
supplemented cell culture media or full serum (FBS). Pre-PEGylated polyplexes 
formed with 440 and 835 underwent immediate aggregation under both conditions 
(Figure 22C-F). Non-modified 454 polyplexes increased from 80 nm to 250 nm with no 
further changes over time. 454 polyplexes post-modified with the monovalent 
structures showed immediate size increase from 100 nm in 10 mM NaCl to 
approximately 200 nm in both conditions. Between 4 h and 24 h these polyplexes 
aggregated to particles >800 nm (Figure 22I-L). For 454 post-modified with 1.0 eq 
(Cys)2-PEG24-GE11 a size of 280 nm in 10 mM NaCl was determined that changed to 
approximately 300 nm after addition of full serum or cell culture media. Between 4 h 
and 24 h these polyplexes underwent no changes in full serum (Figure 22O). As in 
454 polyplexes post-modified with the bivalent structures (Cys)2-PEG24-Ala/GE11 the 
aggregation was less profound, higher stability is suggested. 
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Figure 22 Intensity mean curves maintained by DLS. Full serum (A) or DMEM (supplemented with 10% 
FBS) (B) are displayed in green and polyplexes of the 454/pDNA in 10 mM NaCl in red. These 
references should help to discriminate between polyplex and serum (left column) /media (right column) 
peaks. (C) - (P) Polyplexes with indicated oligomers in FBS (left) / DMEM (right) over time.   
   Results 
   90 
3.2.3 Luciferase gene transfections 
Prior to pDNA transfections, EGFR expression levels of the three chosen cell lines 
were determined (cf. 2.2.14). While the hepatocellular cell line Huh7 and the breast 
cancer cell line MCF-7 both showed high EGFR cell surface expression, the FTC-133 
exhibited low EGFR cell surface expression (cf. Figure 23). For the subsequent 
luciferase gene transfections, cells were either incubated for 45 min or 24 h with pDNA 
complexes and luciferase intensity was determined after 24 h for Huh7 (cf. Figure 
24A), MCF-7 (cf. Figure 24B) as well as FTC-133. Polyplexes post-PEGylated (with 
monovalent or bivalent polymers) were compared to PEG-free core particle complexes 
(454) and 2-arm histidine-containing pre-PEGylated polymers. LPEI-PEG2k-GE11, 
which already has shown high transduction efficacy and EGFR specificity in vitro and 
in vivo, was used as positive control [63, 138, 192].  
 
 
Figure 23 EGFR expression of EGFR positive cell lines Huh7 (A), MCF-7 (B) as well as low EGFR 
expressing cell line FTC-133 (C) are displayed, obtained with a monoclonal mouse anti-human EGFR 
antibody and IgG control. Alexa 488-labeled goat anti-mouse secondary antibody was used for the 
detection of receptor expression by flow cytometry. Control cells are presented in black, EGFR positive 
cells are presented in grey. Receptor screening was performed by Sarah Urnauer (PhD study, University 
Hospital of LMU, Department of Internal Medicine IV). 
 
The EGFR-targeted bivalent structure (Cys)2-PEG24-GE11 coupled to 454 core 
polyplexes at a molar ratio of 1.0 eq demonstrated a strong EGFR-targeting effect, in 
contrast to the alanine containing structure on both receptor positive cell lines. 
Moreover, significantly higher expression levels compared to all other polymers were 
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detected. The pre-PEGylated polyplexes (835 and 440 control) revealed similar 
transfection level as LPEI-PEG2k-GE11 in Huh7 cells and even lower results in MCF-
7 cells. Based on sizes measured by DLS, which showed sizes over 1 µm for both pre-
PEGylated polymers, transfection efficacy might be attributed to high aggregation and 
not due to specific uptake. Transfection of non-PEGylated 454 demonstrated equal (in 
Huh7) or slightly higher (MCF-7) expression level compared to LPEI-PEG2k-GE11. 
None of the polyplexes mediated cytotoxicity after 45 min and 24 h of incubation 
(Figure 25). 
 
 
Figure 24 Luciferase reporter gene expression in two EGFR positive human cancer cell lines. (A) 
Human hepatocellular cancer cells Huh7 and (B) human breast cancer cell line MCF-7. pCMVLuc 
polyplexes were incubated on cells for 45 min (left) or 24 h (right). Untargeted controls are displayed in 
white, while polyplexes targeted with GE11 peptide are marked with pattern. Transfections were 
performed by Sarah Urnauer (PhD study, University Hospital of LMU, Department of Internal Medicine 
IV). 
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The EGFR-targeted bivalent structure (Cys)2-PEG24-GE11 coupled to 454 core 
polyplexes at a molar ratio of 1.0 eq demonstrated a strong EGFR-targeting effect in 
both cell lines, in contrast to the alanine containing structure. Moreover, significantly 
higher expression levels compared to all other polymers were detected. The pre-
PEGylated polyplexes (835 and 440 control) revealed similar transfection level as 
LPEI-PEG2k-GE11 in Huh7 cells and even lower results in MCF-7 cells. Based on sizes 
measured by DLS, which showed sizes over 1 µm for both pre-PEGylated polymers, 
transfection efficacy might be attributed to high aggregation and not due to specific 
uptake. Transfection of non-PEGylated 454 demonstrated equal (in Huh7) or slightly 
higher (MCF-7) expression level compared to LPEI-PEG2k-GE11. None of the 
polyplexes mediated cytotoxicity after 45 min and 24 h of incubation (Figure 25).  
 
 
Figure 25 Cell viability assay of (A) Huh7 and (B) MCF-7 was performed in parallel to luciferase 
transfection. MTT was performed after 45 min (left), and after 24 h (right). Viability assays were 
performed by Sarah Urnauer (PhD study, University Hospital of LMU, Department of Internal Medicine 
IV). 
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For post-integration of PEG onto core polyplexes, monovalent and bivalent structures 
were compared at two different molar ratios. One eq proved to be more efficient than 
0.5 eq. Results for 0.5 eq are displayed in Figure 26A-B, with no occurring cytotoxicity 
(cf. Figure 26C-D). Interestingly, transduction efficacy was not influenced by post-
modification of 454 polyplexes with up to 1.0 eq of (Cys)2-PEG24-Ala in comparison to 
the unshielded core polyplexes, thereby highlighting this approach as possibility to 
circumvent the so-called “PEG-dilemma” of pre-PEGylated structures [163]. It is widely 
accepted that PEI-like polyplexes require a combined effect of osmotic endosomal 
eruption and direct phospholipid destabilization by the cationized vehicle for 
endosomal escape [1, 143, 166]. PEG obviously can interfere with this direct cationic 
membrane destabilization. Consistently, bioreversible PEGyation was introduced to 
resolve this dilemma [61, 62, 64] and also the disulfide conjugation of oligomer and 
PEG used in the present work could possibly be cleaved off by intracellular glutathion 
(GSH) as demonstrated in other work [111, 211, 212]. 
In comparison to Huh7 and MCF-7 cells that demonstrated strong EGFR dependency 
of transfection rates, this was not detected in low EGFR expressing FTC-133 cells. 
FTC-133 cells demonstrated no differences in transfection rates of post-PEGylated 
monovalent and bivalent structures coupled to either GE11 or Ala after 45 min 
incubation time. This further indicates the beneficial EGFR targeting strategy of 
polyplexes post-modified with GE11 targeted PEGylation reagents (cf. Figure 27A). 
At the same time, no polyplex mediated cytotoxicity was observed after 45 min of 
incubation (cf. Figure 27B). 
After 24 h of polyplex incubation, an overall increased transduction efficacy was 
measurable due to unspecific uptake mechanisms that occur after long-time 
incubation. Due to residual positive charge polyplexes tend to adhere unspecifically to 
the negatively charged cell membrane and particles get taken up unspecifically over 
time, leading to a diminished targeting effect. Nevertheless, the advantageous bivalent 
conjugation of EGFR-targeted PEG to 454 is still evident after 24 h of incubation.  
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Figure 26 Transfection of 454 polyplexes PEGylated with 0.5 eq after 45 min (left) and 24 h (right). 
Luciferase gene expression determined in Huh7 (A) and MCF-7 (B). Corresponding MTT assays 
performed in parallel as displayed in (C) and (D) respectively. Assays were performed by Sarah Urnauer 
(PhD study, University Hospital of LMU, Department of Internal Medicine IV).   
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Figure 27 Luciferase gene expression in the low EGFR expressing cell line FTC-133 (A). Transfection 
results after 45 min of polyplex incubation. The corresponding MTT assay was performed in parallel (B). 
Assays were performed by Sarah Urnauer (PhD study, University Hospital of LMU, Department of 
Internal Medicine IV).   
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3.2.4 Cellular binding and internalization of bivalent post-PEGylated 
polyplexes 
For a more detailed investigation, cellular association and uptake of Cy5 labeled pDNA 
complexes were determined by flow cytometry. Best-performing condition (1.0 eq) was 
used. Binding efficiency of bivalent post-PEGylated (EGFR-targeted and untargeted) 
lipopolyplexes in comparison to unshielded lipopolyplexes (454) was examined 
(Figure 28). All three lipopolyplexes showed efficient binding after 30 min incubation 
on ice. Far higher Cy5 fluorescence intensity was measured in cells transfected with 
the post-PEGylated EGFR-targeted bidentate structure. This emphasizes the 
suitability of GE11 as EGFR specific ligand and at the same time demonstrates that 
the bidentate structure represents the most promising post-PEGylation reagent. 
Shielding with PEG did not result in diminished interaction with cell surface, as can be 
seen by comparing fluorescence activity between non-shielded 454 and bivalent post-
PEGylated alanine control (cf. Figure 28A-B). Experiments were also performed with 
monovalent PEGylation reagents, which did not result in any enhancement of binding 
in comparison to 454 and the alanine control in Huh7 and MCF-7 (cf. Figure 29A,C). 
Complementary binding results of LPEI-PEG2k-GE11 and 2-arm pre-PEGylated 
structures are shown in Figure 30A,C. 
Results of uptake studies were consistent with binding studies, showing highest 
intracellular uptake after transfection with the bivalent post-PEGylated structure in 
comparison to unshielded 454 and alanine control (Figure 28 C-D) and lower uptake 
was obtained after transfection with monovalent post-PEGylation complexes (cf. 
Figure 29B,D), LPEI-PEG2k-GE11 and pre-PEGylated structures (cf. Figure 30B,D). 
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Figure 28 Cellular association of 454 polyplexes post-PEGylated with 1.0 eq of bidentate reagents on 
Huh7 (A) and MCF-7 (B) after 30 min incubation at 4 °C as determined by flow cytometry. (C) and (D) 
represent corresponding mean fluorescence intensity (MFI) values. Cellular internalization of polyplexes 
after 45 min of incubation at 37 °C followed by removal of extracellularly bound polyplexes is displayed 
in (E) and (F). Corresponding MFI values can be found in (G) and (H). Logarithmic X-scale in (A) and 
(B) as well as (E) and (F) represents Cy5 fluorescence of polyplexes. Assays were performed by Sarah 
Urnauer (PhD study, University Hospital of LMU, Department of Internal Medicine IV).   
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Figure 29 Flow cytometry results of 454 polyplexes PEGylated with 1.0 eq of monovalent reagents as 
well as corresponding mean fluorescence intensities. Cellular association of polyplexes on Huh7 (A) 
and MCF-7 (C) after 30 min incubation at 4 °C determined by flow cytometry. (B) and (D) cellular 
internalization of polyplexes after 45 min of incubation at 37 °C followed by removal of extracellularly 
bound polyplexes. Logarithmic X-scale in (A) - (D) represents Cy5 fluorescence of polyplexes. Assays 
were performed by Sarah Urnauer (PhD study, University Hospital of LMU, Department of Internal 
Medicine IV).   
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Figure 30 Flow cytometry results of pre-conjugated polyplexes, as well as corresponding mean 
fluorescence intensity. Cellular association of polyplexes on Huh7 (A) and MCF-7 (C) after 30 min 
incubation at 4 °C. In (B) and (D) cellular internalization of polyplexes after 45 min of incubation at 37 
°C followed by removal of extracellularly bound polyplexes. Logarithmic X-scale in (A) - (D) represents 
Cy5 fluorescence of polyplexes. Assays were performed by Sarah Urnauer (PhD study, University 
Hospital of LMU, Department of Internal Medicine IV).   
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For nanoparticles, different uptake pathways are described depending on cell type, 
nanoparticle formulation, nanoparticle size and incorporation of ligands for active 
targeting. Various studies have been performed to rule out the exact mechanisms. 
Size-dependent uptake studies determined that particles up to 500 nm were 
internalized into cells by energy based processes [175, 176]. A clathrin-dependent 
uptake mechanism, as well as caveolae-assisted uptake, was detected for particles up 
to 200 nm. For lipopolyplexes, the clathrin dependent way is the major mechanism, 
whereas for polyplexes, both ways are possible [176].   
The lipopolyplexes used in this study exhibited a size of approximately 200 nm or 
smaller, which suggests a clathrin depend uptake. However, uptake is not only size 
dependent, but also ligand dependent. Referring to this point, a study comparing the 
ligand GE11 and EGF for receptor mediated uptake revealed following that GE11 
targeted polyplexes were taken up into the cell via clathrin-mediated endocytosis. This 
GE11-mediated uptake showed no activation of EGFR with constant EGFR levels after 
transfection and demonstrated an alternative actin-dependent pathway [68].  
In conclusion, EGFR-targeted lipopolyplexes in this study are designed to achieve 
characteristics for an active targeted, clathrin-dependent uptake mechanism, which 
was proved to be the process of lipopolyplexes and polyplexes with the GE11 ligand 
[68].  
After the successful uptake into endosomes, the endosomal buffer capacity of the Stp 
units in the oligomer backbone of the lipopolyplexes leads to protonation. The cationic 
function as well as the hydrophobic domains lead to enhanced interaction with the 
lysosomal membrane followed by destabilization of the membrane and degradation of 
the lipopolyplex and hence release of the pDNA in the cytosol. 
  
3.2.5 Iodide uptake activity after hNIS gene delivery 
After the proof of concept using the sensitive luciferase reporter capability for 
quantifying transduction efficacy, the sodium iodide symporter (NIS) was used as a 
clinically more relevant target gene. NIS features the beneficial dual characteristic as 
diagnostic and therapeutic gene [213, 214].  
This theranostic function gives the possibility of exact determination of tumoral NIS 
gene expression in vivo by non-invasive imaging modalities as well as therapeutic 
investigation by application of cytotoxic radionuclides [63, 65, 192, 215-223].  
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In cell culture studies, NIS gene expression after lipopolyplex mediated delivery can 
be detected by measuring iodide (125I) uptake activity of transfected cells by gamma-
counter analysis. To verify NIS-dependent 125I cell uptake, cells were pretreated with 
the NIS-specific inhibitor perchlorate (NaClO4) that results in a blockade of NIS 
mediated iodide uptake.  
As already observed in transfection, binding and uptake studies with the luciferase 
reporter gene, superiority of the post-integration approach of EGFR-targeted bidentate 
structures over non- and pre-PEGylated structures as well as untargeted complexes 
were confirmed (Figure 31A). Measured iodide uptake was perchlorate-sensitive 
verifying NIS mediated uptake. No effects on cell viability were observed after 
transfection (Figure 31B). The advantageous new EGFR specific delivery vehicles 
combine high transduction efficacy, high biocompatibility, ideal size along with optimal 
shielding that was introduced by post-integration of the bivalent (Cys(NPys)-
STOTDA),-K-dPEG24 via disulfide exchange reaction. 
 
 
Figure 31 (A) Transfection of polyplexes on Huh7 cells. A sodium iodide symporter (NIS) coding pDNA 
was used. After 125I application, iodide uptake was determined as counts per minute (cpm). Results are 
displayed with (black) and without (white) blockade of NIS by application of NaClO4 prior to 
measurement. (B) MTT performed in parallel to transfections. Untargeted controls are displayed in white, 
while polyplexes targeted with GE11 peptide are marked with pattern. Assays were performed by Sarah 
Urnauer (PhD study, University Hospital of LMU, Department of Internal Medicine IV). 
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3.3 Lipo-oligomers optimized towards enhanced lipopolyplex stability 
In chapter 3.2 polyplex post-modification was pointed out to be a promising tool to 
enhance EGFR dependent gene transfer in vitro. Within this study, pDNA 
lipopolyplexes formed with T-shaped 454 were PEGylated via mono- and bivalent 
EGFR targeted reagents. Lipopolyplexes modified with 1.0 eq of (Cys)2-PEG24-GE11 
(cf. Table 11) displayed the highest tumor cell uptake and gene transfer. Considering 
that polyplex stability represents a critical step within in vivo gene delivery, a new library 
of oligomers was designed to increase lipopolyplex stability. The T-shaped oligomer 
454 served as a starting point for this study.  
 
3.3.1 Library design and oligomer synthesis 
Oligomers were generated by SPS. Synthesis was mainly carried out by automated 
peptide synthesis as described in 2.2.1.3.7. For all oligomers synthesis started with a 
2-chorotrityl chloride resin preloaded with Fmoc-L-Cys(Trt)-OH. After loading 
determination, Fmoc was removed and synthesis was conducted to obtain the 
sequences listed in Table 13. Besides terminal cysteines, introduced for triggered 
polyplex stabilization via bioreducible crosslinking [134] and serving as anchors for the 
PEGylation reagents, all oligomers contained tyrosine blocks for hydrophobic 
stabilization via inter-oligomeral - stacking [208]. For nucleic acid binding and 
endosomal buffering all oligomers were equipped with Stp units and centrally placed 
L-Lys(Dde) facilitated orthogonal attachment of two hydrophobic fatty acids after the 
introduction of a Fmoc-L-Lys(Fmoc)-OH for symmetrical branching. These inserted 
oleic or cholanic acids contribute to hydrophobic polyplex stabilization [49, 51, 52, 111]; 
oleic acid is also known to enhance endosomal escape due to a pH-dependent lytic 
potential.  
The library can be divided into three different approaches to enhance oligomer 
mediated lipopolyplex stability.  
Within the first approach, the number of Stp units was increased from 4 to 6 or 8 
respectively. As noted in 3.2.2 an increase of intra-oligomeral cationic charge density 
is known to enhance polyplex compaction and endosomal buffering [224]. Within this 
set also cholanic acid, which was mentioned to improve lipopolyplex stability [111] was 
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introduced alternatively to oleic acid. Thereby the set of oligomers consisted of 454 
and 1021, 1022 and 1023, 1175 and 1176 (firstly mentioned oligomers contain oleic 
acid, followed by cholanic acid containing oligomers, with Stp units increasing from 4 
to 6 to 8 – peripheral Y3 were kept in all oligomers).  
Another approach aimed at the increase of hydrophobic stabilization by introduction of 
peripheral Y6 instead of Y3. As investigated previously, tyrosines have additionally been 
found to stabilize polyplexes via - stacking [52]. Therefore, oligomers containing 4 
and 8 Stp units and peripheral tyrosine hexamers with centrally placed oleic as well as 
cholanic acid were generated. 1173 and 1174 as well as 1177 and 1178 thereby were 
generated (again oleic acid containing structures are mentioned first, followed by 
cholanic acid containing oligomers).  
The last set of oligomers aimed to investigate the effect of histidines within sequence-
defined oligomers. Introduction of histidines significantly enhanced endosomal 
buffering and thereby endosomal escape within sequence-defined oligomers [50, 64]. 
For this study, also another characteristic was taken into account; Histidines, with a 
pKa of 6.5 are only marginally protonated at neutral pH, and thereby exhibit 
hydrophobic properties. The aromatic imidazole ring is therefore thought to contribute 
to stability via - stacking [225]. To investigate the effect on positioning, cationic 
oligomers were built with either 4 or 8 Stp units and histidines were either introduced 
alternately between the Stp units (H-(Stp-H) x) or blockwise (Hy-Stpx) between Y3 and 
Stp. X was either considered as 2 or 4 while Y at the same time is considered as 3 or 
5 respectively, thereby leading to oligomers 1026 and 1024 or 1179 and 1180. Centrally 
placed oleic acid should maintain the fundamental level of stability within all of these 
oligomers.   
To provide an overview of this study, all oligomers are illustrated in Scheme 6 and 
summarized in Table 13. Abbreviations instead of internal ID # are introduced for a 
better understanding. 
PEGylation of lipopolyplexes was conducted with 1.0 eq of the bivalent reagents. 
Synthesis was conducted as described in 2.2.1.4.2 and was discussed previously 
(cf. 3.2.1). They are summarized in Table 14. 
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Table 13 List of oligomers generated for this study. Internal ID, chemical structure from C to N terminus 
and an abbreviation for each oligomer is given. 
ID # Structure Abbreviation 
454 C-Y3-Stp2-K-[K-(OleA)]-Stp2-Y3-C Stp2-Y3-OleA 
1021 C-Y3-Stp2-K-[K-(CholA)]-Stp2-Y3-C Stp2-Y3-CholA 
1022 C-Y3-Stp3-K-[K-(OleA)]-Stp3-Y3-C Stp3-Y3-OleA 
1023 C-Y3-Stp3-K-[K-(CholA)]-Stp3-Y3-C Stp3-Y3-CholA 
1024 C-Y3-H3-Stp2-K-[K-(OleA)]-Stp2-H3-Y3-C Stp2-H3-Y3-OleA 
1026 C-Y3-(H-Stp)2-H-K-[K-(OleA)]-H-(Stp-H)2-Y3-C (Stp-H)2-H-Y3-OleA 
1173 C-Y6-Stp2-K-[K-(OleA)]-Stp2-Y6-C Stp2-Y6-OleA 
1174 C-Y6-Stp2-K-[K-(CholA)]-Stp2-Y6-C Stp2-Y6-CholA 
1175 C-Y3-Stp4-K-[K-(OleA)]-Stp4-Y3-C Stp4-Y3-OleA 
1176 C-Y3-Stp4-K-[K-(CholA)]-Stp4-Y3-C Stp4-Y3-CholA 
1177 C-Y6-Stp4-K-[K-(OleA)]-Stp4-Y6-C Stp4-Y6-OleA 
1178 C-Y6-Stp4-K-[K-(CholA)]-Stp4-Y6-C Stp4-Y6-CholA 
1179 C-Y3-(H-Stp)4-H-K-[K-(OleA)]-H-(Stp-H)4-Y3-C (Stp-H)4-H-Y3-OleA 
1180 C-Y3-H5-Stp4-K-[K-(OleA)]-Stp4-H5-Y3-C Stp4-H5-Y3-OleA 
 
Analytical data (MALDI-MS) of the oligomers can be found in 6.5.5. 
 
Table 14 Sequences of PEGylation reagents (N to C terminus) as well as used abbreviation are 
displayed. Detailed chemical structures can be found in Figure 16C,D. 
ID # Structure Abbreviation 
1060 (Cys(NPys)-STOTDA)

-K-dPEG24-A (Cys)2-PEG24-Ala 
1056 (Cys(NPys)-STOTDA)

-K-dPEG24-YHWYGYTPQNVI (Cys)2-PEG24-GE11 
 
   Results 
   105 
 
Scheme 6 Oligomers generated within this study 
 
3.3.2 Physicochemical polyplex characterization 
3.3.2.1 Size and zeta potential of unmodified as well as post-modified 
lipopolyplexes 
After synthesis, oligomers were investigated biophysically by formation of pDNA 
polyplexes. Thereby, mean particle size (displayed as Z-average), mean PDI and 
mean zeta potential (mV) was determined at N/P 12 with 2 µg pDNA. Within particle 
distribution, a PDI of 1.0 represents the highest polydispersity. All polyplexes displayed 
a size between 68 and 102 nm prior to PEGylation, while the PDI revealed a low 
polydispersity between 0.11 and 0.26 (cf. Table 15). All polyplexes exhibited a positive 
zeta potential between 17 and 30 mV.  
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Table 15 Particle size (Z-average), PDI and zeta potential of pDNA polyplexes formed in HBG buffer 
determined with DLS. Mean of three measurements of the same sample is indicated. Polymer at N/P 
12 and 2 µg pDNA were separately diluted with HBG pH 7.4 to 30 µL each. Then solutions were mixed 
and incubated for 30 min. Polyplexes then were diluted to 800 µl with 10 mM NaCl pH 7.4 prior to 
measurement. 
Compound  Z-Average Mean PDI Mean zeta potential 
Stp2-Y3-OleA (454) 81.5 ± 5.2 0.18 ±0.02 29.9 ± 1.3 
Stp2-Y3-CholA (1021) 69.9 ± 0.6 0.14 ± 0.02 22.4 ± 2.5 
Stp3-Y3-OleA (1022) 76.3 ± 0.4 0.15 ± 0.01 22.8 ± 2.1 
Stp3-Y3-CholA (1023) 73.5 ± 0.7 0.17 ± 0.02 22.5 ± 1.3 
Stp2-H3-Y3-OleA (1024) 79.8 ± 0.9 0.15 ± 0.01 22.5 ± 0.7 
(Stp-H)2-H-Y3-OleA (1026) 75.4 ± 0.8 0.11 ± 0.01 24.8 ± 1.2 
Stp2-Y6-OleA (1173) 99.5 ± 2.1 0.26 ± 0.05 27.1 ± 1.9 
Stp2-Y6-CholA (1174) 101.6 ± 0.5 0.17 ± 0.01 27.4 ± 1.7 
Stp4-Y3-OleA (1175) 71.8 ± 0.3 0.19 ± 0.01 19.2 ± 1.7 
Stp4-Y3-CholA (1176) 67.6 ± 1.5 0.17 ± 0.01 16.7 ± 1.6 
Stp4-Y6-OleA (1177) 80.2 ± 0.5 0.18 ± 0.01 26.7 ± 1.2 
Stp4-Y6-CholA (1178) 75.6 ± 0.6 0.17 ± 0.01 22.6 ± 2.4 
(Stp-H)4-H-Y3-OleA (1179) 78.6 ± 0.3 0.20 ± 0.01 19.5 ± 4.2 
Stp4-H5-Y3-OleA (1180) 72.7 ± 2.0 0.18 ± 0.02 18.8 ± 3.2 
PDI: Polydispersity index. Z-average is displayed in nm and mean zeta potential in mV 
 
With increasing amounts of incorporated Stp, polyplexes containing oleic acids and Y3 
exhibited a decrease between 82 nm (Stp2) and 68 nm (Stp4). This indicates that the 
cargo is compacted better due to elevated cationic charge, resulting in smaller 
nanoparticles. Within the same set of cholanic acid containing oligomers, no notable 
differences were observed. The increase of tyrosines from Y3 to Y6 in oligomers 
containing 4 and 8 Stp units generally led to an increase in size compared to oligomers 
with only Y3. The introduction of histidines, independent of the positioning, did not 
significantly affect polyplex size.  
While post-modification with 1.0 eq (Cys)2-PEG24-Ala did not significantly influence 
polyplex size, all polyplexes exhibit a size below 90 nm. Addition of 1.0 eq (Cys)2-
PEG24-GE11 resulted in increased polyplex sizes. Reduction of zeta potential indicates 
a successful PEGylation (cf. Table 16, Table 17 and Table 18) compared to non-
PEGylated polyplexes can be observed in all cases (cf. Table 15). While polyplexes 
formed with Y3-Stp2/Stp3 (454 and 1021, 1022 and 1023) increased size to more than 
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160 nm, this could not be observed for Y3-Stp4 (1175 and 1176) post-modified with 
GE11, where polyplex size was only increased by approximately 25 nm to below 95 
nm.  
Table 16 Polyplexes were post-modified with 1.0 eq (Cys)2-PEG24-Ala or GE11. Within the cationic 
backbone, the number of Stp units was increased from 4 to 6 or 8, while peripheral tyrosine trimers (Y3) 
was preserved. Oleic acid or cholanic acids were incorporated as central hydrophobic stabilization 
domains.  
PDI: Polydispersity index. Z-average is displayed in nm and mean zeta potential in mV 
 
Table 17 Polyplexes were post-modified with 1.0 eq (Cys)2-PEG24-Ala or GE11. Within the cationic 
backbone, the number of peripheral tyrosines was increased from trimers (Y3) to hexamers (Y6). The 
number of Stp units was increased from 4 to 8. Oleic acid or cholanic acids were incorporated as central 
hydrophobic stabilization domains. 
PDI: Polydispersity index. Z-average is displayed in nm and mean zeta potential in mV 
 
Compound  -  1.0 eq (Cys)2-PEG24-Ala/GE11 Z-Average Mean PDI Mean zeta potential 
Stp2-Y3-OleA (454)  -  Ala 83.8 ± 0.8 0.12 ± 0.02 15.6 ± 0.9 
Stp2-Y3-OleA (454)  -  GE11 283.8 ± 0.4 0.17 ± 0.01 17.7 ± 2.0 
Stp2-Y3-CholA (1021)  -  Ala 89.3 ± 0.4 0.15 ± 0.01 9.3 ± 1.0 
Stp2-Y3-CholA (1021)  -  GE11 166.1 ± 0.7 0.09 ± 0.01 21.6 ± 1.0 
Stp3-Y3-OleA (1022)  -  Ala 85.3 ± 0.5 0.18 ± 0.01 13.3 ± 2.0 
Stp3-Y3-OleA (1022)  -  GE11 336.0 ± 11.5 0.34 ± 0.05 19.2 ± 1.0 
Stp3-Y3-CholA (1023)  -  Ala 80.1 ± 1.4 0.21 ± 0.01 8.6 ± 0.8 
Stp3-Y3-CholA (1023)  -  GE11 168.2 ± 0.9 0.17 ± 0.02 20.6 ± 0.2 
Stp4-Y3-OleA (1175)  -  Ala 72.2 ± 0.6 0.18 ± 0.01 9.1 ± 1.3 
Stp4-Y3-OleA (1175)  -  GE11 82.8 ± 0.9 0.19 ± 0.01 16.7 ± 1.2 
Stp4-Y3-CholA (1176)  -  Ala 72.8 ± 0.9 0.17 ± 0.01 8.6 ± 1.3 
Stp4-Y3-CholA (1176)  -  GE11 93.6 ± 0.4 0.17 ± 0.02 16.6 ± 1.7 
Compound  -  1.0 eq (Cys)2-PEG24-Ala/GE11 Z-Average Mean PDI Mean zeta potential 
Stp2-Y6-OleA (1173)  -  Ala 214.2 ± 9.6 0.44 ± 0.03 2.8 ± 0.3 
Stp2-Y6-OleA (1173)  -  GE11 8778 ± 595 0.46 ± 0.47 13.8 ± 0.6 
Stp2-Y6-CholA (1174)  -  Ala 105.8 ± 0.8 0.18 ± 0.01 4.5 ± 0.6 
Stp2-Y6-CholA (1174)  -  GE11 6152 ± 189 0.22 ± 0.12 17.5 ± 0.6 
Stp4-Y6-OleA (1177)  -  Ala 84.8 ± 0.8 0.16 ± 0.02 11.1 ± 1.6 
Stp4-Y6-OleA (1177)  -  GE11 101.9 ± 0.6 0.13 ± 0.02 20.2 ± 0.3 
Stp4-Y6-CholA (1178)  -  Ala 81.7 ± 0.4 0.17 ± 0.02 10.7 ± 2.4 
Stp4-Y6-CholA (1178)  -  GE11 96.3 ± 0.4 0.16 ± 0.01 18.8 ± 1.0 
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At the same time, introduction of Y6 resulted for oligomers 1173 and 1174 (4 Stp units) 
in severe aggregation of more than 5000 nm (cf. Table 17), this could not be observed 
for 1177 and 1178 (8 Stp units), pointing out that an increased cationic charge is 
beneficial to overcome the risk of aggregation during lipopolyplex PEGylation with 
GE11.   
As observed previously during PEGylation of 454 with GE11 [226], the potential of 
aggregation is linked to an unbalanced ratio between PEG-GE11 and the cationizible 
domain within the oligomer – which was improved by the introduction of additional Stp 
units. It is also known that hydrophobic peptides tend to cause aggregation [209, 210].  
Introduction of histidines notably increased nanoparticle size within polyplexes formed 
with oligomers containing only 4 Stp units (cf. Table 18). At the same time, this could 
not be observed for oligomers with 8 Stp units. A clear conclusion on the positioning 
of histidines could not be drawn, as for 1024 and 1026 (4 Stp units), the blockwise 
positioning exhibited sizes of  850 nm while alternating histidines resulted in  200 
nm particles. For oligomers containing 8 Stp units, only an increase of 30 nm (71 nm 
alternating and 100 nm for blockwise positioning) could be observed, displaying 
contrary effects. However, regarding size control after PEGylation with the bivalent 
GE11 reagent, all oligomers containing 8 Stp units (1175-1180) showed the best 
properties. Comparing oleic acid and cholanic acid as centrally placed hydrophobic 
stabilization domains, polyplexes after post-modification tended to be slightly smaller 
when cholanic acid was incorporated instead of oleic acid.  
Table 18 Polyplexes were post-modified with 1.0 eq (Cys)2-PEG24-Ala or GE11. Histidines, either 
alternately or blockwise, were introduced into oligomers consisting of 4 or 8 Stp units. Tyrosine trimers 
(Y3) and centrally placed oleic acid are intended to maintain polyplex stability due to hydrophobic 
stabilization. 
PDI: Polydispersity index. Z-average is displayed in nm and mean zeta potential in mV 
Compound  -  1.0 eq (Cys)2-PEG24-Ala/GE11 Z-Average  Mean PDI Mean zeta potential 
Stp2-H3-Y3-OleA (1024)  -  Ala 124.8 ± 1.0 0.26 ± 0.01 1.4 ± 0.1 
Stp2-H3-Y3-OleA (1024)  -  GE11 854.0 ± 26.8 0.68 ± 0.05 21.0 ± 0.5 
(Stp-H)2-H-Y3-OleA (1026)  -  Ala 86.6 ± 0.7 0.11 ± 0.01 3.2 ± 0.3 
(Stp-H)2-H-Y3-OleA (1026)  -  GE11 196.4 ± 2.7 0.12 ± 0.02 22.2 ± 1.0 
(Stp-H)4-H-Y3-OleA (1179)  -  Ala 83.7 ± 0.5 0.15 ± 0.01 12.0 ± 1.0 
(Stp-H)4-H-Y3-OleA (1179)  -  GE11 99.8 ± 1.0 0.19 ± 0.01 17.0 ± 1.2 
Stp4-H5-Y3-OleA (1180)  -  Ala 70.5 ± 0.1 0.13 ± 0.01 11.5 ± 2.9 
Stp4-H5-Y3-OleA (1180)  -  GE11 70.8 ± 0.2 0.14 ± 0.01 18.3 ± 1.7 
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3.3.2.2 pDNA compaction in buffer and after polyanionic stress  
pDNA compaction was examined with EtBr exclusion assay. However, none of the 
polyplexes compacted pDNA as good as LPEI, which served as control ( 5% 
remaining EtBr fluorescence). Remaining EtBr fluorescence related to uncomplexed 
pDNA for all tested oligomers was between 7 and 17% for non-PEGylated polyplexes 
(cf. Figure 32). Again, polyplexes formed with Stp4-Y3 oligomers exhibited the highest 
compaction, although differences are not significant. The increase of tyrosines did not 
affect pDNA compaction significantly. Introduction of histidines resulted in the least 
compact particles. These findings are in accordance with previous findings, where it 
was pointed out, that dependent on the used artificial amino acid, pDNA compaction 
was reduced in case of Stp [50]. Comparing oligomers with 4 and 8 Stp units, within all 
settings (Y3 to Y6 and introduction of histidines) pDNA compaction was slightly 
improved for oligomers with increased numbers of Stp units. PEGylation with 1.0 eq of 
the Ala or GE11 containing reagent did not notably affect nucleic acid compaction. 
As a next experiment, pDNA compaction after addition of 250 IU heparin, mediating 
polyanionic stress to the polyplex, was observed. Here, clearly LPEI was most prone 
to releasing 96% of its cargo. Comparing the three groups (only increased cationic 
charge density, increase of tyrosines, and introduction of histidines), polyplex 
resistance towards polyanionic stress can be summarized as follows: Stp2-Y6 > Stp2-
H3  (H-Stp)2-H > Stp4-H5  (H-Stp)4-H  Stp4-Y6 > Stp4-Y3  Stp3-Y3 >Stp2-Y3 (cf. 
Figure 32D-F). These findings correlate with the hypothesis of additional lipopolyplex 
stabilization via hydrophobic domains (such as tyrosines and histidines). PEGylation 
did not clearly influence lipopolyplex stability, in some cases, even an increased 
resistance is observed (cf. Figure 32D).  
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Figure 32 pDNA compaction of oligomers was determined by EtBr assay. After lipopolyplex formation 
(grey bars), followed by post-modification with 1.0 eq of bivalent Ala (white bars) or GE11 (patterned 
bars) the remaining EtBr fluorescence was determined and related to uncomplexed pDNA. (A) 
Oligomers with ascending Stp units. (B) Introduction of tyrosine hexamers into oligomers containing 4 
and 8 Stp units. (C) Alternating or blockwise introduction of histidines into oligomers containing 4 and 8 
Stp units. (D)- (F) Corresponding pDNA compaction after addition of 250 IU of heparin. 
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3.3.2.3 Steric stability of unmodified as well as PEGylated lipopolyplexes 
under physiological salt conditions 
Lipopolyplex stability was further investigated by addition of PBS and nanoparticle 
sizes were determined immediately after addition, after 0.5, 3 and if indicated 24 h. 
This test for colloidal stability under physiological salt conditions exhibit again the 
influence of cationic charge, and thereby pDNA compaction, as lipopolyplexes 
composed of oligomers with 4 or 6 Stp units underwent aggregation within 30 minutes 
(cf. Figure 33A) exhibiting particle sizes of more than 1000 nm. At the same time, 
polyplexes formed with oligomers 1175 or 1176 (Stp4-Y3) increased in size within 30 
min but remained stable for 24h with a particle size of approximately 400 or 200 nm 
respectively. The size difference within these two polyplexes could be explained by the 
enhanced stability mediated by cholanic acid [111]. Introduction of further tyrosines 
into oligomers containing 4 or 8 Stp units was in accordance with results mentioned 
above. Here, an increase of tyrosines weakened lipopolyplex stability, resulting in 
immediate aggregation of polyplexes formed with 1173 and 1174 to particles >800 nm, 
while size only increased from  100 nm to 260 nm in case of 1177 and 1178. Also, 
again within the latter two, cholanic acid (incorporated in 1178), tends to retard particle 
aggregation and thereby increases stability up to 3 h. Compared to oligomers with Stp4-
Y3 (1175 & 1176), introduction of histidines seemed to be beneficial independent of the 
positioning. Here, sizes only increased up to 200 nm, interestingly this effect was less 
pronounced for oligomers with alternating H-Stp repeats than with blockwise 
introduction of histidines (cf Figure 33C). 
In parallel, lipopolyplexes were post-PEGylated with 1.0 eq of (Cys)2-PEG24-Ala and 
treated similarly to non-PEGylated nanoparticles (cf. Figure 33D-F). Here, 
lipopolyplexes remained stable for 24 h. Also, no difference in particle stability could 
be observed for oligomers with 4, 6 or 8 Stp units, nor did the introduction of tyrosines 
or histidines impact polyplex stability. This indicates the strength of this post-
modification approach, enhancing polyplex stability after PEGylation due to the steric 
stabilization as observed for PEGylated PEI complexes [29] as well as pDNA/oligomer 
polyplexes [133]. However, post-modification with 1.0 eq of (Cys)2-PEG24-GE11 
resulted for all lipopolyplexes in immediate aggregation for all polyplexes (cf. Figure 
34). For reasons of control, LPEI-PEG2k-GE11 which was previously found to reliably 
mediate pDNA delivery in vivo [62, 192], was compared to the sequence-defined 
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oligomers, resulting in polyplex aggregation to the same extent as lipopolyplexes most-
modified with 1.0 eq of the bivalent GE11 reagent. Aggregation of PEI was previously 
mentioned to be overcome after addition of PEG [29].  
 
 
Figure 33 Lipopolyplexes after incubation in PBS 7.4 mimicking physiological salt conditions. Polyplex 
size was determined immediately after PBS addition (t=0), after 0.5, 3 and if indicated after 24h. In case 
of aggregation, the samples were not further incubated under steady shaking. No determinable particles 
(as a result of severe aggregation or dissociation over time – resulting in a low count rate at an attenuator 
of 11 or sizes >8000 nm) were marked with *. (A)-(C) displays non-PEGylated lipopolyplexes, while (D)-
(F) displays polyplexes after PEGylation with 1.0 eq (Cys)2-PEG24-Ala.   
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This again pronounces the special behavior of the hydrophobic GE11 within 
polyplexes. However, also aggregation for HGFR targeted polyplexes formed with 
sequence-defined cmb containing oligomers was observed (SM, unpublished data).  
 
 
Figure 34 Lipopolyplexes PEGylated with 1.0 eq of (Cys)2-PEG24-GE11 after addition of PBS 7.4. 
Polyplex size was determined immediately after PBS addition (t=0), after 0.5, 3 and after 24h LPEI-
PEG2k-GE11 was included as control. No determinable particles (as a result of severe aggregation or 
dissociation over time – resulting in a low count rate at an attenuator of 11 or sizes >8000 nm) were 
marked with *. 
 
3.3.2.4 Serum stability of unmodified as well as post-modified lipopolyplexes  
In a last experiment to investigate polyplex stability, (PEGylated) lipopolyplexes were 
incubated in 90% FBS. Changes in size were examined by DLS. In general, all 
polyplexes underwent immediate interaction with the serum, leading to increased 
polyplex sizes, resulting in nanoparticle sizes, determined as intensity mean values of 
250-300 nm. Generally, the majority underwent no further change within 24h, however 
also an additional time point of 4h was investigated. While non-PEGylated polyplexes 
maintained their size without significant changes (apart from 1173 and 1178), 
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polyplexes post-PEGylated with 1.0 eq (Cys)2-PEG24-Ala underwent partial 
aggregation (1026, 1173, 1175 and 1177). Non-PEGylated polyplexes might benefit 
from the formation of a serum corona around the polyplexes (which would also explain 
the increased lipopolyplex size), and remain stable despite the serum interaction. 
However, the formation of a serum corona - especially when attached to PEGylated 
nanostructures - has been demonstrated to also mediate favorable shielding properties 
[206]. Aggregation of polyplexes PEGylated with Ala could be affiliated with a 
decreased surface charge (cf. Table 16, Table 17 and Table 18).  
Lipopolyplexes PEGylated with 1.0 eq (Cys)2-PEG24-GE11 mostly maintained stability 
over 24h, but 1173, 1175 and 1177 (Stp2-Y6-OleA, Stp4-Y3-OleA and Stp4-Y6-OleA) 
underwent severe aggregation, observed by DLS. However, within intensity based size 
distribution, which was required for detection besides serum proteins, small particle 
populations are over pronounced compared to smaller particles, which still could be 
detected as the main populations. Overall polyplexes exhibit a high stability in the 
presence of serum, which was already demonstrated previously [133, 226].  
Results are summarized in Table 19 and detailed intensity mean curves can be found 
in the Appendix (cf. 6.2) due to the large data set.  
Table 19 Summary table of polyplex stability in the presence of 90% serum determined after 24h with 
DLS. Colors represent: No significant change over time, partial population shift within time, total 
aggregation, as far as detectable by DLS. 
 
 
 
 
 
 
 
 
 
ID # non-PEGylated PEGylated with Ala PEGylated with GE11 
454    
1021    
1022    
1023    
1024    
1026    
1173    
1174    
1175    
1176    
1177    
1178    
1179    
1180    
   Results 
   115 
3.3.3 Luciferase gene transfections  
After biophysical evaluation, transfection efficacy of the post-modified lipopolyplexes 
was examined on two different cell lines. KB, a cervical adenocarcinoma cell line as 
well as the previously used hepatocellular carcinoma cell line Huh7 were both found to 
be EGFR positive (cf. Figure 23A and Figure 35).  
 
 
Figure 35 EGFR expression of the EGFR positive cell line KB, obtained with a monoclonal mouse anti-
human EGFR antibody and IgG control. Alexa 488-labeled goat anti-mouse secondary antibody was 
used for the detection of receptor expression by flow cytometry. Control cells are presented in light grey, 
EGFR positive cells are presented in grey. Receptor screening was performed by Wei Zhang 
(postdoctoral study, Pharmaceutical Biotechnology, LMU). 
 
The most stable oligomers were chosen for pDNA transfections. Besides LPEI, 454 
served as control, while the histidine-rich oligomer 1026, also containing 4 Stp but 
additional alternating histidines was investigated. All oligomers containing 8 Stp units 
were evaluated as well, to determine differences in transfection efficacy mediated by 
a variation of Y3 or Y6, differences between oleic acid and cholanic acid and also to 
investigate, if introduction and positioning of histidines influence endosomal escape. 
Lipopolyplexes were formed and post-modified with 1.0 eq of the bivalent reagents to 
investigate EGFR dependent gene delivery.  
However, on both cell lines, after 24 h of incubation, only 454 mediated significant gene 
transfer (cf. Figure 36A and B). This gene transfer is in accordance with previous 
findings [226], but the lack of gene transfer of the newly generated oligomers needed 
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to be evaluated. At the same time, polyplexes did not mediate significant cytotoxicity 
(cf. Figure 36C and D). 
 
 
Figure 36 Luciferase gene expression was determined on the EGFR expressing cell lines Huh 7 (A) 
and KB (B). Transfection results after 24 h of polyplex incubation are shown. The corresponding MTT 
assays were performed in parallel and are displayed in (C) and (D). Assays were performed Ana Krhac 
Levacic (PhD study, Pharmaceutical Biotechnology, LMU). 
 
As pointed out in the previous chapters (cf. 3.3.2.3 and 3.3.2.4), additional introduction 
of Stp into the T-shaped oligomers improved lipopolyplex stability and thereby might 
hinder gene transfer in vitro.   
Generally, when comparing gene transfer of the oligomer 454 in the previous chapter 
(cf. 3.2.3) and in the results shown above, a notable difference was observed. During 
previous work, the influence of a proper cleavage, to prevent hydroxylation of the oleic 
acid’s double bond [200], was not explored and therefore, oligomer cleavage was 
performed with much harsher conditions (90 min of TFA cleavage) than for the 
oligomer used for the current study. The impact of this different cleavage (30 min with 
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a thiol specific scavenger (EDT)) was not prominent for siRNA delivery [200], but it 
might explain the difference observed for pDNA delivery (cf. Figure 37). Further future 
investigations of the influence of hydroxylation of the double bond could be conducted 
by quantitative hydroxylation of the double bond. Gene transfer of the generated 
hydroxyl-stearic acid derivate could be compared to the non-hydroxylated oleic acid 
used for this study (cf. spectrum of 454 in 6.5.5.1.)  
 
 
Figure 37 Comparison of gene transfer of two 454 syntheses, followed by either TFA treatment for 90 
min or for 30 min. Gene transfer of non-PEGylated as well as post-modified polyplexes (with 1.0 eq of 
the bivalent reagents) was performed on Huh7 and KB cells by Ana Krhac Levacic (PhD study, 
Department of Pharmaceutical Biotechnology, LMU). 
 
3.3.4 Ellman’s assay to determine free thiols for polyplex post-modification 
The shorter cleavage time (cf. 2.2.1.2.2), applied for the 454 used in this chapter as 
well as all other oleic acid containing oligomers used for this chapter (cf. Table 13) 
could influence removal of certain sidechain protecting groups. Especially the Trt-
protected thiols within the oligomers’ cysteines are prone to side reactions or 
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uncomplete cleavage. This could later on influence the degree of post-modification 
during polyplex formation and thereby hinder receptor-specific tumor targeting. 
Consequently, an Ellman’s assay for quantification of free thiols was conducted for 
oligomers 454, 1026, 1175-1180. During storage, a certain number of thiols can oxidize 
and form disulfides, and are thereby not available for determination by this colorimetric, 
DTNB based reaction. Generally, 80% or more of the theoretically available thiols are 
considered as acceptable. Within the tested oligomers, only 1180 exhibited a reduced 
number of free thiols (cf. Figure 38). Oleic acid containing oligomers (like 1180) could 
suffer from incomplete removal of the thiol protecting Trt group within 30 min of 
cleavage. Additionally, the excess of reactive triphenylmethyl carbenium ions, released 
during cleavage from the side chains of histidines and cysteines, bear a high potential 
of side reactions during cleavage as they can react with deprotected thiols via an 
nucleophilic addition. 
 
 
Figure 38 Ellman’s assay of the displayed oligomers. % of free thiols are related to the theoretical 
amount of thiols in each sample. All oligomers containing oleic acid (454, 1026, 1175, 1177, 1179, 1180), 
were cleaved for 30 min, while oligomers with cholanic acid (1176, 1178) were cleaved for 90 min. 
Addition of EDT to the cleavage solution was supposed to prevent thiols from side reactions.   
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3.3.5 Cellular polyplex uptake  
To investigate if polyplexes are taken up in an EGFR specific manner, but remain in 
the endosome, and thereby do not mediate gene transfer, FACS analysis with Cy5 
labeled pDNA was carried out. Therefore, non-PEGylated lipopolyplexes, as well as 
polyplexes PEGylated with 1.0 eq of (Cys)2-PEG24-Ala and -GE11 were incubated with 
Huh7 cells for 45 min. A heparin wash was conducted to distinguish between 
internalized and associated lipopolyplexes and Cy5 intensity was investigated 
(cf. Figure 39).  
After 45 min, all cells incubated with lipopolyplexes showed notable uptake compared 
to control cells, indicating that polyplexes are successfully internalized independently 
of the PEGylation. All polyplexes post-modified with the bivalent GE11 reagent exhibit 
a significantly improved uptake compared to lipopolyplexes post-modified with Ala. The 
latter in contrast showed hampered uptake compared to non-PEGylated lipopolyplexes 
within all polyplexes formed with oligomers containing 8 Stp units. This data thereby 
suggests that un-modified polyplexes are taken up unspecifically, via electrostatic 
interaction of the positively charged polyplexes and the negatively charged cell-
surface, which could be reduced by PEGylation with Ala. Introduction of the EGFR 
specific binding peptide GE11 again increased uptake in a tumor-specific manner, 
resulting in a polyplex internalization at least as good as for non-modified 
lipopolyplexes.  
Internalization of the tested lipopolyplexes can be summarized as followed: 454, 1026, 
1077 > 1076, 1178 > 1175, 1179, 1180. The lipo-oligomers with 4 Stp units (454 and 
1026) tended to be internalized to a greater extent than lipo-oligomers consisting of 8 
Stp units, however, also exhibited an increased polyplex size determined by DLS (cf. 
3.3.2.1). Overall all, oligomers in this study confirmed previous findings, that 
lipopolyplex post-modification with bivalent PEGylation reagents exhibits an effective 
tool to mediate EGFR dependent polyplex targeting [226]. GE11 mediated cellular 
uptake is summarized in Figure 40. The optimization of T-shaped oligomers 
significantly improved polyplex stability compared to the well-established oligomer 454, 
however this increased stability could be a limitation regarding gene transfer efficacy. 
Previous results on PEI pointed out two important findings. Firstly, comparing 
pDNA/LPEI complexes and pDNA/BPEI complexes, both complexes quickly facilitated 
endosomal escape, however, the more compact pDNA/BPEI complexes remained 
stable for up to 24h inside the cell and only mediated gene transfer to a minor extent.  
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Figure 39 polyplex internalization of non-PEGylated (red), polyplexes post-modified with (Cys)2-PEG24-
Ala as well as (Cys)2-PEG24-GE11 after 45 min of incubation into Huh7 cells. Lipopolyplexes formed 
with 454 served as control and were compared to lipopolyplexes formed with the novel lipo-oligomers.   
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At the same time, LPEI complexes dissociate rather quickly and thereby mediated 
gene transfer [227]. Also, within this study LPEI polyplexes dissociated rather quickly 
in the presence of heparin, and they are known to be prone to colloidal aggregation 
[29] while polyplexes formed with these novel lipo-oligomers remained stabile within 
these enviroments.  
Also, Ogris and colleagues pointed out, that LPEI polyplexes exhibiting an enhanced 
size due to increased colloidal aggregation, mediated significantly enhanced gene 
transfer in comparison to non-aggregated pDNA/PEI polyplexes [202]. However, 
lipopolyplexes formed with these novel lipo-oligomers exhibit in these regards both 
disadvantages; pDNA compaction as well as colloidal stability is improved, when 
compared to the previously examined 454 or LPEI. 
 
 
Figure 40 Summary of cellular uptake into Huh7 after lipopolyplex post-modification with 1.0 eq of 
(Cys)2-PEG24-GE11. 
 
3.3.6 Gene transfer after enhanced endosomal escape 
Besides the already mentioned increased polyplex stability, the lack of gene transfer 
of these novel oligomers could also be mediated by a hampered release from the 
endosome intracellularily. Therefore, two further experiments have been carried out. 
Chloroquine, as a well established endosomolytic reagent [57, 228], was added to 
Huh7 cells after pDNA lipopolyplex transfection for 45 min. Thereby we wanted to 
investigate, if the limited transfection efficacy is mediated by endosomal entrapment. 
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Cells treated with chloroquine for 4 hours neither showed any cytotoxicity nor 
significantly enhanced gene transfer apart from 454 (cf. Figure 41). However, 1026 
and 1176 tended to mediate slightly improved gene transfer after chloroquine addition 
compared to HBG. 
 
 
Figure 41 Gene transfer of the lipooligomers which mediated the best cellular uptake without (A) and 
with chloroquine addition (B). (PEGylated) lipopolyplexes at N/P 12 were incubated for 45 min and then 
were treated with chloroquine for 4h, prior to a media change and further incubation for 24 h in total. (C) 
and (D) represent the corresponding MTT assays performed in parallel. 
 
As a next experiment, (post-modified) lipopolyplexes were incubated for 2 h on Huh7 
cells, followed by a change towards LPEI (corresponding to N/P 9 per well) enriched 
culture media. Cells were then further cultured for up to 24 h. Previously, Boeckle and 
colleagues [229] as well as Yue and colleagues [230] pointed out that addition of free 
LPEI, with its diaminoethane motif buffering at endosomal pH, onto cells incubated with 
pDNA polyplexes significantly led to increased transfection efficacy.   
However, within this experiment (cf. Figure 42), transfection efficacy tended to be only 
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slightly and unspecifically improved after LPEI addition. But also here, 454 
lipopolyplexes exhibited the hightest gene transfer, indicating that endosomal escape 
does not represent the only bottleneck for successful gene transfer of the novel lipo-
oligomers and enhanced lipopolyplex stability still could contribute to the reduced gene 
transfer in comparison to the less stabile 454 lipopolyplexes. 
 
 
Figure 42 Gene transfer of the lipooligomers which mediated the best cellular uptake without (A) and 
with addition of LPEI (B). (PEGylated) lipopolyplexes were incubated for 2 h and then were treated with 
cell culture media supplemented with LPEI (corresponding to N/P 9 per well) in case of (B) while cell 
culture media was replaced with normal media for (A). Cells were then further incubated for 24 h in total. 
(C) and (D) represent the corresponding MTT assays performed in parallel. 
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4 Discussion 
4.1 Influence of defined hydrophilic blocks within oligoaminoamide 
copolymers: compaction versus shielding of pDNA nanoparticles 
This chapter is based on:  
Morys, S.; Krhac Levacic, A.; Urnauer, S.; Kempter, S.; Kern, S.; Rädler, J.O.; 
Spitzweg, C.; Lächelt, U.; Wagner, E. Influence of Defined Hydrophilic Blocks within 
Oligoaminoamide Copolymers: Compaction versus Shielding of pDNA 
Nanoparticles. Polymers 2017, 9, 142. 
 
Shielding of polyplexes represents an important characteristic required for a successful 
gene delivery [153]. Unshielded polyplexes exhibiting a positive surface charge may 
challenge interaction with blood components, colloidal aggregation due to electrostatic 
interaction or in the worst case an immune response [149].  
Therefore, histidine-rich 2-arm oligomers, decorated with either PEG or peptidic PAS 
as a surface shielding domain were synthesized. This topology was previously shown, 
due to enhanced endosomal buffering [50], to be most suitable for pDNA delivery in 
vitro as well as in vivo [64, 65, 137]. These SPS derived oligomers were decorated 
with highly defined PEG as well as PAS repetitions to determine the optimal ratio of 
hydrophilic shielding blocks and cationic artificial amino acids. They were compared 
side-by-side and with an unshielded control oligomer. Besides a shielding domain, the 
cationic core of these oligomers consisted of the artificial amino acid Stp for nucleic 
acid binding [131], histidines for enhanced endosomal buffering [50], lysine for 
symmetrical branching as well as cysteines for bioreducible crosslinking [131, 134]. 
During extensive biophysical evaluation, oligomers consisting of 12 repetitions of PEG 
were compared to oligomers with 4 PAS repetitions, while 24 PEG repetitions were 
considered equivalent to 8 PAS repetitions. Due to a sophisticated synthesis of PAS 
shielded oligomers, no control oligomer compared to oligomers equipped with PEG48 
was generated. TEM, as well as EtBr compaction, exhibited decreased pDNA 
compaction and a less firm (rod- to worm-like) particle shape with increasing amounts 
of PEG. Similar findings have been made previously for pLL and LPEI/pDNA 
polyplexes decorated with PEG [32, 205]. Within the performed in vitro structure-
activity relationship studies, polyplexes shielded with PEG and PAS of comparable 
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length exhibited similar properties. At the same time, unshielded polyplexes provided 
the highest degree of pDNA compaction as well as the most compact (globule) 
nanoparticle shape determined by TEM. During this study, polyplex stability was 
challenged in the presence of physiological electrolyte concentrations (PBS), in the 
presence of 90% FBS, as well as adhesion to erythrocytes was examined. Here a 
contrary effect could be shown. Unshielded polyplex as well as polyplexes decorated 
with short shielding blocks (PEG12 or PAS4) suffered from immediate colloidal 
instability, while polyplexes decorated with PEG24 or PEG48 as well as PAS8 remained 
size stable for at least 24 h. These results are in accordance with previous findings 
published by Ogris et al. [29]. 
Investigating erythrocyte adhesion of Cy5-labeled polyplexes findings similar to the 
previous experiment were observed. Unshielded polyplexes adhered to erythrocytes 
in a very high manner (>95%), while >20% pDNA could be recovered from polyplexes 
incubated with PEG48 decorated oligomers. During incubation with 90% FBS, firstly all 
polyplexes underwent an initial interaction with serum, leading to polyplex sizes 
approximately increased about 200 nm compared to HBG both measured by DLS. In 
this experiment, polyplexes decorated with PEG24, PEG48 or PAS8 revealed the highest 
potential towards aggregation and polyplex dissociation, which was confirmed by 
another serum assay after incubation with Cy5-labeled pDNA. These findings indicate 
that unshielded polyplexes, exhibiting the highest potential of electrostatical interaction 
with negatively charged serum proteins, could be more stabilized by the formation of a 
serum corona than shielded polyplexes [206].  
Treatment of N2a tumor cells showed significant transfection efficacy for all polyplexes 
apart from polyplexes decorated with PEG48 after long-term incubation for 24 h. 
However, in the short term, sufficient shielding and thereby no significant transfection 
was yet achieved by PEG12 and PAS4.   
To determine tumor-specific delivery, a cMet targeting peptide (cmb) was introduced 
into all oligomers. After treatment to cMet positive Huh7 cells (and DU145 cells), 
untargeted polyplexes decorated with PEG48 demonstrated reduced transfection 
efficacy which could be partially recovered by the introduction of the cmb peptide. 
These findings are in accordance with previous findings [64]. Nevertheless, this results 
highlight the difficulties of polyplex shielding leading to the so-called PEG dilemma 
[167]. Transfection efficacy of cMet targeted polyplexes incorporating PEG48 as a 
shielding agent was significantly reduced in comparison to polyplexes shielded with 
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shorter shielding agents or unshielded polyplexes, leading to a higher specificity of the 
polyplexes due to an improved surface shielding, but a reduced transfection efficacy 
overall.  
In sum, it is evident that opposing requirements have to be dealt with balanced 
measures; both extremes (no shielding or very long shielding) come along with 
disadvantages. The oligomer characteristics are summarized in Table 20. In different 
in vitro experiments, it was pointed out that within two-arm oligoaminoamide pDNA 
polyplexes, the shorter PEG12 domain represents the best compromise. Similar results 
have been recently reported both for shielded LPEI polyplexes [32] and liposomes 
[231]. Polymers containing the targeting peptide cmb also confirmed these findings. 
Within the c-Met targeted polymers, polyplexes shielded with PEG12 showed the most 
pronounced targeting effect and mediated gene transfer in vitro as well as in vivo most 
efficiently. 
 
Table 20 Summary of oligomer characteristics 
Experiment 
Oligomers 
3-arm PEG12 PEG24 PEG48 PAS4 PAS8 
PBS resistance - - + + - + 
Erythrocyte adhesion - ++ ++ +++ + + 
Particle compaction +++ ++ + - ++ + 
Polyplex shape globule rod-like doughnut aggregates cord-like rod-like doughnut 
Heparin resistance + + - - + + 
Serum stability + + - - + - 
Shielding - + ++ +++ + ++ 
Transfection (short term) + - - - - - 
Transfection (long term) + + + - + + 
PBS resistance: +/- indicates Yes/No; Erythrocyte adhesion: +++ lowest adhesion, ++ low adhesion, + increased 
adhesion, – complete adhesion; Particle compaction: +++ highest compaction, ++ mediate compaction, + compaction, 
– no sufficient compaction (evaluated by EtBr exclusion assay and TEM images); Heparin resistance against 250 IU: 
+/- indicates Yes/No; Serum stability: +/– indicates Yes/No; Shielding: +++ zeta potential (ZP) < 2 mV, ++ ZP < 5 mV, 
+ ZP < 10 mV, - ZP > 10 mV; Transfection efficacy of polyplexes on N2a cells (short as well as long-term): + significant 
transfection efficacy compared to untransfected cells, - no transfection signal compared to untreated cells. 
 
 
  
   Discussion 
   127 
4.2 EGFR targeting and shielding of pDNA lipopolyplexes via bivalent 
attachment of a sequence-defined PEG agent 
This chapter is based on: 
Morys S.*, Urnauer S.*, Spitzweg C., Wagner E., EGFR Targeting and Shielding of 
pDNA Lipopolyplexes via Bivalent Attachment of a Sequence-Defined PEG Agent, 
Macromol. Biosci. 2017. (* indicates that authors contributed equally to this work) 
 
pDNA polyplexes can be functionalized with shielding and targeting domains either by 
pre-conjugation or by post-modification strategies. However, as mentioned previously, 
shielding of polyplexes represents an important characteristic required for a successful 
gene delivery to avoid aggregation with blood components, colloidal aggregation due 
to electrostatic interaction or in the worst case an immune response [149, 153]. To 
overcome the emerging disadvantages of PEGylation, tumor cell specific binding can 
be increased by introduction of a targeting domain, consisting of either small molecules 
[122, 135], peptides [50, 61, 62, 65, 139, 140] or proteins [57, 178, 197].  
The current study aimed at the design of EGFR-targeted pDNA delivery shuttles. 
EGFR targeted polyplexes formed of PEG-Stp/His 2-arm oligomers were compared 
with T-shaped lipopolyplexes that were post-modified with mono- or bivalent EGFR 
targeted PEGylation reagents. In a previous approach, pDNA/LPEI polyplexes pre- 
and post-modified with EGF-PEG were already compared side by side, pointing out 
the advantageous strategy of a polyplex post-modification [168]. Within this study, 
GE11 (YHWYGYTPQNVI), a phage-derived peptide, served as a specific ligand for 
the EGFR within sequence-defined oligomers. Pre-PEGylated oligomers consisted of 
the GE11 peptide or alanine, a PEG of exactly 24 repetitions, while the cationic core 
was composed of the artificial amino acid Stp, histidines for enhanced endosomal 
buffering, lysine for symmetrical branching as well as cysteines for bioreducible 
crosslinking. T-shaped oligomer 454 was built with tyrosines for hydrophobic 
stabilization via π – π stacking, cysteines for bioreducible crosslinking as well as it 
served as anchors for the PEGylation reagents. Stp was introduced for nucleic acid 
binding, lysine for symmetrical branching and two oleic acids as central stabilizing, pH-
dependent lytic domains. All reagents used in this study were sequentially generated 
via SPS.   
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Polyplexes assembled via pre- and post-modification strategy were examined to 
understand the biophysical behavior as well as incubated on different cancer cell lines 
to investigate tumor-specific binding, uptake and finally gene transfer of luciferase 
marker gene and sodium iodide symporter (NIS) in vitro.   
Polyplex size, determined by DLS, exhibited aggregation of polyplexes formed with the 
pre-PEGylated GE11-PEG-Stp/His 2-arm oligomer as well as its alanine equipped 
control oligomer. This could be explained by the high degree of PEGylation in 
comparison to a rather small cationizable pDNA compacting domain and the 
associated large amount of hydrophobic GE11 peptide; it is known that hydrophobic 
peptides tend to cause aggregation [209, 210].   
The size of polyplexes formed with the T-shaped lipo-oligomer 454 and pDNA only 
increased from 81.4 nm (non-PEGylated) to a maximum size of 283.8 nm after addition 
of the bivalent Cys2-PEG24-GE11 PEGylation reagent. Besides a reduced zeta 
potential, also release of NPys and a significant reduction of free thiols proved the 
successful post-modification approach. An EtBr compaction assay reproduced the 
findings of size measurement. Pre-PEGylated oligomers compacted pDNA to a lower 
extent (20-25%) than unmodified (8%) or post-modified lipopolyplexes (8-10%). Next, 
polyplex stability was investigated in the presence of 90% FBS and cell culture media 
(supplemented with 10% FBS) via DLS. Within both solvents, pre-PEGylated 
polyplexes underwent aggregation after 24 h or particle dissociation which is in 
accordance with previous results [64, 133]. At the same time, 454/pDNA polyplexes 
underwent immediate interaction with the solvents, leading to increased sizes of 
approximately 250 nm but underwent no further changes over a time of 24 h. 
Lipopolyplexes post-modified with 1.0 eq of monovalent PEGylation reagents revealed 
a lower stability than lipopolyplexes PEGylated with 1.0 eq of the bivalent PEGylation 
reagents. In the latter case, only minor size increase occurred, while the monovalent 
PEGylation reagents tended to destabilize the polyplexes, leading to partially 
aggregation within time.   
Cell experiments were carried out on the EGFR positive cell lines Huh7 and MCF-7 as 
well as the low EGFR expressing cell line FTC-133.  
Firstly, transfection efficacy was investigated by determination of luciferase 
expression. Here, gene transfer was highly enhanced in an EGFR dependent manner 
by lipopolyplexes modified with the bivalent Cys2-PEG24-GE11 reagent after 45 min. 
But also, lipopolyplexes PEGylated with the monovalent Cys-PEG24-GE11 exhibited a 
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target specificity compared to unmodified lipopolyplexes. Pre-PEGylated polyplexes, 
as well as LPEI-PEG2k-GE11, mediated gene transfer less efficiently than the 
unmodified lipopolyplexes. Incubation of the polyplexes on cells for 24 h led to 
generally increased transfection efficacy, while the trend remained unaffected. 
Transfections on the EGFR low expressing cell line FTC-133 pointed out the EGFR 
dependency of the transfections on Huh7 and MCF-7 as no enhanced gene transfer 
could be investigated by the GE11 targeted polyplexes. Within all transfections, no 
cytotoxicity could be observed.   
Secondly, cellular binding and uptake of the polyplexes was investigated on Huh7 and 
MCF-7 cells. Here, the polyplexes post-modified with 1.0 eq of the bivalent EGFR 
targeted PEGylation reagent mediated a significantly higher cellular binding than 
polyplexes PEGylated with 1.0 eq of the monovalent reagent, while both reagents were 
superior to unmodified lipopolyplexes. However, all polyplexes showed a higher 
specificity than polyplexes formed with LPEI-PEG2k-GE11 and pre-PEGylated 
polyplexes. In the latter case, a GE11 mediated targeting effect was observed, but this 
might be due to the previously mentioned severe aggregation of GE11-PEG24-Stp/His 
polyplexes.  
As a last experiment, polyplexes were formed with a NIS (sodium iodide symporter) 
expressing pDNA and incubated on Huh7 cells. The NIS gene can be introduced to 
achieve a tumor-specific iodide uptake for theranostic as well as therapeutic use [213, 
214]. Here the theranostic 125I was chosen to demonstrate the capabilities of the 
system. Also within these transfections, the lipopolyplexes post-modified with the 1.0 
eq of the bivalent EGFR targeted PEGylation reagent mediated the highest gene 
transfer, corresponding with the highest iodide uptake.   
Overall, this work is very consistent with previous work pointing out that post-
modification offers an auspicious tool for shielding and targeting of pDNA [29, 142, 
156, 160, 168, 232-234] as well as of siRNA polyplexes [169, 170]. The superior effect 
of the bivalent over monovalent PEGylation reagents is well consistent with similar 
findings applying multivalent coatings of nucleic acid nanoparticles [160, 232, 233]. 
Also, this approach offers a possibility to overcome GE11 mediated polyplex 
aggregation, and diminishes negative side-effects of PEGylation, such as reduced 
cellular binding. Also, reduced endosomal escape due to the introduction of a targeting 
ligand and a very effective lipo-oligomer based polyplex core could be overcome with 
this post-modification approach.   
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4.3 Lipo-oligomers optimized towards enhanced lipopolyplex stability 
Within this chapter, oligomers for an in vivo translation of the lipopolyplex PEGylation 
approach were designed. Lipo-oligomer 454 served as a starting point and was 
stepwise modified. Nucleic acid compaction (1), hydrophobic stabilization (2) and 
enhanced endosomal escape (3) was to be improved by varying the relevant functional 
groups. The main aim of this study was the optimization of lipopolyplex stability after 
PEGylation with the previously investigated bivalent shielding reagents (cf 3.2). 
Oligomers generated for this study can be subdivided into three groups.   
Within the first group, the effect of prolonging the positively charged binding domain 
within the carrier (Stp domain) was investigated. Stp, which is known, to mediate 
nucleic acid compaction and endosomal buffering [131, 134] was increased from 4 Stp 
units (within 454) up to 6 and 8 units respectively. Also, the stabilizing effect of tyrosine 
from peripherally placed trimers (Y3) [52] to hexamers was investigated, as they are 
known to stabilize via inter-oligomeral - stacking of the aromatic rings [208]. 
Additional stabilization within 454 was obtained by two centrally placed oleic acids. 
These hydrophobic domains, also facilitating endosomal release via pH-dependent 
lytic activity [51], were compared to cholanic acid, which previously elevated stability 
within siRNA lipopolyplexes [111]. Within the last group of oligomers, histidines were 
introduced alternately between the Stp units, as well as blockwise between tyrosines 
and Stp. Histidine is known to improve endosomal escape via enhanced endosomal 
buffering due to its imidazole side chain (pKa=6.5) [50, 105], but it is also hypothesized 
to interact inter-molecularly via - stacking [225, 235].   
These oligomers were evaluated within different assays for lipopolyplex stability before 
and after PEGylation with 1.0 eq Cys2-PEG24-Ala and GE11.  
First, size of non-PEGylated polyplexes was investigated. All polyplexes exhibited a 
particle size between 70 and 102 nm, a PDI (whereas 1.0 represents the highest 
polydispersity) between 0.12 and 0.26 and a positive surface potential between 17 and 
30 mV. These results are in accordance with previous findings, pointing out that, non-
PEGylated lipopolyplexes exhibit a positive zeta potential [226]. Polyplex size and 
polydispersity also meet criteria for a PEGylation approach for in vivo gene delivery, 
where sizes between 20 and 400 nm were found to be best suitable for gene delivery 
into solid tumors [41, 236]. PEGylation with 1.0 eq of the bivalent Cys2-PEG24-Ala 
resulted for all lipopolyplexes in only minor increased particle sizes between 72 and 90 
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nm, but a highly decreased zeta potential (between 1.5 and 12 mV), indicating the 
successful PEGylation reaction. However, introduction of 1.0 eq of the bivalent Cys2-
PEG24-GE11 reagent resulted in partial aggregation. As reported previously, the 
hydrophobic GE11 peptide is known to promote aggregation within pre-PEGylated 
polyplexes and enhanced particles sizes in case of 454 [226]. An increase in size was 
identified for all oligomers containing only 4 Stp units, whereas sizes ranged from 284 
nm (454) to >5000 nm in case of oligomers containing Y6 (1173 and 1174). An increase 
to 6 Stp units (1022 and 1023) did not completely help to overcome this aggregation, 
however with size decreased to a lower extent in case of cholanic acid bearing 
polyplexes. Lipopolyplexes formed with oligomers containing 8 Stp units exhibited 
nanoparticle sizes between 71 and 102 nm, and thereby just an increase of 
approximately 25 nm during PEGylation with Cys2-PEG24-GE11. Polyplexes formed 
with cholanic acid containing oligomers tended to maintain smaller particle sizes than 
oleic acid containing polyplexes. Summarizing these findings, we conclude, that the 
elevated cationic charge is helping to overcome the aggregation potential of 
hydrophobic peptides [209, 210] such as GE11 by increased nucleic acid compaction. 
Consequently, an EtBr compaction assay was carried out to investigate if increased 
cationic chain-length comes along with improved cargo compaction. For non-
PEGylated lipopolyplexes, a remaining EtBr fluorescence was determined between 8 
and 17%, while LPEI, which was used as a control exhibited less than 5 % free EtBr 
fluorescence. PEGylation with 1.0 eq of the bivalent reagents, independent if Ala or 
GE11 was spiked, did not significantly influence nucleic acid compaction. No 
differences between oleic acid and cholanic acid could be observed, but oligomers with 
8 Stp units generally tended to mediate a slightly improved pDNA compaction 
compared to oligomers containing only 4 Stp units.   
250 IU heparin was added to the same samples, and nucleic acid compaction after 
polyanionic stress was determined. Here, all lipopolyplexes mediated higher 
resistance, leading to a maximum of 60% EtBr fluorescence, than LPEI complexes, 
which released nucleic acid almost completely (>95%). Interestingly, within this 
experiment polyplexes with Stp2-Y6 (1173 and 1174) retained 60% of pDNA. All other 
polyplexes maintained pDNA compaction between 40 and 50%, which was already 
shown for 454 previously [226]. Generally, no notable differences between polyplexes 
comprising oleic or cholanic acid as stability inducing domains could be observed. 
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PEGylation of lipopolyplexes did not negatively influence pDNA compaction after 
polyanionic stress as observed previously for pre-PEGylated polyplexes [133].  
As a next experiment, after polyplex formation, stability within physiological salt 
concentrations, mediated by PBS solution buffered at pH 7.4, was investigated. Here, 
non-PEGylated polyplexes formed with oligomers consisting of 6 or less Stp units 
underwent colloidal aggregation with sizes more than 1000 nm. After three hours, all 
polyplexes apart from polyplexes formed with oligomers containing 8 Stp units were 
either dissociated or exhibited a size of several 1000 nm. Oligomers 1175-1180 
comprising 8 Stp units increased to a maximum size of 370 nm, however, mostly 
exhibited a size below 250 nm, indicating that the combination of hydrophobic 
stabilization via peripheral tyrosines (at least trimers) as well as fatty acids 
(independent if cholanic or oleic acid was introduced) and 8 Stp units per oligomer 
significantly increased polyplex stability against colloidal stress. Stability of these non-
PEGylated lipopolyplexes was maintained for 24 h. PEGylation with 1.0 eq bivalent 
reagents resulted in different findings. While all polyplexes PEGylated with Ala 
underwent no aggregation within 24 h, giving proof of the successful PEGylation of 
these polyplexes, lipopolyplexes PEGylated with GE11 underwent immediate 
aggregation, latest after 30 min of incubation with PBS. To point out that the behavior 
of GE11 is linked to lipopolyplexes solely, the well-established LPEI-PEG2k-GE11 [62, 
192] was additionally included in this study, however also underwent aggregation 30 
min after addition of PBS. This again points out the special behavior of GE11 within 
polyplexes. Nevertheless, this GE11 mediated aggregation is only an indicator for a 
reduced stability compared to polyplexes PEGylated with the less hydrophobic Ala, as 
LPEI-PEG2k-GE11 is well known to mediate EGFR specific gene transfer in-vivo [192, 
237].   
In a last experiment evaluating biophysical properties, polyplex stability in the presence 
of serum was investigated. Therefore, polyplexes were formed and incubated in 90% 
FBS. In general, as mentioned previously [226], polyplexes remained stable for 24h. 
All lipopolyplexes underwent immediate interaction with serum, displayed in an 
increased size of around 300 nm. This is most likely due to the formation of a serum 
corona. This interaction is known to facilitate stability, especially for PEGylated 
polyplexes, and thereby significantly contributes to their stability over time [206]. 
However, polyplexes PEGylated with Ala tended to (partially) aggregate to a greater 
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extent than lipopolyplexes PEGylated with GE11, indicating that lipopolyplexes post-
modified with GE11 form a more stable serum corona.  
Overall these data suggest, that PEGylation is beneficial for lipopolyplex stability and 
emphasizes that an increased cationic charge density, is required to overcome GE11 
mediated polyplex aggregation and to enhance polyplex stability compared to 
polyplexes formed with oligomers of 4 or 6 Stp units.   
Next, lipopolyplexes were post-modified with 1.0 eq of Cys2-PEG24-Ala/GE11 and gene 
transfer was investigated on the two EGFR positive cell lines Huh7 and KB. After 24 h 
of incubation on the cells, only the PEGylated 454/pDNA polyplex mediated notable 
gene transfer in an EGFR specific manner. All other tested oligomers mediated no 
gene transfer compared to buffer-treated cells, but also none of the polyplexes 
mediated cytotoxicity within 24 h on the cells. A reason for this could be the enhanced 
stability of the lipopolyplexes generated from the novel oligomers as investigated by 
different stress-inducing stability assays. An increased cationic charge density as well 
as hydrophobic domains (Y6 or cholanic acid), mediated a significantly enhanced 
lipopolyplex stability in vitro and thereby could hinder DNA release.   
Consequently, cellular internalization was investigated. FACS analysis revealed 
significant intracellular uptake for all Cy5-labeled pDNA/oligomer complexes. A 
reduced cellular uptake of the lipopolyplexes PEGylated with 1.0 eq of the bivalent Ala 
control reagent was observed, pointing out that polyplex shielding hinders unspecific 
cellular uptake in comparison to unmodified lipopolyplexes. Similar findings have been 
made previously for PEGylated PEI complexes [164]. At the same time, post-
modification with 1.0 eq of the bivalent EGFR targeted GE11 PEGylation reagent 
facilitated cellular uptake at least as good as non-PEGylated core lipopolyplexes. Ogris 
et al. previously already pointed out in a PEI based work that EGFR-targeting is only 
affected to a minor extent by PEGylation [54].   
Overall, lipopolyplexes formed with oligomers containing 4 Stp units (454 and 1026) 
mediated a higher uptake than polyplexes formed with oligomers containing 8 Stp units 
(1175-1180).  
Polyplexes with the highest uptake (454, 1026, 1176, 1177, 1178) were transfected 
again but within these transfections endosomolytic LPEI and chloroquine was added 
afterwards to reduce the possible lack of endosomal escape during gene delivery. This 
experiment was conducted as polyplexes formed with the novel lipo-oligomers were 
successfully taken up in a EGFR specific manner, but could not mediate gene transfer. 
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Although chloroquine is also known to facilitate polyplex dissociation intracellularly 
[238, 239], significantly improved transfection efficacy was only found for polyplexes 
formed with 454. Endosomal escape could be enhanced for parts of the novel 
oligomers (1026, 1176), although only in a minor extent. Thereby, it still could be 
considered that the herein generated lipopolyplexes suffer from their enhanced 
polyplex stability in comparison to the more labile 454/pDNA polyplexes as all 
polyplexes were internalized facilitating gene transfer theoretically.   
However, polyplexes formed with the newly generated lipo-oligomers might retain their 
cargo in subsequent steps preventing transformation of the pDNA towards its protein. 
This question could only be addressed by time consuming microscopy techniques 
requiring high expertise and labeling of pDNA as well as the oligomers for 
determination of cellular trafficking. 
In general, for all experiments, an equimolar amount of PEG per cysteine within all 
oligomers was used. This not only resulted in a two-fold excess of PEG per oligomer 
(as all oligomers contain two cysteines) but also in a two-fold excess of NPys (due to 
its bivalency) per cysteine of the oligomer. Although this excess mediated the best 
gene transfer (data not shown) for 454/pDNA polyplexes PEGylated with these bivalent 
reagents, the excess of reactive PEGylation reagents might reduce uptake to a certain 
extent, referring to the previously mentioned PEG dilemma [163]. Sizes of (PEGylated) 
lipopolyplexes were approximately 100 nm for oligomers containing 8 Stp units (1175-
1180), with an enhanced stability in the presence of physiological salt concentrations. 
At the same time (post-modified) 454 and 1026 pDNA polyplexes exhibited particle 
sizes of at least 200 nm. This increased size could at least partially help to compensate 
cellular uptake reduced by the excess of PEGylation reagents as larger particles might 
be taken up more efficiently [240, 241]. Ogris and colleagues [202] previously showed 
that polyplex size also plays a critical role for gene transfer itself, pointing out that larger 
polyplexes lead to at least 10x increased gene transfer due to improved endosomal 
escape.   
The excess of NPys during PEGylation in this surrounding could hinder oligomer 
crosslinking, theoretically leading to mono-functionalized oligomer-PEG constructs 
and not oligomer-oligomer constructs crosslinked by a bivalent linker. Although this 
mechanism is not clearly described, it was previously [242, 243] pointed out that 
pLL/pDNA polyplexes modified with pHMPA equipped with multiple attachment sites 
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mediated superior stability over linear (semitelechelic) pHMPA structures, considerably 
because of intermolecular cross-linking. However, for this shielding with enhanced 
stability, a slower reaction kinetic is described, suggesting that further experiments 
could be carried out after an enlonged PEGylation reaction with a lower amount of 
PEGylation reagent.  
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5 Summary 
Non-viral gene delivery depicts a promising alternative to the classical, established 
method of viral gene delivery [1]. However, for a successful gene delivery by artificial 
vectors, these carriers need to display several functionalities. Besides the ability to 
bind and compact the cargo, they are also required to shade the nucleic acid from 
degradation. During formulation of the nanoparticles (so-called polyplexes), the 
particles need to exhibit a suitable size between 5.5 and 400 nm to accumulate within 
the tissue of interest [39, 40]. To tailor these vehicles to its needs, such as preventing 
the nucleic acid from degradation, or to reduce interaction with blood components 
[153], solid phase synthesis (SPS) was recently introduced [95, 98, 117, 131, 134]. 
Thereby, oligomers could be generated to draw clear-cut structure-activity 
relationships.  
This first part of the study focuses on the optimization of shielding domains within 
sequence-defined oligomers (oligoaminoamides), which were generated by 
incorporation of novel artificial polyamino acids [131] for nucleic acid binding and 
compaction. Hereby, the strategy of pre-PEGylation, implying that a hydrophilic block 
of defined ethylene oxide repetitions was incorporated during oligomer synthesis, was 
applied to optimize pDNA delivery. To overcome the hampered transfection efficacy 
mediated by PEG [167], a hepatocyte growth factor receptor (HGFR) binding peptide 
(cmb) [181], that was previously found to mediate tumor-specific gene delivery in vitro 
as well as in vivo [64, 65], was introduced. Opposing requirements had to be dealt with 
while comparing shielding agents (PEG and peptidic Pro-Ala-Ser repeats) of different 
repetitions; both extremes (no shielding or very long shielding) have their drawbacks 
within two-arm oligoaminoamide pDNA polyplexes. However, it is concluded that a 
shorter shielding domain consisting of 12 PEG repetitions displays the best 
compromise for HGFR targeted gene delivery - this could also be shown by 
intratumoral delivery in vivo.  
Besides pre-PEGylation, also the introduction of a targeted PEGylation reagent after 
polyplex formation facilitates tumor-specific gene delivery [169, 170]. This approach 
was explored within the second part of this thesis for EGFR (epidermal growth factor 
receptor) targeted pDNA polyplexes, complexed by a cysteine-containing sequence-
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defined lipo-oligomer (454 [52]). Therefore, the EGFR specific peptide GE11 
(YHWYGYTPQNVI) was linked to PEG of 24 repetitions and activated terminal 
cysteines (one or two respectively) which were assembled as mono- or bivalent 
PEGylation reagents via SPS. During biophysical evaluation and in vitro testing on 
different EGFR positive or low expressing tumor cells, pDNA lipopolyplexes post-
modified with the bivalent PEGylation reagent via disulfide exchange chemistry, 
exhibited the highest EGFR dependent tumor uptake and gene expression, while 
circumventing polyplex aggregation observed for pre-PEGylated GE11 targeted 2-arm 
oligomers, which were evaluated side by side within this study.  
Lipopolypexes are described to mediate increased polyplex stability, which is known 
to be of high importance for in vivo gene delivery. However, post-modified 454/pDNA 
polyplexes lack stability. Therefore new oligomers with increased cationic charge 
(mediated by increased Stp units from 4 to 6 or 8), improved hydrophobic stabilization 
(due to introduction of Y6 and/ or cholanic acid instead of oleic acid) as well as 
additional histidines (for endosomal buffering as well as potential stabilization via 
imidazole mediated - stacking [225, 235]) were introduced and then carefully 
evaluated via biophysical experiments to determine polyplex behavior in the presence 
of (poly)anionic stress and in the presence of serum. Here the novel oligomers 1175-
1180 exhibited a significantly improved polyplex stability compared to 454. While in 
vitro transfections of the post-modified lipopolyplexes could not mediate gene delivery 
within 24 h, significant receptor-dependent cellular polyplex uptake was observed after 
45 min for oligomers 1026, 1177 as well as 1176 and 1178 as well as 454. 
Transfections of these post-modified polyplexes followed by addition of endosomolytic 
LPEI or chloroquine pointed out the functionality of this assay, as gene transfer could 
be significantly improved for 454/pDNA polyplexes. However, gene transfer was not 
notably enhanced for all other lipopolyplexes. This indicates that polyplexes formed 
with the newly generated lipo-oligomers might retain their cargo in subsequent steps 
preventing transformation of the pDNA towards its protein. Future in vivo experiments 
could show if stability was sufficiently improved to resist effects occurring in vivo and 
lipopolyplexes can overcome the intracellular barriers towards successful gene 
delivery. 
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6 Appendix 
6.1 Abbreviations 
Boc   tert-Butoxycarbonyl protecting group  
CholA  5β-Cholanic acid 
DAMP 3,3′-Diamino-N-methyldipropylamine;  
DCM   Dichloromethane  
DIPEA  N,N-Diisopropylethylamine  
DLS  Dynamic light scattering 
DMEM  Dulbecco’s modified Eagle’s medium  
DMF   N,N-Dimethylformamide  
DNA   Desoxyribonucleic acid  
EDTA  Ethylendiaminetetraacetic acid  
EGF/EGFR Epidermal growth factor (receptor) 
EtBr   Ethidium bromide  
FBS   Fetal bovine serum  
Fmoc   Fluorenylmethoxycarbonyl protecting group  
FolA   Folic acid  
FR   Folate receptor  
GSH   Glutathione 
Gtt  Glutaroyl triethylene tetramine 
HBG   Hepes-buffered glucose  
HBTU  2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate  
HEPES  N-(2-hydroxethyl) piperazine-N‘-(2-ethansulfonic acid)  
HGF/HGFR Hepatocyte growth factor (receptor) 
HOBt   1-Hydroxybenzotriazole  
Inf7  An endosomolytic influenza virus derived peptide  
kDa  Kilodalton 
LMW   Low molecular weight  
LPEI   Linear polyethylenimine  
mM  Millimolar 
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mRNA  Messenger RNA 
MTBE  Methyl tert-butyl ether  
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
mV  Millivolt 
MWCO Molecular weight cut-off  
N/P   Nitrogen to phosphates ratio  
NEM   N-ethylmaleimide 
NHS   N-Hydroxysuccinimide 
nm  Nanometer 
NMP   N-Methyl-2-pyrrolidone  
NMR   Nuclear magnetic resonance  
OEI   Oligoethylenimine 
OleA  Oleic acid 
PAA   Polyamino acid  
pCMVLuc  Plasmid encoding for firefly luciferase under the control of the 
cytomegaly virus (CMV) promoter  
pHPMA  Poly-N-(2-hydroxypropyl)methacrylamide 
PDI   Polydispersity index  
pDNA  Plasmid DNA  
PEG   Polyethylene glycol  
BPEI  Branched polyethylenimine 
LPEI   Linear Polyethylenimine 
PAMAM Poly(amidoamine) 
pKa  -log10 Ka (acid dissociation constant) 
pLL  Polylysine  
PyBOP  Benzotriazol-1-yloxy-tripyrrolidinophosphonium hexafluorophosphate  
RLU   Relative light units  
RNA   Ribonucleic acid  
RP-HPLC  Reversed-phase high-performance liquid chromatography  
RT   Room temperature  
SEC   Size-exclusion chromatography  
siRNA  Small interfering RNA 
Spermine N,N-(butane-1,4-diyl)bis(propane-1,3-diamine) 
Sph   Succinyl-pentaethylene hexamine  
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SPS   Solid-phase synthesis  
Stp   Succinyl-tetraethylene pentamine  
STOTDA N-Fmoc-N″-succinyl-4,7,10-trioxa-1,13-tridecanediamine  
Tat  Transactivator of Transcription  
TBE  Tris-boric acid-EDTA buffer  
TEPA  Tetraethylene pentamine  
TETA   Triethylene tetramine  
TFA   Trifluoroacetic acid  
THF   Tetrahydrofuran  
TIS   Triisopropylsilane  
TKI   Tyrosine kinase inhibitor 
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6.2 Serum stability of optimized T-shapes determined by DLS 
 
Intensity mean curves of oligomers 454, 1021 and 1022 un-PEGylated, PEGylated with 1.0 eq (Cys)2-
PEG24-Ala and GE11 as determined by DLS measurement. Red curve: t=0 h, green curve t=4 h and 
blue after 24 h. Color of bars below the graphs indicate classification according to Table 19. 
 
 
Intensity mean curves of oligomers 1023, 1024 and 1026 un-PEGylated, PEGylated with 1.0 eq (Cys)2-
PEG24-Ala and GE11 as determined by DLS measurement. Red curve: t=0 h, green curve t=4 h and 
blue after 24 h. Color of bars below the graphs indicate classification according to Table 19.   
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Intensity mean curves of oligomers 1173, 1174 and 1175 un-PEGylated, PEGylated with 1.0 eq (Cys)2-
PEG24-Ala and GE11 as determined by DLS measurement. Red curve: t=0 h, green curve t=4 h and 
blue after 24 h. Color of bars below the graphs indicate classification according to Table 19. 
 
 
Intensity mean curves of oligomers 1176, 1177 and 1178 un-PEGylated, PEGylated with 1.0 eq (Cys)2-
PEG24-Ala and GE11 as determined by DLS measurement. Red curve: t=0 h, green curve t=4 h and 
blue after 24 h. Color of bars below the graphs indicate classification according to Table 19. 
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Intensity mean curves of oligomers 1179 and 1180 un-PEGylated, PEGylated with 1.0 eq (Cys)2-
PEG24-Ala and GE11 as determined by DLS measurement. Red curve: t=0 h, green curve t=4 h and 
blue after 24 h. Color of bars below the graphs indicate classification according to Table 19. 
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6.3 Summary of SPS derived oligomers 
Table 21 Summary of SPS derived oligomers 
Oligomer 
ID 
Topology Sequence (N→C) Proton. 
amines 
Chapter 
440 PEGylated 2-arm [C-(H-Stp)
4
-H]-K-dPEG
24
-A 26 3.2 
442 PEGylated 2-arm KSLSRHDHIHHH-{[C-(H-Stp)4-H]-K-H-dPEG24}-K 26 3.1 
454 T-Shape C-Y3-Stp2-K-[K(OleA)]-Stp2-Y3-C 13 3.2, 3.3 
689 3-arm [C-(H-Stp)
3
-H]-K-H-(Stp-H)
3
-C 29 3.1 
694 PEGylated 2-arm KSLSRHDHIHHH-{[C-(H-Stp)4-H]-K-H-dPEG24-dPEG24}-K 26 3.1 
835 PEGylated 2-arm [C-(H-Stp)
4
-H]-K-dPEG
24
-YHWYGYTPQNVI 26 3.2 
901 PASylated 2-arm KSLSRHDHIHHH-{[C-(H-Stp)4-H]-K-H-(PAS)8}-K 26 3.1 
996 PEGylated 2-arm KSLSRHDHIHHH-{[C-(H-Stp)4-H)-K-H-dPEG12}-K 26 3.1 
1000 PASylated 2-arm KSLSRHDHIHHH-{[C-(H-Stp)4-H]-K-H-(PAS)4}-K 26 3.1 
1021 T-Shape C-Y3-Stp2-K-[K-(CholA)]-Stp2-Y3-C 13 3.3 
1022 T-Shape C-Y3-Stp3-K-[K-(OleA)]-Stp3-Y3-C 25 3.3 
1023 T-Shape C-Y3-Stp3-K-[K-(CholA)]-Stp3-Y3-C 25 3.3 
1024 T-Shape C-Y3-H3-Stp2-K-[K-(OleA)]-Stp2-H3-Y3-C 13 3.3 
1026 T-Shape C-Y3-(H-Stp)2-H-K-[K-(OleA)]-H-(Stp-H)2-Y3-C 13 3.3 
1078 3-arm KSLSRHDHIHHH-{[C-(H-Stp)3-H]-K-H-(Stp-H)3}-K 29 3.1 
1088 PEGylated 2-arm {[C-(H-Stp)
4
-H]-K-H-dPEG
12
}-K 26 3.1 
1091 PEGylated 2-arm {[C-(H-Stp)
4
-H]-K-H-dPEG
24
}-K 26 3.1 
1094 PASylated 2-arm {[C-(H-Stp)
4
-H]-K-H-(PAS)
4
}-K 26 3.1 
1097 PASylated 2-arm {[C-(H-Stp)
4
-H]-K-H-(PAS)
8
}-K 26 3.1 
1120 PEGylated 2-arm {[C-(H-Stp)
4
-H]-K-H-dPEG
24
-dPEG
24
}-K 26 3.1 
1173 T-Shape C-Y6-Stp2-K-[K-(OleA)]-Stp2-Y6-C 13 3.3 
1174 T-Shape C-Y6-Stp2-K-[K-(CholA)]-Stp2-Y6-C 13 3.3 
1175 T-Shape C-Y3-Stp4-K-[K-(OleA)]-Stp4-Y3-C 25 3.3 
1176 T-Shape C-Y3-Stp4-K-[K-(CholA)]-Stp4-Y3-C 25 3.3 
1177 T-Shape C-Y6-Stp4-K-[K-(OleA)]-Stp4-Y6-C 25 3.3 
1178 T-Shape C-Y6-Stp4-K-[K-(CholA)]-Stp4-Y6-C 25 3.3 
1179 T-Shape C-Y3-(H-Stp)4-H-K-[K-(OleA)]-H-(Stp-H)4-Y3-C 25 3.3 
1180 T-Shape C-Y3-H5-Stp4-K-[K-(OleA)]-Stp4-H5-Y3-C 25 3.3 
 
6.4 Summary of SPS derived shielding reagents 
Table 22 Summary of SPS derived shielding reagents 
ID Name Sequence (C→N) Chapter 
1059 Cys-PEG24-Ala Cys(NPys)-dPEG24-A 3.2, 3.3 
999 Cys-PEG24-GE11 Cys(NPys)-dPEG24-YHWYGYTPQNVI 3.2, 3.3 
1060 (Cys)2-PEG24-Ala (Cys(NPys)-STOTDA)-K-dPEG24-A 3.2, 3.3 
1056 (Cys)2-PEG24-GE11 (Cys(NPys)-STOTDA)-K-dPEG24-YHWYGYTPQNVI 3.2, 3.3 
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6.5 Analytical data 
6.5.1 MALDI-TOF MS of Dde-K-(S-A-P)8-OH 
 
 
Calculated mass [M-H] of C104H161N26O36: 2350.16 g/mol 
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6.5.2 MALDI-TOF MS of the targeting peptides cmb and GE11 
 
MALDI-MS of cmb peptide: Calculated mass [M+H] of C70H110N28O18: 1630.9 g/mol 
 
 
MALDI-MS of GE11 peptide: Calculated mass [M+H] of C75H97N17O19: 1541.7 g/mol 
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6.5.3 1H NMR spectra of oligomers 
440: Sequence (N->C): [C-(H-Stp)
4
-H]α,ε-K-dPEG24-A 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 1.3-1.45 (comp, 3H, βH alanine), 1.6-
2.0 (comp, 6H, βγδH lysine), 2.4-2.6 (comp, 34 H, -CO-CH2-CH2-CO- succinic acid -
CO-CH2-dPEG24 ), 3.0 -3.65 (comp, 156 H, -CH2- tepa, εH lysine, βH cysteine, βH 
histidine), 3.70 (s, 98H, -CH2-O-dPEG24, -CH2-N-dPEG24), 3.75-4.75 (comp, 15 H, αH 
cysteine, lysine, histidine), 4.79 (s, HDO), 7.2-7.4 (m, 11 H, aromatic H histidine), 8.5-
8.7 (m, 11 H, aromatic H histidine). comp indicates a group of overlaid protons.   
   Appendix 
   148 
442: Sequence (N->C): KSLSRHDHIHHH -[(C-(H-Stp)4-H)α,εK-H-dPEG24]ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.7-0.95 (comp, 17H, βγδH leucine, 
βγδH isoleucine), 1.35-1.8 (comp, 24H, βγδH lysine, βγδH arginine), 2.3-2.7 (comp, 
34 H, -CO-CH2-CH2-CO- succinic acid), 2.8 -3.15 (comp, 34 H, βH histidine, βH 
asparagine) 3.20-3.55 (comp, 132 H, -CH2- tepa, βH cysteine), 3.6 (s, 98H, -CH2-O-
dPEG24) 3.65-4.7 (comp, 37 H, αH amino acids, βH serine, εH lysine), 4.79 (s, HDO), 
7.2-7.3 (m, 16 H, aromatic H histidine), 8.5-8.7 (m, 16 H, aromatic H histidine). comp 
indicates a group of overlaid protons.   
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689: Sequence (N->C): [C-(H-Stp)3-H]α,ε-K-H-(Stp-H)3-C 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 1.1-1.4 (comp, 6H, βγδH lysine), 2.3-
2.7 (comp, 36 H, -CO-CH2-CH2-CO- succinic acid), 2.9-3.8 (comp, 176 H, -CH2- tepa, 
βH cysteine, βH histidine, εH lysine), 4.1-4.7 (comp, 16 H, αH cysteine, lysine, 
histidine), 4.79 (s, HDO), 7.2-7.4 (m, 11 H, aromatic H histidine), 8.5-8.7 (m, 11 H, 
aromatic H histidine). comp indicates a group of overlaid protons. 
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694: Sequence (N->C): KSLSRHDHIHHH -[(C-(H-Stp)4-H)α,εK-H-dPEG24-dPEG24]ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.7-0.95 (comp, 17H, βγδH leucine, 
βγδH isoleucine), 1.35-1.8 (comp, 24H, βγδH lysine, βγδH arginine), 2.3-2.7 (comp, 
36 H, -CO-CH2-CH2-CO- succinic acid), 2.8 -3.15 (comp, 36H, βH histidine, βH 
asparagine) 3.20-3.55 (comp, 132H, -CH2- tepa, βH cysteine), 3.7 (s, 196H, -CH2-O-
dPEG24) 3.72-4.7 (comp, 37 H, αH amino acids, βH serine, εH lysine), 4.79 (s, HDO), 
7.2-7.3 (m, 16 H, aromatic H histidine), 8.5-8.7 (m, 16H, aromatic H histidine). comp 
indicates a group of overlaid protons.   
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835: Sequence (N->C): [C-(H-Stp)
4
-H]-K-dPEG24-YHWYGYTPQNVI 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.75-1.0 (m, 19H, γH threonine β-
CH3 γδH isoleucine, β-CH3 valine), 1.60-1.80 (m, 6H, βγδH lysine), 2.35-2.54 (m, 34 
H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- dPEG24), 3.1-3.65 (m, 174 H, -CH2- 
tepa, H asparagine, βH cysteine, βH histidine, βH tryptophan, βH tyrosine, δH 
proline, βH asparagine, βH valine, εH lysine), 3.74-3.8 (m, 98 H, -CH2-O- dPEG24, -
CH2-N- dPEG24), 4.1-4.65 (m, 26 H, αH amino acids), 4.75 (s, HDO), 6.7-7.42 (m, 29 
H, aromatic ring H tyrosine, tryptophan, imidazole), 8.52-8.70 (m, 11 H, imidazole).   
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901: Sequence (N->C): KSLSRHDHIHHH-[(C-(H-Stp)4-H)α,εK-H-(PAS)8]ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.7-0.95 (comp, 17H, βγδH leucine, 
βγδH isoleucine), 1.3-1.4 (td, 24H, -CH3 H alanine), 1.5-1.9 (comp, 24H, βγδH lysine, 
βγδH arginine), 1.75-2.25 (comp, 48H, -CH2 proline), 2.5-2.7 (comp, 32H, -CO-CH2-
CH2-CO- succinic acid), 2.8-3.25 (comp, 34H, βH histidine, βH asparagine), 3.3-3.6 
(comp, 132 H, -CH2- tepa, βH cysteine), 3.75-4.7 (comp, 77H, βH serine, εH lysine, 
αH amino acids), 4.79 (s, HDO), 7.25-7.4 (m, 16 H, aromatic H histidine), 8.6-8.65 
(m, 16 H, aromatic H histidine). comp indicates a group of overlaid protons.   
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996: Sequence (N->C): KSLSRHDHIHHH -[(C-(H-Stp)4-H)α,εK-H-dPEG12]ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.7-0.95 (comp, 17H, βγδH leucine, 
βγδH isoleucine), 1.35-1.8 (comp, 24H, βγδH lysine, βγδH arginine), 2.3-2.7 (comp, 
34 H, -CO-CH2-CH2-CO- succinic acid), 2.45-2.55 (t, 2 H, asparagine), 2.8 -3.15 
(comp, 32 H, β histidine) 3.20-3.52 (comp, 132 H, -CH2- tepa, βH cysteine), 3.6 (s, 
50H, -CH2-O-dPEG12) 3.65-4.7 (comp, 37 H, αH amino acids, βH serine, εH lysine), 
4.79 (s, HDO), 7.2-7.3 (m, 16 H, aromatic H histidine), 8.5-8.7 (m, 16 H, aromatic H 
histidine). comp indicates a group of overlaid protons.   
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1000: Sequence (N->C): KSLSRHDHIHHH-[(C-(H-Stp)4-H)α,εK-H-(PAS)4]ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.7-0.95 (comp, 17H, βγδH leucine, 
βγδH isoleucine), 1.3-1.4 (td, 12H, -CH3 H alanine), 1.5-1.9 (comp, 24H, βγδH lysine, 
βγδH arginine), 1.95-2.45 (comp, 24H, -CH2 proline), 2.5-2.7 (comp, 36H, -CO-CH2-
CH2-CO- succinic acid), 3.0 (t, 2 βH, asparagine), 3.15-3.3 (comp, 34H, βH histidine), 
3.3-3.6 (comp, 132 H, -CH2- tepa, βH cysteine), 3.75-4.7 (comp, 57H, βH serine, εH 
lysine, αH amino acids), 4.79 (s, HDO), 7.3-7.4 (m, 16 H, aromatic H histidine), 8.6-8.8 
(m, 16 H, aromatic H histidine). comp indicates a group of overlaid protons.   
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1078: Sequence (N->C): KSLSRHDHIHHH-[(C-(H-Stp)3-H)α,εK-H-(Stp-H)3]ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.7-0.95 (comp, 17H, βγδH leucine, 
βγδH isoleucine), 1.35-1.8 (comp, 24H, βγδH lysine, βγδH arginine), 2.3-2.7 (comp, 
36 H, -CO-CH2-CH2-CO- succinic acid), 2.6-2.85 (t, 2 H, asparagine), 2.95 -3.2 (comp, 
34 H, β histidine) 3.25-3.6 (comp, 150 H, -CH2- tepa, βH cysteine), 3.65-4.7 (comp, 16 
H, αH amino acids, βH serine, εH lysine), 4.79 (s, HDO), 7.2-7.4 (m, 17 H, aromatic H 
histidine), 8.5-8.7 (m, 17 H, aromatic H histidine). comp indicates a group of overlaid 
protons. 
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1088: Sequence (N->C): {[C-(H-Stp)4-H]α,ε-K-H-dPEG12}ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 1.1-1.4 (comp, 12H, βγδH lysine), 
2.3-2.7 (comp, 34 H, -CO-CH2-CH2-CO- succinic acid -CO-CH2-dPEG12 ), 2.9-3.65 
(comp, 154 H, -CH2- tepa, βH cysteine, βH histidine), 3.70 (s, 48H, -CH2-O-dPEG12, -
CH2-N-dPEG12), 3.75-3.85 (m, 4H, εH lysine) 4.1-4.7 (comp, 15 H, αH cysteine, lysine, 
histidine), 4.79 (s, HDO), 7.2-7.4 (m, 11 H, aromatic H histidine), 8.5-8.7 (m, 11 H, 
aromatic H histidine). comp indicates a group of overlaid protons. 
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1091: Sequence (N->C): {[C-(H-Stp)4-H]α,ε-K-H-dPEG24}ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 1.1-1.4 (comp, 12H, βγδH lysine), 
2.3-2.7 (comp, 34 H, -CO-CH2-CH2-CO- succinic acid -CO-CH2-dPEG24 ), 2.9-3.65 
(comp, 154 H, -CH2- tepa, βH cysteine, βH histidine), 3.70 (s, 98H, -CH2-O-dPEG24, -
CH2-N-dPEG24), 3.75-3.85 (m, 4H, εH lysine) 4.1-4.7 (comp, 15 H, αH cysteine, lysine, 
histidine), 4.79 (s, HDO), 7.2-7.4 (m, 11 H, aromatic H histidine), 8.5-8.7 (m, 11 H, 
aromatic H histidine). comp indicates a group of overlaid protons. 
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1094: Sequence (N->C): {[C-(H-Stp)4-H]α,ε-K-H-(PAS)4}ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 1.3-1.4 (td, 12H, -CH3 H alanine), 
1.45-1.9 (comp, 12H βγδH lysine), 1.95-2.45 (comp, 24H, -CH2 proline), 2.5-2.7 
(comp, 32 H, -CO-CH2-CH2-CO- succinic acid), 3.1-3.65 (comp, 154 H, -CH2- tepa, βH 
cysteine, βH histidine), 3.70-3.90 (m, 16H, αεH lysine, βH serine, αH cysteine ) 4.1-4.7 
(comp, 23 H, αH histidine, αH serine, αH proline, αH alanine), 4.79 (s, HDO), 7.2-7.4 
(m, 11 H, aromatic H histidine), 8.5-8.7 (m, 11 H, aromatic H histidine). comp indicates 
a group of overlaid protons. 
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1097: Sequence (N->C): {[C-(H-Stp)4-H]α,ε-K-H-(PAS)8}ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 1.3-1.4 (td, 24H, -CH3 H alanine), 
1.45-1.9 (comp, 12H βγδH lysine), 1.95-2.45 (comp, 48H, -CH2 proline), 2.5-2.7 
(comp, 32 H, -CO-CH2-CH2-CO- succinic acid), 3.1-3.65 (comp, 154 H, -CH2- tepa, βH 
cysteine, βH histidine), 3.70-3.90 (m, 24H, αεH lysine, βH serine, αH cysteine ) 4.1-4.7 
(comp, 35 H, αH histidine, αH serine, αH proline, αH alanine), 4.79 (s, HDO), 7.2-7.4 
(m, 11 H, aromatic H histidine), 8.5-8.7 (m, 11 H, aromatic H histidine). comp indicates 
a group of overlaid protons. 
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1120: Sequence (N->C): {[C-(H-Stp)4-H]α,ε-K-H-dPEG24-dPEG24}ε-K 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 1.1-1.4 (comp, 12H, βγδH lysine), 
2.3-2.7 (comp, 34 H, -CO-CH2-CH2-CO- succinic acid -CO-CH2-dPEG24 ), 2.9-3.65 
(comp, 154 H, -CH2- tepa, βH cysteine, βH histidine), 3.70 (s, 196H, -CH2-O-dPEG24, 
-CH2-N-dPEG24), 3.75-3.85 (m, 4H, εH lysine) 4.1-4.7 (comp, 15 H, αH cysteine, 
lysine, histidine), 4.79 (s, HDO), 7.2-7.4 (m, 11 H, aromatic H histidine), 8.5-8.7 (m, 11 
H, aromatic H histidine). comp indicates a group of overlaid protons. 
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6.5.4 RP-HPLC of oligomers 
440: 
 
 
 
442: 
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689: 
 
 
 
694: 
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835: 
 
 
 
901: 
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996:  
 
 
 
1000: 
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1078: 
  
 
 
1088: 
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1091: 
 
 
 
1094:  
 
  
   Appendix 
   167 
1097: 
 
 
 
1120: 
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6.5.5 Mass spectra of oligomers 
Table 23 Table summarizing mass data of oligomers. Mass data was recorded with a Bruker MALDI-
TOF instrument 
Oligomer Molecular formula [M-H]- calc. [M-H]- found 
454 (Stp2-Y3-OleA) 
 
3072.0 3074.8 
1021 (Stp2-Y3-CholA) 
 
3229.2 3225.9 
1022 (Stp3-Y3-OleA) 
 
3615.7 3615.8 
1023 (Stp3-Y3-CholA) 
 
3771.0 3769.2 
1024 (Stp2-H3-Y3-OleA) 
 
3895.9 3893.7 
1026 ((Stp-H)2-H-Y3-OleA) 
 
3895.9 3893.1 
1173 (Stp2-Y6-OleA) 
 
4052.1 4047.9 
1174 (Stp2-Y6-CholA) 
 
4208.3 4205.9 
1175 (Stp4-Y3-OleA) 
 
4158.5 4154.5 
1176 (Stp4-Y3-CholA) 
 
4314.7 4312.4 
1177 (Stp4-Y6-OleA) 
 
5137.5 5133.2 
1178 (Stp4-Y6-CholA) 
 
5293.7 5286.2 
1179 ((Stp-H)4-H-Y3-OleA) 
 
5529.8 5525.9 
1180 (Stp4-H5-Y3-OleA) 
 
5529.8 5522.7 
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6.5.5.1 Full mass spectra of oligomers 
454: 
 
 
1021: 
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1022:  
 
 
 
1023: 
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1024:  
 
 
 
1026: 
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1173: 
 
 
 
1174:  
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1175:  
 
 
 
1176:  
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1177:  
 
 
 
1178:  
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1179:  
 
1180:  
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6.5.6 Mass spectra of shielding reagents 
Table 24 Table summarizing mass data of shielding reagents. Mass data was recorded with a 
Thermoscientific LTQ FT Ultra Fourier transform ion cyclotron and an IonMax source. 
Shielding agent ID Molecular formula [M+X]+ calc. [M+X]+ found 
Cys(NPys)-PEG24-Ala 1059 C62H115N5O30S2 1495.7 [Na] 1492.8 [Na] 
Cys(NPys)- PEG24-GE11 999 C134H205N21O47S2 2948.3 [Na] 2945.4 [Na] 
Cys(NPys)2-PEG24-Ala 1060 C104H186N14O44S4 2486.9 [Na] 2484.3 [Na] 
Cys(NPys)2- PEG24-GE11 1056 C176H276N30O61S4 3938.5 [Na] 3940.0 [Na] 
 
6.5.6.1 Full mass spectra of shielding reagents 
 
1059 (Cys(NPys)-PEG24-Ala): 
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999 (Cys(NPys)- PEG24-GE11): 
 
 
 
1060 (Cys(NPys)2-PEG24-Ala): 
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1056 (Cys(NPys)2- PEG24-GE11): 
 
 
 
6.5.7 RP-HPLC of shielding reagents 
 
1059 (Cys(NPys)-PEG24-Ala): 
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999 (Cys(NPys)- PEG24-GE11): 
 
 
 
1060 (Cys(NPys)2-PEG24-Ala): 
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1056 (Cys(NPys)2- PEG24-GE11): 
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